2-aminoquinazoline derivatives as P70S6 kinase inhibitors

ABSTRACT

The invention provides compound that inhibit or modulate the activity of p70S6 kinase, the compounds being of the formula (1): 
                         
or a salt, tautomer or N-oxide thereof;
 
wherein:
         one of Y and Z is R 3  and the other is Ar 2 ;   Q 1  is an optionally substituted C 1-8  alkylene group; and wherein a carbon atom of the C 1-8  alkylene group may optionally be replaced by a cyclopropane-1,1-diyl or cyclobutane-1,1-diyl group provided that the total number of carbon atoms in an alkylene group containing such a replacement does not exceed 8;   Q 2  is a bond or an optionally substituted C 1-8  alkylene group   R 1  is selected from hydrogen, NR x R y  and a group Cy 1 ;   R x  and R y  are each is selected from hydrogen, C 1-4  hydrocarbyl or hydroxy-C 1-4  hydrocarbyl; or NR x R y  forms an optionally substituted 4 to 7-membered heterocyclic ring;   Cy 1  is an optionally substituted C-linked 3 to 7 membered monocyclic non-aromatic carbocyclic or heterocyclic;   R 2  and R 4  are each is selected from hydrogen, fluorine, chlorine, optionally substituted C 1-2  alkyl and optionally substituted C 1-2  alkoxy;   R 3  is selected from hydrogen, fluorine, chlorine, optionally substituted C 1-2  alkyl and optionally substituted C 1-2  alkoxy;   Ar 1  is an optionally substituted monocyclic 5 or 6-membered aryl or heteroaryl ring; and   Ar 2  is an optionally substituted bicyclic 8 to 11-membered heteroaryl group.       

     The compounds are useful in medicine, for example in the treatment of a disease or condition selected from cancers, neurodevelopmental diseases and neurodegenerative diseases.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a national stage filing under section 371 ofInternational Application No. PCT/EP2016/073489, filed on Sep. 30, 2016,and published on Apr. 6, 2017 as WO 2017/055592, which claims priorityto Great Britain Application No. 1614037.8, filed on Aug. 16, 2016 andto Great Britain Application No. 1517451.9, filed on Oct. 2, 2015. Theentire contents of WO 2017/055592 are hereby incorporated herein byreference.

This invention relates to compounds that inhibit or modulate theactivity of p70S6 kinase, pharmaceutical compositions containing thecompounds and the therapeutic uses of the compounds.

BACKGROUND OF THE INVENTION

The enzyme, p70S6 kinase (also known as p70S6K, p70S6K1, pS6K, S6K,S6K1) is a serine-threonine kinase and a member of the AGC family. It isa downstream effector of the phosphatidylinositol 3 kinase(PI3K)/AKT/mammalian target of rapamycin (mTOR) signalling pathway andp70S6K undergoes phosphorylation and activation in response to growthfactors such as IGF-I, EGF, TGF-[alpha] and HGF.

Activation of p70S6K in turn phosphorylates a number of proteinsinvolved in protein translation including Ribosomal protein S6 (RPS6),eIF4B and eEF2K. The net effect of this is to promote translationleading to an increase in protein synthesis in a cell. High levels ofprotein synthesis are required for cellular proliferation. It has alsobeen shown that p70S6K has a necessary role in the mitotic cycle of acell (Lane et al, Nature, 1993, 363(6425):170-2).

The kinase p70S6K has been shown to be constitutively activated in humantumour cells, leading to tumour cell proliferation. Inhibition of themTOR/p70S6K pathway has been shown to lead to a decrease in tumour cellproliferation and an increase in tumour cell apoptosis (Pene et al(2002) Oncogene 21, 6587 and Le et al (2003) Oncogene 22, 484).Inhibition of p70S6K activity would therefore present an attractiveapproach for the treatment of cancer.

The mTOR/p70S6K pathway has been shown to be activated in renal cellcarcinoma and is inhibited by CCI-779 (Robb, V. A.; Karbowniczek, M.;Klein-Szanto, A. J.; Henske, E. P. J Urol 2007, 177, 346-52).Furthermore, patients with glioblastoma multiforme whose tumours expresshigh levels of phosphorylated p70S6K have been found to benefit fromtreatment with CCI-779 (Galanis et al. J. Clin. Oncol. 2005, 23,5294-304).

In addition, a significant linear association between time to diseaseprogression and inhibition of p70S6K activity in peripheral bloodmononuclear cells (PBMCs) following administration of the mTOR inhibitorCCI-779 has been reported for Renal Cell Carcinoma patients by Peralbaet al [(2003) Clinical Cancer Research 9, 2887]. This indicates thatactivity of p70S6K is a driver of disease in this setting and thatp70S6K activity can be potentially be used as a clinical biomarker.

The gene RPS6KB1 that codes for p70S6K, is localized to chromosomalregion 17q23 and this region is amplified in Breast Cancer (Cancer Res.(1999) 59: 1408-11 Localization of pS6K to Chromosomal Region 17q23 andDetermination of Its Amplification in Breast Cancer). This leads toover-expression of p70S6K protein and a statistically significantassociation between amplification and poor prognosis has been observedin breast cancer patients (Detecting activation of ribosomal protein S6kinase by complementary DNA and tissue microarray analysis. J. Natl.Cancer Inst. 2000; 92:1252-9).

Furthermore, Belletti et al published that S6K1 mediates survival andrecurrence of Breast Cancer following surgery (Mol Oncol. 2014 May;8(3):766-80).

P70S6K has a role in migration and invasion of ovarian cancer (p70 S6kinase in the control of actin cytoskeleton dynamics and directedmigration of ovarian cancer cells, Oncogene (2011), 1-13). In addition,it has been revealed that p70S6K has a role in promoting invasion,migration and metastasis of highly aggressive Triple-Negative BreastCancer cells (Targeting p70S6K Prevented Lung Metastasis in a BreastCancer Xenograft Model, Akar et al, Molecular Cancer Therapeutics(2010), 9 (5), 1180 and Hung et al, S6K1 promotes invasiveness of breastcancer cells in a model of metastasis of triple-negative breast cancer,Am. J. Transl, Res. 2014 Jul. 18; 6(4):361-76).

In addition, Lymphangioleiomyomatosis (LAM) is a disease typified byhyper-activation of the PI3K/Akt/mTOR/p70S6K axis due to mutationinactivation of the repressor complex, Tuberous Sclerosis Complex (TSC).LAM cells are also metastatic, giving rise to metastasis in the lung.

LAM is a rare destructive lung disease, almost exclusively of women, andis associated with the metastasis of tuberin-null cells (Taveira-DaSilvaet al. (2006). Cancer Control. 2006; 13:276-285). Metastatic lesionsdevelop in distant organs including lungs, kidney and lymph nodes,representing a severe and debilitating disease burden.

LAM occurs either sporadically or as a manifestation of TuberousSclerosis Complex (TSC), a dominant autosomal inherited disorder (Expertreview on http://www.orpha.net). LAM and TSC disorders are characterizedby nullifying mutations in tumour suppressors TSC1 or TSC2 leading tohyper activation of mTOR and of S6K1. This in turn drives cell growth &proliferation of LAM cells (Holz et al. (2014), Cell Cycle 2014;13:371-382). S6K1 is also known to promote metastasis in other cancers:breast (Akar et al. (2010), Mol Cancer Ther; 9(5)) and ovarian (Wong etal. (2011), Oncogene (2011) 30, 2420-2432). Due to the reliance of LAMcells on S6K1, and of the likely role of S6K1 in the metastatic process,it is anticipated that an S6K1 inhibitor will have disease-modifyingproperties for LAM.

Sporadic LAM has a prevalence of approximately 1 in 125,000 birthswhereas Pulmonary LAM, arising from TSC, has a prevalence ofapproximately 1 in 15,000 births (figures from internet rare diseasedatabase, http://www.orpha.net). No approved therapies exist for LAM andhence LAM is currently classified as an orphan disease.

Given that p70S6K promotes translation, it is known that p70S6K has acrucial role in the pathology of diseases that rely on excessive proteinsynthesis (for example, Fragile X Syndrome, Genetic Removal of p70 S6Kinase 1 Corrects Molecular, Synaptic, and Behavioral Phenotypes inFragile X Syndrome Mice. Klann et al, Neuron, Volume 76, Issue 2,p325-337, 18 Oct. 2012). Furthermore, p70S6K has a role in the pathologyof cancers involving synthesis of oncogenic proteins such as c-Myc e.g.pancreatic cancer (The mTORC1/S6K1 Pathway Regulates GlutamineMetabolism through the eIF4B Dependent Control of c-Myc Translation,Blenis et al, Current Biology, Volume 24, Issue 19, p2274-2280, 6 Oct.2014). For treatment of these conditions it would be advantageous to usean orally bioavailable p70S6K inhibitor to correct the excessive proteinsynthesis.

P70S6K has been implicated in the pathology of a number of cancers ofthe brain. Such conditions include, but are not limited to:

-   -   Brain metastases arising from cancers elsewhere in the body, for        example brain metastases arising from a breast cancer such as        Triple-Negative Breast Cancer (Distant metastasis in        triple-negative breast cancer. Neoplasma 2013; 60: 290-294)    -   Brain metastases from metastatic breast cancer (Central nervous        system or brain metastases traditionally occur in 10-16% of        metastatic breast cancer patients and are associated with a        dismal prognosis—see Breast Dis. 2006-2007; 26:139-47.)    -   Gliomas and Glioblastomas (S6K1 Plays a Key Role in Glial        Transformation, Cancer Research (2008), 68(16), 6516-6523)

Furthermore, a p70S6K inhibitor may be particularly useful for treatingthe following cancers which are reliant on p70S6K signalling:

-   -   Bladder cancer    -   Breast cancer    -   Colo-rectal cancer (CRC)    -   Diffuse large B-cell lymphomas (DLBCL)    -   Gallbladder cancer    -   Gliomas and Glioblastomas    -   Head and Neck cancers    -   Hepatocellular carcinoma    -   Human Olfactory Neuroblastoma    -   Leukaemias    -   Lymphomas    -   Nasopharyngeal carcinoma    -   Neuroendocrine cancer    -   Non-Small Cell Lung Cancer (NSCLC)    -   Small cell lung cancer    -   Ovarian cancer    -   Pancreatic cancer    -   Pheochromocytoma    -   Renal Cell Carcinoma (RCC)    -   Squamous cell carcinoma    -   Metastases, for example bone metastases and lung metastases

P70S6K also has a crucial role in the pathology of a number ofneurodevelopmental diseases (many referenced in The Autistic Neuron:Troubled Translation?. Bear et al, Cell 135, Oct. 31, 2008). Inparticular, these diseases are caused by the excessive protein synthesisthat is driven by P70S6K. Such conditions include, but are not limitedto:

-   -   Fragile X Syndrome, a rare neuro-developmental disease caused by        excessive levels of p70S6K activity    -   Autism and Autism Spectrum Disorders    -   Fragile X-associated tremor/ataxia syndrome (FXTAS)    -   Angleman's syndrome    -   Tuberous sclerosis    -   PTEN hamartoma syndrome    -   MECP2 duplication syndrome    -   Neurofibromatosis    -   Alzheimer's Disease (refer to (1) Oddo et al, Reducing Ribosomal        Protein S6 Kinase 1 Expression Improves Spatial Memory and        Synaptic Plasticity in a Mouse Model of Alzheimer's Disease, The        Journal of Neuroscience, Oct. 14, 2015, 35(41):14042-14056        and (2) Genetic reduction of mammalian target of rapamycin        ameliorates Alzheimer's disease-like cognitive and pathological        deficits by restoring hippocampal gene expression signature,        Journal of Neuroscience (2014), 34(23), 7988-7998)    -   Down Syndrome (mTOR Hyperactivation in Down Syndrome Hippocampus        Appears Early During Development, Journal of Neuropathology &        Experimental Neurology (2014), 73(7), 671-683)        PTEN Hamartoma Syndrome

PTEN hamartoma tumour syndrome (PHTS) encompasses four major clinicallydistinct syndromes associated with germline mutations in the tumoursuppressor PTEN. These allelic disorders, Cowden syndrome,Bannayan-Riley-Ruvalcaba syndrome, Proteus syndrome, and Proteus-likesyndrome are associated with unregulated cellular proliferation leadingto the formation of hamartomas (benign and malignant tumours of thethyroid, breast, and endometrium) (Genetics in Medicine (2009) 11,687-694). The absence of PTEN leads to loss of down-regulation ofphosphorylated Akt which in turn allows for unchecked survival, growthand proliferation of the cells in question. As S6K1 is a key effector ofAkt, an S6K1 inhibitor may have utility in controlling the growth of thecancer. Prevalence of PHTS is currently unknown.

Neurofibromatosis Type 1

Neurofibromatosis type 1 is a condition characterized by changes in skincolouring (pigmentation) and the growth of tumours along nerves in theskin, brain, and other parts of the body. The signs and symptoms of thiscondition vary widely among affected people. Most adults withneurofibromatosis type 1 develop neurofibromas, which are noncancerous(benign) tumours that are usually located on or just under the skin.These tumours may also occur in nerves near the spinal cord or alongnerves elsewhere in the body. Some people with neurofibromatosis type 1develop cancerous tumours that grow along nerves. These tumours, whichusually develop in adolescence or adulthood, are called malignantperipheral nerve sheath tumours. People with neurofibromatosis type 1also have an increased risk of developing other cancers, including braintumours and cancer of blood-forming tissue (leukaemia).

Neurofibromatosis type 1 occurs in 1 in 3,000 to 4,000 people worldwideand currently surgery is the main treatment option; it is classed as anorphan disease as no targeted therapies exist(http://ghr.nlm.nih.gov/condition/neurofibromatosis-type-1)

Mutations in the NF1 gene cause neurofibromatosis type 1. The NF1 geneprovides instructions for making neurofibromin protein. This protein isproduced in many cells, including nerve cells and specialized cellssurrounding nerves (oligodendrocytes and Schwann cells). Neurofibrominacts as a tumour suppressor. Mutations in the NF1 gene lead to theproduction of a non-functional version of neurofibromin that cannotregulate cell growth and division. As a result, tumours such asneurofibromas can form along nerves throughout the body. An S6K1inhibitor may control growth of cells expressing mutated NF1 gene bydampening production of neurofibromin protein and other proteinsessential to growth of the tumour.

Role of P70S6 in Neurological Diseases

P70S6K also has a crucial role in the pathology of a number ofneurodevelopmental diseases (many referenced in The Autistic Neuron:Troubled Translation?. Bear et al, Cell 135, Oct. 31, 2008). Inparticular, these diseases are caused by the excessive protein synthesisthat is driven by P70S6K.

It is well known that precise translation control (protein synthesis) isabsolutely required for neurological processes of the brain such aslong-lasting synaptic plasticity and the formation of long-term memory.Moreover, alterations in translational control are a commonpathophysiological feature of human neurological disorders, includingdevelopmental disorders, neuropsychiatric disorders, andneurodegenerative diseases.

Furthermore, it is known that translational control mechanisms aresusceptible to modification by small molecules that penetrate the brain(Klann and Santini, Dysregulated mTORC1-dependent translational control:from brain disorders to psychoactive drugs, Front. Behav. Neurosci., 8Nov. 2011, doi: 10.3389/fnbeh.2011.00076).

S6K1 is well known as a master regulator of protein biosynthesis via itsrole in translation initiation as well as phosphorylation and activationof various substrates that drive protein production (eIF4B, PDCD4, SKAR,eEF2K, RPS6—for review refer to Ma and Blenis, Nature Reviews MolecularCell Biology 10, 307-318 (May 2009), doi:10.1038/nrm2672).

The following disorders are typified by underlying aberrations inregulation of protein translation which is linked to the pathologiesobserved. An S6K1 inhibitor, which acts by reducing excessive proteintranslation may therefore have utility as a therapy in such disorders.

It is possible to classify certain disorders into sub-groups: (1)Neurodevelopmental Disorders (2) Neurodegenerative Diseases. Within eachsub-class the disorders are linked by common themes:

1. Neurodevelopmental Disorders

Neurodevelopmental disorders are defined as diseases caused by abnormaldevelopment of the brain during the first two decades of life. It ispossible to define a subgroup of these disorders that are characterizedby single-gene mutations. A common molecular abnormality in several ofthese disorders is loss-of-function mutations and/or deletion of genesthat encode proteins that normally repress the mTORC1 signallingpathway. These disorders are listed below.

Fragile X Syndrome

Fragile X syndrome (FXS) is a genetic condition that gives rise to arange of developmental problems including learning disabilities andcognitive impairment. Usually, males are more severely affected by thisdisorder than females, owing to the fact that the condition is inheritedvia the X-chromosome. Affected individuals usually have delayeddevelopment of speech and language by age 2. Most males with FXS havemild to moderate intellectual disability, while about one-third ofaffected females are intellectually disabled. Children with FXS may alsohave anxiety and hyperactive behaviour such as fidgeting or impulsiveactions. They may have attention deficit disorder (ADD), which includesan impaired ability to maintain attention and difficulty focusing onspecific tasks.

About one-third of individuals with FXS have features of autism spectrumdisorders that affect communication and social interaction. Seizuresoccur in about 15 percent of males and about 5 percent of females withFXS. Most males and about half of females with FXS have characteristicphysical features that become more apparent with age. These featuresinclude a long and narrow face, large ears, a prominent jaw andforehead, unusually flexible fingers, flat feet, and in males, enlargedtesticles (macro-orchidism) after puberty. FXS occurs in approximately 1in 4,000 males and 1 in 8,000 females.

Mutations in the Fmr1 gene cause FXS. The Fmr1 gene providesinstructions for making a protein called fragile X mental retardation 1protein, or FMRP. This protein helps regulate the production of otherproteins and plays a role in the development of synapses, which arespecialized connections between nerve cells. Synapses are critical forrelaying nerve impulses.

Nearly all cases of FXS are caused by a mutation in a DNA segment, knownas the CGG triplet repeat, in the Fmr1 gene. Normally, this DNA segmentis repeated in the range between 5 and 44 times (more commonly either 29or 30 times). In people with FXS, however, the CGG segment is repeatedmore than 200 times. The abnormally expanded CGG segment turns off(silences) the Fmr1 gene, which prevents the gene from producing FMRP.

FMRP is a repressor of protein translation. In the case of FXS patients,who either experience a loss or shortage of FMRP, there is no repressionof translation, leading to excessive production of an array of proteinsnormally controlled by FMRP. A number of these proteins are expressed inthe neurons and control synaptic plasticity (memory formation, learning,ability to store information). Lack of control of production of theseproteins leads to the neuropathological state observed in FXS patients.Klann et al published that S6K1 has a central role in the excessivetranslation of these proteins and that genetic knock-out of S6K1resulted in correction of phenotypes in the mouse model of FXS (GeneticRemoval of p70 S6 Kinase 1 Corrects Molecular, Synaptic, and BehavioralPhenotypes in Fragile X Syndrome Mice. Neuron 76, 325-337, 2012). It hasbeen determined that S6K1 inhibitors described herein also have theability to dampen protein synthesis in the neurons, leading tocorrection of aberrant phenotypes in a mouse model of FXS.

Furthermore, Tassone et al (Genes, Brain and Behavior (2012), doi:10.1111/j.1601-183X.2012.00768.x) published that lymphocytes isolatedfrom the blood of human FXS patients exhibited higher levels ofphosphorylated (activated) p70S6K and also higher levels ofphosphorylated RPS6, the direct substrate of S6K1. This confirms thatp70S6K is more highly activated in human FXS patients and supports thenotion of inhibiting p70S6K activity in order to correct the disease. Inaddition, this represents a possible clinical biomarker so as to assessthe pharmacodynamics effect of the p70S6K inhibitor in the clinic.

Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS)

Fragile X-associated tremor/ataxia syndrome (FXTAS) is a rareneurodegenerative disorder characterized by adult-onset progressiveintention tremor and gait ataxia. It is an X-linked genetic disorder andas such, the disease primarily affects males (Orphanet rare diseasedatabase, http://www.orpha.net/consor/cgi-bin/index.php?lng=EN)

Prevalence is estimated at 1-9 in 100,000 individuals. The age of onsetof tremor and/or ataxia in males is about 60 years. The clinicalpresentation is variable with dominant manifestations including:intention tremor, progressive cerebellar gait ataxia, frontal executivedysfunction, cognitive decline, peripheral neuropathy, and dysautonomia.Other signs include mild Parkinsonism and psychiatric manifestations(depression, anxiety and agitation) with possible progression todementia. Carrier females generally have less severe manifestations thanmales but also have an increased risk of primary ovarian insufficiency,chronic muscle pain, and hypothyroidism. FXTAS is caused by a CGGtrinucleotide repeat expansion (55-200 repeats) in the permutation rangeof the Fmr1 gene. There is no specific treatment for FXTAS that targetsthe underlying pathological mechanism; FXTAS is therefore classed as anorphan disease. The CGG trinucleotide repeat expansion often leads toreduced levels of FMRP protein, a repressor of protein translation. Thisleads to excessive protein translation which may be counter-acted by useof an S6K1 inhibitor.

Autism and Autism Spectrum Disorders

Autism spectrum disorder (ASD) and autism are terms for a group ofcomplex disorders of brain development. The disorders are characterizedby difficulties in social interaction, verbal and nonverbalcommunication and repetitive behaviours. A publication in 2013 titledthe Diagnostic and Statistical Manual of Mental Disorders (DSM-5)brought together all autism disorders into one umbrella diagnosis ofASD. Previously, they were recognized as distinct subtypes, includingautistic disorder, childhood disintegrative disorder, pervasivedevelopmental disorder—not otherwise specified (PDD-NOS) and Aspergersyndrome. The U.S. Centers for Disease Control and Prevention (CDC)identify around 1 in 68 American children as on the autism spectrum.Studies also show that autism is four to five times more common amongboys than girls. An estimated 1 out of 42 boys and 1 in 189 girls arediagnosed with autism in the United States. Overall, ASD affects over 3million individuals in the U.S. and tens of millions worldwide (AutismSpeaks website, http://www.autismspeaks.org/). Moreover, governmentautism statistics suggest that prevalence rates are on the increase.Fragile X syndrome (FXS) is the most common inherited cause ofintellectual disabilities and the most common known cause of autismworldwide (Penagarikano et al (2007). The pathophysiology of Fragile XSyndrome. Annu. Rev. Genomics Hum. Genet. 8, 109-129). This causativelink between FXS and autism indicates that an S6K1 inhibitor thatexhibits efficacy in treating FXS may also be useful in treatment ofautism and ASDs.

Angelman Syndrome

Angelman syndrome (AS) is a neurogenetic disorder that is usuallydiagnosed in infants and is characterized by developmental delay, severeintellectual disability, absent speech, exuberant behaviour with happydemeanor, motor impairment, and epilepsy. AS is caused by deficientUBE3A gene expression that may be caused by various abnormalities ofchromosome 15 (Dan, B., Angelman syndrome: Current understanding andresearch prospects. Epilepsia, 2009. 50(11): p. 2331-2339). Although notprecisely known, prevalence of AS among children and young adults isbetween 1/10,000 and 1/20,000 defining AS as a rare disease. Mutationsin the E3 ubiquitin ligase UBE3A have been identified in AS, suggestingthat ubiquitin-dependent protein turnover may be impaired in thisdisorder, possibly leading to elevated synaptic protein levels (Jiangand Beaudet, 2004). Furthermore, it has been disclosed that S6K1inhibition can improve hippocampal synaptic plasticity and learning in amouse model of Angelman syndrome (Cellular and Molecular Life Sciencespp 1-12). An S6K1 kinase inhibitor would exert its effect by reducingtranslation of synaptic protein levels.

Tuberous Sclerosis Complex

Tuberous sclerosis complex is a genetic disorder characterized by thegrowth of numerous noncancerous (benign) tumours in many parts of thebody. These tumours can occur in the skin, brain, kidneys, and otherorgans, in some cases leading to significant health problems. Tuberoussclerosis complex also causes developmental problems, and the signs andsymptoms of the condition vary from person to person.

Tuberous sclerosis complex often affects the brain, causing seizures,behavioural problems such as hyperactivity and aggression, andintellectual disability or learning problems. Some affected childrenhave the characteristic features of autism, a developmental disorderthat affects communication and social interaction, as described above.Benign brain tumours can also develop in people with tuberous sclerosiscomplex; these tumours can cause serious or life-threateningcomplications. Tuberous sclerosis complex affects about 1 in 6,000people (http://ghr.nlm.nih.gov/condition/tuberous-sclerosis-complex)

Mutations in the TSC1 or TSC2 gene can cause tuberous sclerosis complex.The TSC1 and TSC2 genes provide instructions for making the proteinshamartin and tuberin, respectively. These proteins are involved in thesignalling network of the PI3K pathway and act as tumour suppressors,inhibiting the activation of mTOR via Rheb-GTP. When TSC1 or TSC2 aremutated this leads to loss of tumour suppressor function, leading tomTOR hyper-activation.

Importantly, the mTORC1 inhibitor rapamycin has been shown to beeffective in ameliorating learning and memory deficits in TSC2heterozygous knockout mice (Ehninger et al., 2008b), suggesting thatuncontrolled mTORC1 signalling is a core molecular mechanism involved inthe behavioural abnormalities.

One of the functional effectors of mTOR is S6K1; therefore, inhibitingS6K1 function may have ameliorative effects in the disease

MECP2 Duplication Syndrome

MECP2 duplication syndrome is a genetic condition that is inherited inan X-linked pattern and occurs almost exclusively in males. It ischaracterized by moderate to severe intellectual disability. Most peoplewith this condition also have weak muscle tone in infancy, feedingdifficulties, poor or absent speech, and seizures that may not improvewith treatment or muscle stiffness (spasticity). Individuals with MECP2duplication syndrome have delayed development of motor skills such assitting and walking. Many individuals with MECP2 duplication syndromehave recurrent respiratory tract infections. These respiratoryinfections are a major cause of death in affected individuals, withalmost half succumbing by age 25. The prevalence of MECP2 duplicationsyndrome is unknown; approximately 120 affected individuals have beenreported in the scientific literature. MECP2 duplication syndrome arisesdue to a duplication of the MECP2 gene which leads to excessiveproduction of MeCP2 protein in the brain. MeCP2 is a regulator ofexpression of other genes. Whilst MeCP2 is critical for normal brainfunction, an excess can lead to abnormal regulation of the target genes(http://ghr.nlm.nih.gov/condition/mecp2-duplication-syndrome). An S6K1inhibitor may reduce production of MeCP2 protein via global dampening oftranslation and may have utility as therapeutic intervention in thisdisease.

Down Syndrome

Down syndrome (DS) or Down's syndrome, also known as trisomy 21, is agenetic disorder caused by the presence of all or part of a third copyof chromosome 21 (Patterson, D (July 2009). “Molecular genetic analysisof Down syndrome.” Human Genetics 126 (1): 195-214). It is typicallyassociated with physical growth delays, characteristic facial features,and mild to moderate intellectual disability. DS is the most commonchromosome abnormality in humans, occurring in about one per 1000 babiesborn each year (Weijerman, M E; de Winter, J P (December 2010).“Clinical practice. The care of children with Down syndrome”. Europeanjournal of pediatrics 169 (12): 1445-52).

Recent publications have identified that mTOR hyper-activation plays arole in DS in the early stages of development. In control (non-DS)hippocampi phosphorylated S6 was only detected prenatally; it becameundetectable 2 months postnatally. Conversely, for DS patients,phosphorylated S6 and phosphorylated S6 kinase were detected prenatallyand persisted throughout postnatal development. This was linked toincreased expression of phosphorylated S6 protein (RPS6), phosphorylatedp70S6K, phosphorylated eukaryotic initiation factor 4E binding protein1, and phosphorylated mTOR in DS hippocampus compared with controls (JNeuropathol Exp Neurol. 2014 July; 73(7):671-83). Furthermore, it hasbeen suggested that mTOR inhibitors such as Rapamycin or other Rapalogsmay be of utility in treating Cognitive Deficits associated with DS (CNSNeurol Disord Drug Targets. 2014 February; 13(1):34-40). As S6K1controls phosphorylation and activation of S6 protein, an S6K1 inhibitormay be of therapeutic utility in counteracting the hyper-activated mTORsignalling in DS patients.

2. Neurodegenerative Diseases

Alzheimer's Disease

The clinical symptoms of Alzheimer's disease (AD) include a gradualmemory loss and subsequent dementia, and neuropathological deposition ofsenile plaques and neurofibrillary tangles. AD accounts for 60% to 70%of cases of dementia (Burns, A; Lliffe, S (5 Feb. 2009). “Alzheimer'sdisease.” BMJ (Clinical research ed.) 338: b158). It is a devastatingand relatively widespread disease—as of 2010, there were between 21 and35 million people worldwide with AD (“Survival in dementia andpredictors of mortality: a review”. International journal of geriatricpsychiatry 28 (11): 1109-24).

At the molecular level, AD is associated with (1) the progressiveaccumulation of amyloid β-peptides (Aβ) in the form of extracellularamyloid plaques in the human brain and (2) tau hyperphosphorylation.Recent publications have implicated the PI3K/mTOR signalling pathway inthe pathogenesis of the disease. For example, genetic knock-out of mTORprotein in Tg2576 mice, a widely used animal model of AD, was found tosuppress amyloid-β deposits and rescue memory deficits in the animals(J. Neurosci. 2014 Jun. 4; 34(23):7988-98). Furthermore, testing ofpost-mortem brain tissue from human AD patients highlighted thatalteration of mTOR signalling and autophagy occurs at early stages ofAD, leading to a significant increase of Aβ (1-42) levels andhyper-activation of the PI3K/Akt/mTOR pathway (J. Neurochem. 2015 Jan.27). The expression level of S6K1, the mTOR downstream target, wasincreased in these samples suggesting that a therapeutic intervention byan S6K1 inhibitor may be of utility to control synthesis of amyloid βprotein and to dampen signalling from mTOR. Furthermore, increasedlevels of phosphorylated mTOR and S6K1 were also found in some of thebrain areas affected in AD, such as cortex, of double APP/PS1 transgenicmice, a model of AD (Lafay-Chebassier et al., 2005).

In addition, Oddo et al (Reducing Ribosomal Protein S6 Kinase 1Expression Improves Spatial Memory and Synaptic Plasticity in a MouseModel of Alzheimer's Disease, The Journal of Neuroscience, Oct. 14,2015, 35(41):14042-14056) published data that supports the followingconclusions: (1) S6K1 activity is upregulated in the brains of ADpatients (2) in a mouse model of AD, S6K1 activity in brain is alsohigher than control (3) Genetic reduction of S6K1 in the AD model mouse(via haplodeficiency) (1) improved synaptic plasticity and spatialmemory deficits, and (2) reduced accumulation of Amyloid-B (AB) andphospho-tau/total tau levels, the key neuropathological hallmarks of AD.This validation gives credence to the hypothesis that manipulation ofS6K1 activity via a small molecule S6K1 inhibitor could be a validtherapeutic approach in AD.

Huntington's Disease

Huntington's disease is an inherited, progressive brain disorder thatcauses uncontrolled movements, emotional problems, and loss of thinkingability (cognition); there are two forms of the disease: (1) adult-onsetHuntington's disease, the most common form of this disorder, whichusually appears in a person's thirties or forties and (2) Juvenile-onsetHuntington's disease, which is less common and begins in childhood oradolescence. In both forms the disease is progressive with affectedindividuals usually living for only 10 to 15 years after signs andsymptoms appear. Huntington's disease affects an estimated 3 to 7 peopleper 100,000 of European ancestry.

Huntington's disease is caused by mutations in the HTT gene which leadsto production of an abnormally long version of the huntingtin (Htt)protein. The elongated protein is cut into smaller, toxic fragments thatbind together and accumulate in neurons, disrupting the normal functionsof these cells. The dysfunction and eventual death of neurons in certainareas of the brain underlie the signs and symptoms of Huntington'sdisease. Recent publications have shown that mutant Htt contributes tothe pathogenesis of HD by enhancing mTORC1 activity (Sci. Signal., 28Oct. 2014, Vol. 7, Issue 349, p. ra103).

One of the functional effectors of mTOR signalling is S6K1; therefore,inhibiting S6K1 function may have ameliorative effects in the disease.In addition, inhibiting S6K1 may limit the production of huntingtinprotein via dampening of global protein translation.

Parkinson's Disease

Parkinson's disease (PD) is a progressive neurodegenerative conditionresulting from the death of the dopamine-containing cells of thesubstantia nigra. People with PD classically present with the symptomsand signs associated with parkinsonism, namely bradykinesia, rigidityand rest tremor. PD is a common, chronic, progressive neurologicalcondition, estimated to affect 100-180 people per 100,000 of thepopulation (between 6 and 11 people per 6000 of the general populationin the UK) and has an annual incidence of 4-20 per 100,000. There is arising prevalence with age and a higher prevalence and incidence of PDin males (https://www.nice.org.uk/guidance/cg035/chapter/introduction).

Whilst PD traditionally has been considered a non-genetic disorder, atleast 5% of people are now known to have forms of the disease that occurbecause of a mutation of one of several specific genes. Mutations inspecific genes have been conclusively shown to cause PD. These genescode for alpha-synuclein (SNCA), parkin (PRKN), leucine-rich repeatkinase 2 (LRRK2 or dardarin), PTEN-induced putative kinase 1 (PINK1),DJ-1 and ATP13A2 (Lesage S, Brice A; Brice (April 2009). “Parkinson'sdisease: from monogenic forms to genetic susceptibility factors”. Hum.Mol. Genet. 18 (R1): R48-59).

Recent studies addressing the mechanism of neurodegeneration in PDdemonstrate the involvement of the mTORC1 signalling pathway in thesurvival mechanism of dopaminergic neurons. In vivo and in vitro studiesshow that degeneration induced by treatment with PD toxins, such as6-OHDA and MPTP, leads to upregulation of RTP801, a protein encoded by aRTP801 stress-responsive gene, which in turn reduces mTOR kinaseactivity. It has been proposed that the molecular mechanism, linkinghigh levels of RTP801 to mTORC1 inhibition and neurodegenerationinvolves TSC2 and Akt (Deyoung et al., 2008; Malagelada et al., 2008).Genetic manipulations that interfere with TSC2 or increase theexpression of a constitutively active form of Akt protected against thePD toxins and prevented the increase in RTP801 (Malagelada et al.,2008). However, rapamycin was reported as a neuroprotective agent bothin cell culture and in a MPTP mouse model (mouse model of PD). It wasproposed that rapamycin may enhance Akt activity through inhibition ofmTORC1-dependent activation of S6K1 and the subsequent reduction ofphospho-IRS-1, which is a scaffold protein involved in the activation ofPI3K and Akt (Shah et al., 2004). It therefore may also be the case thatan inhibitor of S6K1 (a main effector of mTOR) will uncouple the samenegative feedback loop to IRS-1, leading to activation of Akt andincreased survival in the neurons of PD patients. An S6K1 inhibitor maytherefore exhibit therapeutic effects when dosed to a PD patient.

For treatment of all the above described diseases it would beadvantageous to use an orally bioavailable P70S6K inhibitor withproperties allowing penetration of the brain in sufficient concentrationto achieve efficacy.

It would therefore be beneficial to develop compounds that have theability to inhibit p70S6 kinase.

The Invention

The present invention provides a class of novelarylalkylamino-substituted quinazolines as inhibitors of p70S6 kinase.

In a first embodiment (Embodiment 1.0) of the invention, there isprovided a compound of the formula (1):

or a salt, tautomer or N-oxide thereof;wherein:

-   -   one of Y and Z is R³ and the other is Ar²;    -   Q¹ is a C₁₋₈ alkylene group optionally substituted by one or two        substituents selected from hydroxy and C₁₋₄ hydrocarbyloxy,        provided that when a hydroxy substituent is present, there are        at least two carbon atoms between the hydroxy substituent and        the nitrogen atom to which Q² is attached; and wherein a carbon        atom of the C₁₋₈ alkylene group may optionally be replaced by a        cyclopropane-1,1-diyl or cyclobutane-1,1-diyl group provided        that the total number of carbon atoms in an alkylene group        containing such a replacement does not exceed 8;    -   Q² is a bond or a C₁₋₈ alkylene group optionally substituted by        one or two substituents selected from hydroxy and C₁₋₄        hydrocarbyloxy, provided that when a hydroxy substituent is        present, there are at least two carbon atoms between the hydroxy        substituent and the nitrogen atom to which Q² is attached;    -   R¹ is selected from hydrogen, NR^(x)R^(y) and a group Cy¹;    -   R^(x) and R^(y) are the same or different and each is selected        from hydrogen, C₁₋₄ hydrocarbyl or hydroxy-C₁₋₄ hydrocarbyl; or        NR^(x)R^(y) forms a 4 to 7-membered heterocyclic ring containing        a total of 1 or 2 heteroatom ring members of which one is N and        the other is selected from N, O and S and oxidised forms        thereof, the heterocyclic ring being optionally substituted with        one or two substituents selected from C₁₋₄ hydrocarbyl, oxo,        amino, mono-C₁₋₄ hydrocarbylamino, di-C₁₋₄hydrocarbylamino,        fluorine and hydroxy, provided that there are at least two        carbon atoms in line between the amino, mono-C₁₋₄        hydrocarbylamino, di-C₁₋₄hydrocarbylamino and hydroxy        substituents when present and the nitrogen atom of the        NR^(x)R^(y) group;    -   Cy¹ is a C-linked 3 to 7 membered monocyclic non-aromatic        carbocyclic or heterocyclic group containing 0, 1 or 2        heteroatom ring members selected from N, O and S and oxidised        forms of S, wherein the carbocyclic and heterocyclic groups are        optionally substituted with one or two substituents selected        from C₁₋₃ hydrocarbyl, fluorine, oxo and hydroxy;    -   R² and R⁴ are the same or different and each is selected from        hydrogen, fluorine, chlorine, C₁₋₂ alkyl and C₁₋₂ alkoxy,        wherein each C₁₋₂ alkyl and C₁₋₂ alkoxy is optionally        substituted with two or more fluorine atoms;    -   R³ is selected from hydrogen, fluorine, chlorine, C₁₋₂ alkyl and        C₁₋₂ alkoxy, wherein each C₁₋₂ alkyl and C₁₋₂ alkoxy is        optionally substituted with two or more fluorine atoms;    -   Ar¹ is a monocyclic 5 or 6-membered aryl or heteroaryl ring        containing 0, 1 or 2 heteroatom ring members selected from O, N        and S, the aryl or heteroaryl being optionally substituted with        1, 2 or 3 substituents R⁵ which are the same or different and        are selected from halogen, cyano and a group R^(a)—R^(b);        R^(a) is a bond, O, CO, X³C(X⁴), C(X⁴)X³, X³C(X⁴)X³, S, SO, SO₂,        NR^(c), SO₂NR^(c) or NR^(c)SO₂;        R^(b) is:    -   hydrogen;    -   a carbocyclic or heterocyclic group having from 3 to 7 ring        members, of which 0, 1, 2 or 3 are heteroatom ring members        selected from O, N and S and oxidised forms of S, the        carbocyclic or heterocyclic group being optionally substituted        with one or more substituents R⁶; and    -   an acyclic C₁₋₈ hydrocarbon group optionally substituted with        one or more substituents selected from hydroxy; oxo; halogen;        cyano; carboxy; amino; mono- or di-C₁₋₄ alkylamino; and        carbocyclic and heterocyclic groups having from 3 to 7 ring        members, of which 0, 1, 2 or 3 are heteroatom ring members        selected from O, N and S and oxidised forms of S, the        carbocyclic or heterocyclic group being optionally substituted        with one or more substituents R⁶; wherein one or two but not all        of the carbon atoms of the acyclic C₁₋₈ hydrocarbon group may        optionally be replaced by O, S, SO, SO₂, NR^(c), X³C(X⁴),        C(X⁴)X³ or X³C(X⁴)X³;        R⁶ is selected from the substituents R⁵ except that R⁶ does not        consist of or contain a carbocyclic or heterocyclic group;        X³ is O, S or NR^(c); and        X⁴ is ═O, ═S or ═NR^(c); and        R^(c) is hydrogen or C₁₋₄ hydrocarbyl;    -   Ar² is a bicyclic 8 to 11-membered heteroaryl group containing        1, 2, 3 or 4 heteroatom ring members selected from O, N and S        and being optionally substituted with 1, 2 or 3 substituents R⁷        selected from oxo, fluorine; chlorine; bromine; C₁₋₄ hydrocarbyl        optionally substituted with one or more fluorine atoms; C₁₋₄        hydrocarbyloxy optionally substituted with one or more fluorine        atoms; hydroxy; cyano; N(R^(c))₂; R^(c)—C(O)—;        R^(c)—C(O)N(R^(c))—; (R^(c))₂NC(O)—; R—SO₂NR^(c)—;        R^(c)—NHC(O)NH—; (R^(c))₂NSO₂—; and five and six-membered        monocyclic groups containing from 0 to 3 heteroatom ring members        selected from O, N and S, the five and six-membered monocyclic        groups being unsubstituted or substituted with one or more        substituents R⁸ selected from C₁₋₄ hydrocarbyl, C₁₋₄        hydrocarbyloxy, cyano, hydroxy, oxo, halogen, amino, mono-C₁₋₄        hydrocarbylamino and di-C₁₋₄hydrocarbylamino and wherein the        hydrocarbyl moieties when present are optionally substituted        with fluorine, C₁₋₂ alkoxy, hydroxy, amino,        mono-di-C₁₋₂alkylamino or di-C₁₋₄alkylamino;    -   and wherein, in each substituent consisting of or containing a        hydrocarbyl group, the hydrocarbyl group is selected from alkyl,        alkenyl, alkynyl and cycloalkyl groups and combinations thereof.

In another embodiment (Embodiment 1.1) of the invention, there isprovided a compound of the formula (1):

or a salt, tautomer or N-oxide thereof;wherein:

-   -   one of Y and Z is R³ and the other is Ar²;    -   Q¹ is a C₁₋₈ alkylene group optionally substituted by one or two        substituents selected from hydroxy and C₁₋₄ hydrocarbyloxy,        provided that when a hydroxy substituent is present, there are        at least two carbon atoms between the hydroxy substituent and        the nitrogen atom to which Q² is attached;    -   Q² is a bond or a C₁₋₈ alkylene group optionally substituted by        one or two substituents selected from hydroxy and C₁₋₄        hydrocarbyloxy, provided that when a hydroxy substituent is        present, there are at least two carbon atoms between the hydroxy        substituent and the nitrogen atom to which Q² is attached;    -   R¹ is selected from hydrogen, NR^(x)R^(y) and a group Cy¹;    -   R^(x) and R^(y) are the same or different and each is selected        from hydrogen, C₁₋₄ hydrocarbyl or hydroxy-C₁₋₄ hydrocarbyl; or        NR^(x)R^(y) forms a 4 to 7-membered heterocyclic ring containing        a total of 1 or 2 heteroatom ring members of which one is N and        the other is selected from N, O and S and oxidised forms        thereof, the heterocyclic ring being optionally substituted with        one or two substituents selected from C₁₋₄ hydrocarbyl, oxo,        amino, mono-C₁₋₄ hydrocarbylamino, di-C₁₋₄hydrocarbylamino,        fluorine and hydroxy, provided that there are at least two        carbon atoms in line between the amino, mono-C₁₋₄        hydrocarbylamino, di-C₁₋₄hydrocarbylamino and hydroxy        substituents when present and the nitrogen atom of the        NR^(x)R^(y) group;    -   Cy¹ is a C-linked 3 to 7 membered monocyclic non-aromatic        carbocyclic or heterocyclic group containing 0, 1 or 2        heteroatom ring members selected from N, O and S and oxidised        forms of S, wherein the carbocyclic and heterocyclic groups are        optionally substituted with one or two substituents selected        from C₁₋₃ hydrocarbyl, fluorine, oxo and hydroxy;    -   R² and R⁴ are the same or different and each is selected from        hydrogen, fluorine, chlorine, C₁₋₂ alkyl and C₁₋₂ alkoxy,        wherein each C₁₋₂ alkyl and C₁₋₂ alkoxy is optionally        substituted with two or more fluorine atoms;    -   R³ is selected from hydrogen, fluorine, chlorine, C₁₋₂ alkyl and        C₁₋₂ alkoxy, wherein each C₁₋₂ alkyl and C₁₋₂ alkoxy is        optionally substituted with two or more fluorine atoms;    -   Ar¹ is a monocyclic 5 or 6-membered aryl or heteroaryl ring        containing 0, 1 or 2 heteroatom ring members selected from O, N        and S, the aryl or heteroaryl being optionally substituted with        1, 2 or 3 substituents R⁵ which are the same or different and        are selected from halogen, cyano and a group R^(a)-R^(b);        R^(a) is a bond, O, CO, X³C(X⁴), C(X⁴)X³, X³C(X⁴)X³, S, SO, SO₂,        NR^(c), SO₂NR^(c) or NR^(c)SO₂;        R^(b) is:    -   hydrogen;    -   a carbocyclic or heterocyclic group having from 3 to 7 ring        members, of which 0, 1, 2 or 3 are heteroatom ring members        selected from O, N and S and oxidised forms of S, the        carbocyclic or heterocyclic group being optionally substituted        with one or more substituents R⁶; and    -   an acyclic C₁₋₈ hydrocarbon group optionally substituted with        one or more substituents selected from hydroxy; oxo; halogen;        cyano; carboxy; amino; mono- or di-C₁₋₄ alkylamino; and        carbocyclic and heterocyclic groups having from 3 to 7 ring        members, of which 0, 1, 2 or 3 are heteroatom ring members        selected from O, N and S and oxidised forms of S, the        carbocyclic or heterocyclic group being optionally substituted        with one or more substituents R⁶; wherein one or two but not all        of the carbon atoms of the acyclic C₁₋₈ hydrocarbon group may        optionally be replaced by O, S, SO, SO₂, NR^(c), X³C(X⁴),        C(X⁴)X³ or X³C(X⁴)X³;        R⁶ is selected from the substituents R⁵ except that R⁶ does not        consist of or contain a carbocyclic or heterocyclic group;        X³ is O, S or NR^(c); and        X⁴ is ═O, ═S or ═NR^(c); and        R^(c) is hydrogen or C₁₋₄ hydrocarbyl;    -   Ar² is a bicyclic 8 to 11-membered heteroaryl group containing        1, 2, 3 or 4 heteroatom ring members selected from O, N and S        and being optionally substituted with 1, 2 or 3 substituents R⁷        selected from oxo, fluorine; chlorine; bromine; C₁₋₄ hydrocarbyl        optionally substituted with one or more fluorine atoms; C₁₋₄        hydrocarbyloxy optionally substituted with one or more fluorine        atoms; hydroxy; cyano; N(R^(c))₂; R^(c)—C(O)—;        R^(c)—C(O)N(R^(c))—; (R^(c))₂NC(O)—; R—SO₂NR^(c)—;        R^(c)—NHC(O)NH—; (R^(c))₂NSO₂—; and five and six-membered        monocyclic groups containing from 0 to 3 heteroatom ring members        selected from O, N and S, the five and six-membered monocyclic        groups being unsubstituted or substituted with one or more        substituents R⁸ selected from C₁₋₄ hydrocarbyl, C₁₋₄        hydrocarbyloxy, cyano, hydroxy, oxo, halogen, amino, mono-C₁₋₄        hydrocarbylamino and di-C₁₋₄hydrocarbylamino and wherein the        hydrocarbyl moieties when present are optionally substituted        with fluorine, C₁₋₂ alkoxy, hydroxy, amino,        mono-di-C₁₋₂alkylamino or di-C₁₋₄alkylamino;    -   and wherein, in each substituent consisting of or containing a        hydrocarbyl group, the hydrocarbyl group is selected from alkyl,        alkenyl, alkynyl and cycloalkyl groups and combinations thereof.

Particular and preferred compounds of the formula (1) are as defined inthe Embodiments 1.2 to 1.92 below.

1.2 A compound according to Embodiment 1.0 or 1.1 wherein Y is Ar² and Zis R³.

1.3 A compound according to Embodiment 1.0 or 1.1 wherein Y is R³ and Zis Ar².

1.4 A compound according to Embodiment 1.0 or 1.1 having the formula(2):

or a salt, tautomer or N-oxide thereof;wherein R¹, R², R³, R⁴, Ar¹, Ar², Q¹ and Q² are all as defined inEmbodiment 1.0 or 1.1.

1.4A A compound according to Embodiment 1.0 wherein Q¹ is a C₁₋₆alkylene group optionally substituted by one or two substituentsselected from hydroxy and C₁₋₄ hydrocarbyloxy, provided that when ahydroxy substituent is present, there are at least two carbon atomsbetween the hydroxy substituent and the nitrogen atom to which Q² isattached; and wherein a carbon atom of the C₁₋₆ alkylene group mayoptionally be replaced by a cyclopropane-1,1-diyl orcyclobutane-1,1-diyl group provided that the total number of carbonatoms in an alkylene group containing such a replacement does not exceed6.

1.4B A compound according to Embodiment 1.4A wherein Q¹ is a C₁₋₅alkylene group optionally substituted by one or two substituentsselected from hydroxy and C₁₋₄ hydrocarbyloxy, provided that when ahydroxy substituent is present, there are at least two carbon atomsbetween the hydroxy substituent and the nitrogen atom to which Q² isattached; and wherein a carbon atom of the C₁₋₅ alkylene group mayoptionally be replaced by a cyclopropane-1,1-diyl orcyclobutane-1,1-diyl group provided that the total number of carbonatoms in an alkylene group containing such a replacement does not exceed5.

1.4C A compound according to Embodiment 1.4B wherein Q¹ is a C₁₋₄alkylene group optionally substituted by one or two substituentsselected from hydroxy and C₁₋₄ hydrocarbyloxy, provided that when ahydroxy substituent is present, there are at least two carbon atomsbetween the hydroxy substituent and the nitrogen atom to which Q² isattached; and wherein a carbon atom of the C₁₋₄ alkylene group mayoptionally be replaced by a cyclopropane-1,1-diyl orcyclobutane-1,1-diyl group provided that the total number of carbonatoms in an alkylene group containing such a replacement does not exceed4.

1.4D A compound according to Embodiment 1.4C wherein Q¹ iscyclopropane-1,1-diyl.

1.4E A compound according to Embodiment 1.4C wherein Q¹ iscyclobutane-1,1-diyl.

1.5 A compound according to any one of Embodiments 1.0 to 1.4 wherein Q¹is C₁₋₆ alkylene optionally substituted by one or two substituentsselected from hydroxy and C₁₋₄ hydrocarbyloxy, provided that when ahydroxy substituent is present, there are at least two carbon atomsbetween the hydroxy substituent and the nitrogen atom to which Q² isattached.

1.6 A compound according to Embodiment 1.5 wherein Q¹ is C₁₋₄ alkyleneoptionally substituted by one or two substituents selected from hydroxyand C₁₋₄ hydrocarbyloxy, provided that when a hydroxy substituent ispresent, there are at least two carbon atoms between the hydroxysubstituent and the nitrogen atom to which Q² is attached.

1.7 A compound according to Embodiment 1.6 wherein the C₁₋₄ alkylene isoptionally substituted by one hydroxy substituent, provided that thereare at least two carbon atoms between the hydroxy substituent and thenitrogen atom to which Q² is attached.

1.8 A compound according to any one of Embodiments 1.0 to 1.4 wherein Q¹is a group of the formula —(CR^(f)R^(g))_(p)— wherein p is 1 to 8, eachR^(f) is independently selected from hydrogen and methyl, and each R^(g)is independently selected from hydrogen, C₁₋₄ alkyl andhydroxyl-C₁₋₄alkyl, provided that no more than one R^(G) may be largerthan methyl and provided that the total number of carbon atoms in—(CR^(f)R^(g))_(p)— does not exceed 8.

1.9 A compound according to Embodiment 1.8 wherein the total number ofcarbon atoms in —(CR^(f)R^(g))_(p)— is in the range 1 to 6.

1.10 A compound according to Embodiment 1.9 wherein the total number ofcarbon atoms in —(CR^(f)R^(g))_(p)— is in the range 1 to 4.

1.11 A compound according to any one of Embodiments 1.8 to 1.10 whereinp is 1 or 2.

1.12 A compound according to Embodiment 1.11 wherein p is 1.

1.13 A compound according to any one of Embodiments 1.8 to 1.12 whereinR^(f) is hydrogen and R^(g) is selected from hydrogen, methyl, ethyl,isopropyl and hydroxymethyl.

1.13A A compound according to any one of Embodiments 1.8 to 1.12 whereinR^(f) is hydrogen and R^(g) is selected from hydrogen, methyl, ethyl,isopropyl, hydroxymethyl and hydroxyethyl.

1.14 A compound according to Embodiment 1.13 wherein Q¹ is selected fromCH₂, CH(CH₃) and CH(CH₂OH).

1.14A A compound according to Embodiment 1.13A wherein Q¹ is selectedfrom CH₂, CH(CH₃), CH(CH₂OH) and CH(CH₂CH₂OH).

1.15 A compound according to Embodiment 1.13 wherein Q¹ is CH(CH₃).

1.16 A compound according to any one of Embodiments 1.0 to 1.4 whereinthe moiety —N(Q²-R¹)-Q¹-Ar¹ has the formula:

wherein R⁹ is hydrogen or a C₁₋₄ alkyl optionally substituted withhydroxyl.

1.17 A compound according to any one of Embodiments 1.0 to 1.4 whereinthe moiety -(Q²-R¹)N-Q¹-Ar¹ has the formula:

wherein R⁹ is hydrogen or a C₁₋₄ alkyl optionally substituted withhydroxyl.

1.18 A compound according to Embodiment 1.16 or 1.17 wherein R⁹ ishydrogen, methyl, ethyl, isopropyl or hydroxymethyl.

1.18A A compound according to Embodiment 1.16 or 1.17 wherein R⁹ ishydrogen, methyl, ethyl, isopropyl, hydroxymethyl or hydroxyethyl.

1.19 A compound according to Embodiment 1.18 wherein R⁹ is hydrogen,methyl or hydroxymethyl.

1.19A A compound according to Embodiment 1.18A wherein R⁹ is hydrogen,methyl, hydroxymethyl or hydroxyethyl.

1.20 A compound according to Embodiment 1.18 wherein R⁹ is hydrogen.

1.21 A compound according to Embodiment 1.18 wherein R⁹ is methyl.

1.22 A compound according to Embodiment 1.18 wherein R⁹ ishydroxymethyl.

1.22A A compound according to Embodiment 1.18 wherein R⁹ ishydroxyethyl.

1.23 A compound according to any one of Embodiments 1.0 to 1.22 whereinQ² is a bond or C₁₋₆ alkylene.

1.24 A compound according to Embodiment 1.23 wherein Q² is a bond orC₁₋₃ alkylene.

1.25 A compound according to Embodiment 1.24 wherein Q² is selected froma bond, CH₂, CH₂CH₂ and CH₂CH₂CH₂.

1.26 A compound according to Embodiment 1.25 wherein Q² is a bond, CH₂,or CH₂CH₂.

1.27 A compound according to Embodiment 1.26 wherein Q² is a bond.

1.28 A compound according to Embodiment 1.26 wherein Q² is CH₂.

1.29 A compound according to any one of Embodiments 1.0 to 1.28 whereinR¹ is selected from hydrogen and a group Cy¹.

1.30 A compound according to Embodiment 1.29 wherein R¹ is hydrogen.

1.31 A compound according to Embodiment 1.29 wherein R¹ is a group Cy¹.

1.32 A compound according to any one of Embodiments 1.0 to 1.29 and 1.31wherein Cy¹ is selected from C₃₋₇ cycloalkyl and C-linked 4 to 7membered non-aromatic heterocyclic groups containing 1 or 2 heteroatomring members selected from N, O and S, wherein the cycloalkyl andheterocyclic groups are optionally substituted with one or twosubstituents selected from C₁₋₃ hydrocarbyl, fluorine, oxo and hydroxy.

1.33 A compound according to Embodiment 1.32 wherein Cy¹ is selectedfrom C₃₋₆ cycloalkyl and C-linked 4 to 6 membered non-aromaticheterocyclic groups containing 1 or 2 heteroatom ring members selectedfrom O and S, wherein the cycloalkyl and heterocyclic groups areoptionally substituted with one or two substituents selected from C₁₋₃hydrocarbyl, fluorine, oxo and hydroxy.

1.34 A compound according to Embodiment 1.33 wherein Cy¹ is selectedfrom C₃₋₆ cycloalkyl and C-linked 4 to 6 membered saturated non-aromaticheterocyclic groups containing 1 heteroatom ring member selected from Oand S, wherein the cycloalkyl and heterocyclic groups are optionallysubstituted with one or two substituents selected from saturated C₁₋₃hydrocarbyl, fluorine, oxo and hydroxy.

1.35 A compound according to Embodiment 1.33 wherein Cy¹ is selectedfrom C₃₋₆ cycloalkyl and C-linked 4 to 6 membered saturated non-aromaticheterocyclic groups containing 1 heteroatom ring member selected from O,wherein the cycloalkyl and heterocyclic groups are optionallysubstituted with one or two substituents selected from C₁₋₃ alkyl,fluorine, oxo and hydroxy.

1.36 A compound according to Embodiment 1.33 wherein Cy¹ is selectedfrom C₃₋₆ cycloalkyl and C-linked 4 to 6 membered saturated non-aromaticheterocyclic groups containing 1 heteroatom ring member selected from O,wherein the cycloalkyl and heterocyclic groups are unsubstituted orsubstituted with one or two substituents selected from methyl, fluorine,oxo and hydroxy.

1.37 A compound according to Embodiment 1.33 wherein Cy¹ is selectedfrom cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydropyranand tetrahydrofuran.

1.38 A compound according to Embodiment 1.33 wherein Cy¹ istetrahydropyran.

1.39 A compound according to Embodiment 1.32 wherein Cy¹ is selectedfrom C-linked 4 to 7 membered non-aromatic heterocyclic groupscontaining a first ring member which is nitrogen and optionally a secondring member selected from N, O and S, wherein the heterocyclic groupsare optionally substituted with one or two substituents selected fromC₁₋₃ hydrocarbyl, fluorine, oxo and hydroxy.

1.40 A compound according to Embodiment 1.39 wherein Cy¹ is selectedfrom C-linked 4 to 7 membered saturated heterocyclic groups containing afirst ring member which is nitrogen and optionally a second ring memberselected from N, O and S, wherein the heterocyclic groups are optionallysubstituted with one or two substituents selected from saturated C₁₋₃hydrocarbyl, fluorine, oxo and hydroxy.

1.41 A compound according to Embodiment 1.40 wherein Cy¹ is selectedfrom C-linked 4 to 7 membered saturated heterocyclic groups containing afirst ring member which is nitrogen and optionally a second ring memberselected from N, O and S, wherein the heterocyclic groups are optionallysubstituted with one or two substituents selected from C₁₋₃ alkyl,cyclopropyl, fluorine and hydroxy.

1.42 A compound according to Embodiment 1.41 wherein Cy¹ is selectedfrom C-linked azetidine, pyrrolidine, piperidine, piperazine,morpholine, homomorpholine and thiomorpholine, each being optionallysubstituted with one or two substituents selected from C₁₋₃ alkyl,cyclopropyl, fluorine and hydroxy.

1.43 A compound according to Embodiment 1.41 wherein Cy¹ is C-linkedmorpholine.

1.44 A compound according to any one of Embodiments 1.0 to 1.28 whereinR¹ is NR^(x)R^(y).

1.45 A compound according to any one of Embodiments 1.0 to 1.28 and 1.44wherein R^(x) and R^(y) are the same or different and each is selectedfrom hydrogen, C₁₋₄ hydrocarbyl or hydroxy-C₁₋₄ hydrocarbyl.

1.46 A compound according to Embodiment 1.45 wherein R^(x) and R^(y) arethe same or different and each is selected from hydrogen, saturated C₁₋₄hydrocarbyl or saturated hydroxy-C₁₋₄ hydrocarbyl.

1.47 A compound according to Embodiment 1.46 wherein R^(x) and R^(y) arethe same or different and each is selected from hydrogen, C₁₋₄ alkyl,cyclopropyl, methylcyclopropyl, cyclopropylmethyl, and hydroxy-C₂₋₄alkyl.

1.48 A compound according to Embodiment 1.47 wherein R^(x) and R^(y) arethe same or different and each is selected from hydrogen and C₁₋₄ alkyl.

1.49 A compound according to Embodiment 1.48 wherein R^(x) and R^(y) arethe same or different and each is selected from hydrogen and C₁₋₃ alkyl.

1.50 A compound according to Embodiment 1.49 wherein NR^(x)R^(y) isselected from amino, methylamino and dimethylamino.

1.51 A compound according to Embodiment 1.49 wherein NR^(x)R^(y) isdimethylamino.

1.52 A compound according to any one of Embodiments 1.0 to 1.28 and 1.44wherein NR^(x)R^(y) forms a 4 to 7-membered heterocyclic ring containinga total of 1 or 2 heteroatom ring members of which one is N and theother is selected from N, O and S and oxidised forms thereof, theheterocyclic ring being optionally substituted with one or twosubstituents selected from C₁₋₄ hydrocarbyl, oxo, amino, mono-C₁₋₄hydrocarbylamino, di-C₁₋₄hydrocarbylamino, fluorine and hydroxy,provided that there are at least two carbon atoms in line between theamino, mono-C₁₋₄ hydrocarbylamino, di-C₁₋₄hydrocarbylamino and hydroxysubstituents when present and the nitrogen atom of the NR^(x)R^(y)group.

1.53 A compound according to Embodiment 1.52 wherein NR^(x)R^(y) forms a4 to 7-membered non-aromatic heterocyclic ring containing a total of 1or 2 heteroatom ring members of which one is N and the other is selectedfrom N, O and S, the heterocyclic ring being optionally substituted withone or two substituents selected from C₁₋₄ hydrocarbyl, oxo, amino,saturated mono-C₁₋₄ hydrocarbylamino, saturated di-C₁₋₄hydrocarbylamino, fluorine and hydroxy, provided that there are at leasttwo carbon atoms in line between the amino, saturated mono-C₁₋₄hydrocarbylamino, saturated di-C₁₋₄ hydrocarbylamino and hydroxysubstituents when present and the nitrogen atom of the NR^(x)R^(y)group.

1.54 A compound according to Embodiment 1.53 wherein NR^(x)R^(y) forms asaturated 4 to 7-membered heterocyclic ring containing a total of 1 or 2heteroatom ring members of which one is N and the other is selected fromN, O and S, the heterocyclic ring being optionally substituted with oneor two substituents selected from C₁₋₄ alkyl, fluorine, oxo, amino,mono-C₁₋₄ alkylamino, di-C₁₋₄alkylamino and hydroxy.

1.55 A compound according to Embodiment 1.54 wherein NR^(x)R^(y) forms asaturated 4 to 7-membered heterocyclic ring containing a total of 1 or 2heteroatom ring members of which one is N and the other is selected fromN, O and S, the heterocyclic ring being optionally substituted with oneor two substituents selected from C₁₋₃ alkyl, fluorine oxo, amino,mono-C₁₋₂ alkylamino, di-C₁₋₂alkylamino and hydroxy.

1.56 A compound according to Embodiment 1.55 wherein NR^(x)R^(y) forms asaturated 4 to 7-membered heterocyclic ring containing a total of 1 or 2heteroatom ring members of which one is N and the other is selected fromN, O and S, the heterocyclic ring being optionally substituted with oneor two substituents selected from methyl, fluorine, oxo, amino,methylamino, dimethylamino and hydroxy.

1.57 A compound according to Embodiment 1.55 wherein NR^(x)R^(y) forms aheterocyclic ring selected from azetidine, pyrrolidine, piperidine,piperazine, morpholine, homomorpholine and thiomorpholine, each beingoptionally substituted with one or two substituents selected from C₁₋₃alkyl, fluorine and hydroxy.

1.57 A compound according to Embodiment 1.55 wherein NR^(x)R^(y) forms aheterocyclic ring selected from azetidine, pyrrolidine, piperidine,piperazine, morpholine, homomorpholine and thiomorpholine, each beingoptionally substituted with one or two substituents selected from C₁₋₃alkyl, fluorine and hydroxy.

1.57A A compound according to any one of Embodiments 1.0 to 1.28 whereinR¹ is selected from:

-   -   hydrogen;    -   a group Cy¹ wherein Cy¹ is selected from 4 to 7 membered        saturated heterocyclic groups containing a first ring member        which is nitrogen and optionally a second ring member selected        from N, O and S, wherein the heterocyclic groups are optionally        substituted with one or two substituents selected from C₁₋₃        alkyl, cyclopropyl, fluorine and hydroxyl; and    -   NR^(x)R^(y), wherein R^(x) and R^(y) are the same or different        and each is selected from hydrogen, C₁₋₄ alkyl, cyclopropyl,        methylcyclopropyl, cyclopropylmethyl, and hydroxy-C₂₋₄ alkyl.

1.58 A compound according to any one of Embodiments 1.0 to 1.57A whereinR² is selected from hydrogen, fluorine, chlorine, methyl, methoxy,trifluoromethyl and trifluoromethoxy.

1.59 A compound according to Embodiment 1.58 wherein R² is hydrogen.

1.60 A compound according to any one of Embodiments 1.0 to 1.59 whereinR³ is selected from hydrogen, fluorine, chlorine, methyl, methoxy,trifluoromethyl and trifluoromethoxy.

1.61 A compound according to Embodiment 1.60 wherein R³ is hydrogen.

1.62 A compound according to any one of Embodiments 1.0 to 1.61 whereinR⁴ is selected from hydrogen, fluorine, chlorine, methyl, methoxy,trifluoromethyl and trifluoromethoxy.

1.63 A compound according to Embodiment 1.62 wherein R⁴ is hydrogen.

1.64 A compound according to any one of Embodiments 1.0 to 1.63 whereinAr¹ is a monocyclic aryl or heteroaryl ring selected from phenyl, furyl,thienyl, pyridyl and pyrimidinyl, each optionally substituted with 1, 2or 3 substituents R⁵ which are the same or different and are as definedin Embodiment 1.1.

1.65 A compound according to Embodiment 1.64 wherein Ar¹ is a monocyclicaryl or heteroaryl ring selected from phenyl, furyl, thienyl andpyridyl, each optionally substituted with 1, 2 or 3 substituents R⁵which are the same or different and are as defined in Embodiment 1.1.

1.66 A compound according to Embodiment 1.65 wherein Ar¹ is a phenylring optionally substituted with 1, 2 or 3 substituents R⁵ which are thesame or different and are as defined in Embodiment 1.1.

1.67 A compound according to any one of Embodiments 1.0 to 1.66 whereinAr¹ is unsubstituted or substituted with 1, 2 or 3 substituents R⁵ whichare the same or different and are selected from fluorine, chlorine,bromine, cyano and a group R^(a)—R^(b);

R^(a) is a bond, O, CO, NR^(c)C(═O), C(═O)NR^(c), NR^(c)C(═O)NR, C(═O)O, OC(═O), S, SO, SO₂, NR^(c), SO₂NR^(c) or NR^(c)SO₂;

R^(b) is:

-   -   hydrogen;    -   a carbocyclic or heterocyclic group having from 3 to 7 ring        members, of which 0, 1, 2 or 3 are heteroatom ring members        selected from O, N and S and oxidised forms of S, the        carbocyclic or heterocyclic group being optionally substituted        with one or more substituents R⁶; and    -   an acyclic C₁₋₈ hydrocarbon group optionally substituted with        one or more substituents selected from hydroxy; oxo; halogen;        cyano; amino; mono- or di-C₁₋₄ alkylamino; and carbocyclic and        heterocyclic groups having from 3 to 7 ring members, of which 0,        1, 2 or 3 are heteroatom ring members selected from O, N and S        and oxidised forms of S, the carbocyclic or heterocyclic group        being optionally substituted with one or more substituents R⁶;        wherein one or two but not all of the carbon atoms of the        acyclic C₁₋₈ hydrocarbon group may optionally be replaced by O,        S, SO, SO₂ or NR^(c);        R⁶ is selected from the substituents R⁵ except that R⁶ does not        consist of or contain a carbocyclic or heterocyclic group; and        R^(c) is hydrogen or C₁₋₄ hydrocarbyl.

1.68 A compound according to Embodiment 1.67 wherein Ar¹ isunsubstituted or substituted with 1, 2 or 3 substituents R⁵ which arethe same or different and are selected from fluorine, chlorine, bromine,cyano and a group R^(a)—R^(b);

R^(a) is a bond, O, CO, NR^(c)C(═O), C(═O)NR^(c), NR^(c)C(═O)NR, C(═O)O, OC(═O), S, SO, SO₂, NR^(c), SO₂NR^(c) or NR^(c)SO₂;

R^(b) is:

-   -   hydrogen;    -   a non-aromatic carbocyclic or heterocyclic group having from 3        to 6 ring members, of which 0, 1 or 2 are heteroatom ring        members selected from O, N, S and SO₂, the non-aromatic        carbocyclic or heterocyclic group being optionally substituted        with one or more substituents R⁶; and    -   an acyclic C₁₋₈ hydrocarbon group optionally substituted with        one or more substituents selected from hydroxy; oxo; halogen;        cyano; amino; mono- or di-C₁₋₄ alkylamino; and non-aromatic        carbocyclic and heterocyclic groups having from 3 to 6 ring        members, of which 0, 1 or 2 are heteroatom ring members selected        from O, N, S and SO₂, the carbocyclic or heterocyclic group        being optionally substituted with one or more substituents R⁶;        wherein one or two but not all of the carbon atoms of the        acyclic C₁₋₈ hydrocarbon group may optionally be replaced by O,        S, SO, SO₂ or NR^(c);        R⁶ is selected from the substituents R⁵ except that R⁶ does not        consist of or contain a carbocyclic or heterocyclic group; and        R^(c) is hydrogen or C₁₋₄ hydrocarbyl.

1.69 A compound according to Embodiment 1.68 wherein Ar¹ isunsubstituted or substituted with 1, 2 or 3 substituents R⁵ which arethe same or different and are selected from fluorine, chlorine, bromine,cyano and a group R^(a)—R^(b);

R^(a) is a bond, O, CO, NR^(c)C(═O), C(═O)NR^(c), SO₂, NR^(c), SO₂NR^(c)or NR^(c)SO₂;

R^(b) is:

-   -   hydrogen;    -   a non-aromatic carbocyclic or heterocyclic group having from 3        to 6 ring members, of which 0, 1 or 2 are heteroatom ring        members selected from O, N and S, the non-aromatic carbocyclic        or heterocyclic group being optionally substituted with one or        more substituents R⁶; and    -   a saturated acyclic C₁₋₈ hydrocarbon group optionally        substituted with one or more substituents selected from hydroxy;        oxo; fluorine; cyano; amino; mono- or di-C₁₋₂ alkylamino; and        non-aromatic carbocyclic and heterocyclic groups having from 3        to 6 ring members, of which 0, 1 or 2 are heteroatom ring        members selected from O, N and S and oxidised forms of S, the        carbocyclic or heterocyclic group being optionally substituted        with one or more substituents R⁶; wherein one or two but not all        of the carbon atoms of the acyclic C₁₋₈ hydrocarbon group may        optionally be replaced by O or NR^(c);        R⁶ is selected from the substituents R⁵ except that R⁶ does not        consist of or contain a carbocyclic or heterocyclic group; and        R^(c) is hydrogen, C₁₋₄ alkyl, cyclopropyl or cyclopropylmethyl.

1.70 A compound according to any one of Embodiments 1.0 to 1.66 whereinAr¹ is unsubstituted or is substituted with 1, 2 or 3 substituents R⁵selected from a group L¹-Cy²; fluorine; chlorine; bromine; C₁₋₃ alkyl;C₁₋₃ alkoxy; trifluoromethyl; difluoromethyl; hydroxy; cyano;trifluoromethoxy; difluoromethoxy; amino; mono-C₁₋₃ alkylamino; di-C₁₋₃alkylamino; C₁₋₃ alkanoyl; C₁₋₃ alkanoylamino; carbamoyl; mono-C₁₋₃alkyl carbamoyl; di-C₁₋₃ alkyl carbamoyl; a group O—(CH₂)_(k)—OR¹⁰; anda group O_(m)—(CH₂)_(n)—NR¹¹R¹²; R¹⁰ is hydrogen or C₁₋₃ alkyl; R¹¹ ishydrogen or C₁₋₃ alkyl; R¹² is hydrogen or C₁₋₃ alkyl; k is 2, 3 or 4; mis 0 or 1; and n is 1, 2, 3 or 4 provided that when m is 1 then n is 2,3 or 4; L¹ is a bond or a linker group selected from C₁₋₄ alkylene,—(CH₂)_(p)—NH—(CH₂)_(q)—, —(CH₂)_(p)—N(CH₃)—(CH₂)_(q)—,—(CH₂)_(p)—C(═O)—(CH₂)_(q)—, —(CH₂)_(p)—C(═O)NH—(CH₂)_(q)—,—(CH₂)_(p)—C(═O)N(CH₃)—(CH₂)_(q)—, —(CH₂)_(p)—NHC(═O)—(CH₂)_(q)— and—(CH₂)_(p)—N(CH₃)C(═O)—(CH₂)_(q)—; p and q are each independently 0, 1,2 or 3 provided that the total of p and q does not exceed 4; and Cy² isa non-aromatic carbocyclic or heterocyclic ring of three to seven ringmembers, containing 0, 1 or 2 heteroatom ring members selected from O, Nand S and being optionally substituted by one, two or three substituentsselected from hydroxy, C₁₋₄ hydrocarbyl, C₁₋₄ hydrocarbyl-C(═O), oxo,amino, mono-C₁₋₄ hydrocarbylamino, di-C₁₋₄ hydrocarbylamino andfluorine.

1.70A A compound according to any one of Embodiments 1.0 to 1.66 whereinAr¹ is unsubstituted or is substituted with 1, 2 or 3 substituents R⁵selected from a group L¹-Cy²; fluorine; chlorine; bromine; C₁₋₃ alkyl;C₁₋₃ alkoxy; trifluoromethyl; difluoromethyl; hydroxy; cyano;trifluoromethoxy; difluoromethoxy; amino; mono-C₁₋₃ alkylamino; di-C₁₋₃alkylamino; C₁₋₃ alkanoyl; C₁₋₃ alkylsulphonylamino; C₁₋₃ alkanoylamino;carbamoyl; mono-C₁₋₃ alkyl carbamoyl; di-C₁₋₃ alkyl carbamoyl; a groupO—(CH₂)_(k)—OR¹⁰; and a group O_(m)—(CH₂)_(n)—NR¹¹R¹²; R¹⁰ is hydrogenor C₁₋₃ alkyl; R¹¹ is hydrogen or C₁₋₃ alkyl; R¹² is hydrogen or C₁₋₃alkyl; k is 2, 3 or 4; m is 0 or 1; and n is 1, 2, 3 or 4 provided thatwhen m is 1 then n is 2, 3 or 4; L¹ is a bond or a linker group selectedfrom C₁₋₄ alkylene, —(CH₂)_(p)—NH—(CH₂)_(q)—,—(CH₂)_(p)—N(CH₃)—(CH₂)_(q)—, —(CH₂)_(p)—C(═O)—(CH₂)_(q)—,—(CH₂)_(p)—C(═O)NH—(CH₂)_(q)—, —(CH₂)_(p)—C(═O)N(CH₃)—(CH₂)_(q)—,—(CH₂)_(p)—NHC(═O)—(CH₂)_(q)— and —(CH₂)_(p)—N(CH₃)C(═O)—(CH₂)_(q)—; pand q are each independently 0, 1, 2 or 3 provided that the total of pand q does not exceed 4; and Cy² is a non-aromatic carbocyclic orheterocyclic ring of three to seven ring members, containing 0, 1 or 2heteroatom ring members selected from O, N and S and being optionallysubstituted by one, two or three substituents selected from hydroxy,C₁₋₄ hydrocarbyl, C₁₋₄ hydrocarbyl-C(═O), oxo, amino, mono-C₁₋₄hydrocarbylamino, di-C₁₋₄ hydrocarbylamino and fluorine.

1.71 A compound according to Embodiment 1.70 wherein Ar¹ isunsubstituted or is substituted with 1, 2 or 3 substituents R⁵ selectedfrom a group L¹-Cy²; fluorine; chlorine; bromine; C₁₋₃ alkyl; C₁₋₃alkoxy; trifluoromethyl; difluoromethyl; hydroxy; cyano;trifluoromethoxy; difluoromethoxy; amino; mono-C₁₋₃ alkylamino; di-C₁₋₃alkylamino; C₁₋₃ alkanoyl; C₁₋₃ alkanoylamino; carbamoyl; mono-C₁₋₃alkyl carbamoyl; di-C₁₋₃ alkyl carbamoyl; a group O—(CH₂)_(k)—OR¹⁰; anda group O_(m)—(CH₂)_(n)—NR¹¹R¹²; R¹⁰ is hydrogen, methyl or ethyl; R¹¹is hydrogen, methyl or ethyl; R¹² is hydrogen, methyl; or ethyl; k is 2or 3; m is 0 or 1; and n is 1, 2 or 3 provided that when m is 1 then nis 2 or 3; L¹ is a bond or a linker group selected from C₁₋₄ alkylene,—(CH₂)_(p)—NH—(CH₂)_(q)—, —(CH₂)_(p)—N(CH₃)—(CH₂)_(q)—,—(CH₂)_(p)—C(═O)—(CH₂)_(q)—, —(CH₂)_(p)—C(═O)NH—(CH₂)_(q)—,—(CH₂)_(p)—C(═O)N(CH₃)—(CH₂)_(q)—, —(CH₂)_(p)—NHC(═O)—(CH₂)_(q)— and—(CH₂)_(p)—N(CH₃)C(═O)—(CH₂)_(q)—; p and q are each independently 0, 1or 2; and Cy² is a non-aromatic carbocyclic ring of three to six ringmembers or a heterocyclic ring of five or six ring members, containing 1or 2 heteroatom ring members selected from O, N and S, the carbocyclicand heterocyclic rings each being optionally substituted by one, two orthree substituents selected from hydroxy, C₁₋₄ alkyl, cyclopropyl,cyclopropylmethyl, C₁₋₄ alkanoyl, cyclopropylcarbonyl, oxo and fluorine.

1.71A A compound according to Embodiment 1.70A wherein Ar¹ isunsubstituted or is substituted with 1, 2 or 3 substituents R⁵ selectedfrom a group L¹-Cy²; fluorine; chlorine; bromine; C₁₋₃ alkyl; C₁₋₃alkoxy; trifluoromethyl; difluoromethyl; hydroxy; cyano;trifluoromethoxy; difluoromethoxy; amino; mono-C₁₋₃ alkylamino; di-C₁₋₃alkylamino; C₁₋₃ alkanoyl; C₁₋₃ alkylsulphonylamino; C₁₋₃ alkanoylamino;carbamoyl; mono-C₁₋₃ alkyl carbamoyl; di-C₁₋₃ alkyl carbamoyl; a groupO—(CH₂)_(k)—OR¹⁰; and a group O_(m)—(CH₂)_(n)—NR¹¹R¹²; R¹⁰ is hydrogen,methyl or ethyl; R¹¹ is hydrogen, methyl or ethyl; R¹² is hydrogen,methyl; or ethyl; k is 2 or 3; m is 0 or 1; and n is 1, 2 or 3 providedthat when m is 1 then n is 2 or 3; L¹ is a bond or a linker groupselected from C₁₋₄ alkylene, —(CH₂)_(p)—NH—(CH₂)_(q)—,—(CH₂)_(p)—N(CH₃)—(CH₂)_(q)—, —(CH₂)_(p)—C(═O)—(CH₂)_(q)—,—(CH₂)_(p)—C(═O)NH—(CH₂)_(q)—, —(CH₂)_(p)—C(═O)N(CH₃)—(CH₂)_(q)—,—(CH₂)_(p)—NHC(═O)—(CH₂)_(q)— and —(CH₂)_(p)—N(CH₃)C(═O)—(CH₂)_(q)—; pand q are each independently 0, 1 or 2; and Cy² is a non-aromaticcarbocyclic ring of three to six ring members or a heterocyclic ring offive or six ring members, containing 1 or 2 heteroatom ring membersselected from O, N and S, the carbocyclic and heterocyclic rings eachbeing optionally substituted by one, two or three substituents selectedfrom hydroxy, C₁₋₄ alkyl, cyclopropyl, cyclopropylmethyl, C₁₋₄ alkanoyl,cyclopropylcarbonyl, oxo and fluorine.

1.72 A compound according to Embodiment 1.71 wherein Ar¹ isunsubstituted or is substituted with 1, 2 or 3 substituents R⁵ selectedfrom a group L¹-Cy²; fluorine; chlorine; bromine; C₁₋₃ alkyl; C₁₋₃alkoxy; trifluoromethyl; difluoromethyl; hydroxy; cyano;trifluoromethoxy; difluoromethoxy; amino; mono-C₁₋₂ alkylamino; di-C₁₋₂alkylamino; C₁₋₃ alkanoyl; C₂₋₃ alkanoylamino; carbamoyl; mono-C₁₋₃alkyl carbamoyl; di-C₁₋₃ alkyl carbamoyl; a group O—(CH₂)_(k)—OR¹⁰; anda group O_(m)—(CH₂)_(n)—NR¹¹R¹²; R¹⁰ is hydrogen, methyl or ethyl; R¹¹is hydrogen, methyl or ethyl; R¹² is hydrogen, methyl; or ethyl; k is 2or 3; m is 0 or 1; and n is 1, 2 or 3 provided that when m is 1 then nis 2 or 3; L¹ is a bond or a linker group selected from C₁₋₄ alkylene,—(CH₂)_(p)—NH—(CH₂)_(q)—, —(CH₂)_(p)—N(CH₃)—(CH₂)_(q)—,—(CH₂)_(p)—C(═O)—(CH₂)_(q)—, —(CH₂)_(p)—C(═O)NH—(CH₂)_(q)—,—(CH₂)_(p)—C(═O)N(CH₃)—(CH₂)_(q)—, —(CH₂)_(p)—NHC(═O)—(CH₂)_(q)— and—(CH₂)_(p)—N(CH₃)C(═O)—(CH₂)_(q)—; p and q are each independently 0 or1; and Cy² is a non-aromatic heterocyclic ring selected from azetidine,pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine,tetrahydrofuran, and tetrahydropyran, the heterocyclic ring beingoptionally substituted by one or two substituents selected from hydroxy,C₁₋₄ alkyl, cyclopropyl, cyclopropylmethyl, C₁₋₄ alkanoyl,cyclopropylcarbonyl, oxo and fluorine.

1.72A A compound according to Embodiment 1.71A wherein Ar¹ isunsubstituted or is substituted with 1, 2 or 3 substituents R⁵ selectedfrom a group L¹-Cy²; fluorine; chlorine; bromine; C₁₋₃ alkyl; C₁₋₃alkoxy; trifluoromethyl; difluoromethyl; hydroxy; cyano;trifluoromethoxy; difluoromethoxy; amino; mono-C₁₋₂ alkylamino; di-C₁₋₂alkylamino; C₁₋₃ alkanoyl; C₁₋₂ alkylsulphonylamino; C₂₋₃ alkanoylamino;carbamoyl; mono-C₁₋₃ alkyl carbamoyl; di-C₁₋₃ alkyl carbamoyl; a groupO—(CH₂)_(k)—OR¹⁰; and a group O_(m)—(CH₂)_(n)—NR¹¹R¹²; R¹⁰ is hydrogen,methyl or ethyl; R¹¹ is hydrogen, methyl or ethyl; R¹² is hydrogen,methyl; or ethyl; k is 2 or 3; m is 0 or 1; and n is 1, 2 or 3 providedthat when m is 1 then n is 2 or 3; L¹ is a bond or a linker groupselected from C₁₋₄ alkylene, —(CH₂)_(p)—NH—(CH₂)_(q)—,—(CH₂)_(p)—N(CH₃)—(CH₂)_(q)—, —(CH₂)_(p)—C(═O)—(CH₂)_(q)—,—(CH₂)_(p)—C(═O)NH—(CH₂)_(q)—, —(CH₂)_(p)—C(═O)N(CH₃)—(CH₂)_(q)—,—(CH₂)_(p)—NHC(═O)—(CH₂)_(q)— and —(CH₂)_(p)—N(CH₃)C(═O)—(CH₂)_(q)—; pand q are each independently 0 or 1; and Cy² is a non-aromaticheterocyclic ring selected from azetidine, pyrrolidine, piperidine,piperazine, morpholine, thiomorpholine, tetrahydrofuran, andtetrahydropyran, the heterocyclic ring being optionally substituted byone or two substituents selected from hydroxy, C₁₋₄ alkyl, cyclopropyl,cyclopropylmethyl, C₁₋₄ alkanoyl, cyclopropylcarbonyl, oxo and fluorine.

1.73 A compound according to Embodiment 1.72 wherein Ar¹ isunsubstituted or is substituted with 1, 2 or 3 substituents R⁵ selectedfrom a group L¹-Cy²; fluorine; chlorine; bromine; C₁₋₂ alkyl; C₁₋₂alkoxy; trifluoromethyl; difluoromethyl; hydroxy; cyano;trifluoromethoxy; difluoromethoxy; amino; mono-C₁₋₂ alkylamino; di-C₁₋₂alkylamino; acetyl; acetylamino; carbamoyl; mono-C₁₋₂ alkyl carbamoyl;di-C₁₋₂ alkyl carbamoyl; dimethylaminoethoxy; wherein L₁ is selectedfrom a bond, O, NH, N(CH₃), NHC(═O), C(═O)NH, N(CH₃)C(═O) andC(═O)N(CH₃); and Cy² is selected from piperidine, piperazine, morpholineand tetrahydropyran, the heterocyclic ring being optionally substitutedby one or two substituents selected from hydroxy, methyl and oxo.

1.73A A compound according to Embodiment 1.72A wherein Ar¹ isunsubstituted or is substituted with 1, 2 or 3 substituents R⁵ selectedfrom a group L¹-Cy²; fluorine; chlorine; bromine; C₁₋₂ alkyl; C₁₋₂alkoxy; trifluoromethyl; difluoromethyl; hydroxy; cyano;trifluoromethoxy; difluoromethoxy; C₁₋₂ alkylsulphonylamino; amino;mono-C₁₋₂ alkylamino; di-C₁₋₂ alkylamino; acetyl; acetylamino;carbamoyl; mono-C₁₋₂ alkyl carbamoyl; di-C₁₋₂ alkyl carbamoyl;dimethylaminoethoxy; wherein L₁ is selected from a bond, O, NH, N(CH₃),NHC(═O), C(═O)NH, N(CH₃)C(═O) and C(═O)N(CH₃); and Cy² is selected frompiperidine, piperazine, morpholine and tetrahydropyran, the heterocyclicring being optionally substituted by one or two substituents selectedfrom hydroxy, methyl and oxo.

1.74 A compound according to Embodiment 1.73 wherein Ar¹ isunsubstituted or substituted with 1, 2 or 3 substituents R⁵ selectedfrom fluorine, chlorine, bromine, methyl, hydroxy, methoxy,trifluoromethyl, difluoromethyl, cyano, trifluoromethoxy,difluoromethoxy, morpholinyl, piperazinyl, N-methylpiperazinyl anddimethylaminoethoxy.

1.74A A compound according to Embodiment 1.73A wherein Ar¹ isunsubstituted or substituted with 1, 2 or 3 substituents R⁵ selectedfrom fluorine, chlorine, bromine, methyl, hydroxy, methoxy,trifluoromethyl, difluoromethyl, cyano, trifluoromethoxy,difluoromethoxy, methylsulphonylamino, morpholinyl, piperazinyl,N-methylpiperazinyl and dimethylaminoethoxy.

1.75 A compound according to any one of Embodiments 1.0 to 1.66 whereinAr¹ is unsubstituted or substituted with 1, 2 or 3 substituents R⁵selected from L¹-Cy²; fluorine, chlorine, methyl, hydroxy, methoxy,trifluoromethyl, difluoromethyl, trifluoromethoxy anddimethylaminoethoxy; wherein L₁ is selected from a bond, 0, NH, NHC(═O),C(═O)NH and C(═O)N(CH₃); and Cy² is selected from piperidine,piperazine, morpholine and tetrahydropyran, the heterocyclic ring beingoptionally substituted by one or two substituents selected from methyland oxo.

1.75A A compound according to any one of Embodiments 1.0 to 1.66 whereinAr¹ is unsubstituted or substituted with 1, 2 or 3 substituents R⁵selected from L¹-Cy²; fluorine, chlorine, methyl, hydroxy, methoxy,trifluoromethyl, difluoromethyl, trifluoromethoxy, methylsulphonylaminoand dimethylaminoethoxy; wherein L₁ is selected from a bond, 0, NH,NHC(═O), C(═O)NH and C(═O)N(CH₃); and Cy² is selected from piperidine,piperazine, morpholine and tetrahydropyran, the heterocyclic ring beingoptionally substituted by one or two substituents selected from methyland oxo.

1.76 A compound according to Embodiment 1.75 wherein Ar¹ isunsubstituted or substituted with 1, 2 or 3 substituents R⁵ selectedfrom fluorine, chlorine, bromine, methyl, methoxy, trifluoromethyl,difluoromethyl, cyano, trifluoromethoxy and difluoromethoxy.

1.76A A compound according to Embodiment 1.75A wherein Ar¹ isunsubstituted or substituted with 1, 2 or 3 substituents R⁵ selectedfrom fluorine, chlorine, bromine, methyl, hydroxyl, methoxy,methylsulphonylamino, trifluoromethyl, difluoromethyl, cyano,trifluoromethoxy and difluoromethoxy.

1.77 A compound according to Embodiment 1.76 wherein Ar¹ isunsubstituted or substituted with 1, 2 or 3 substituents R⁵ selectedfrom fluorine, chlorine, methyl, methoxy, trifluoromethyl andtrifluoromethoxy.

1.77A A compound according to Embodiment 1.76A wherein Ar¹ isunsubstituted or substituted with 1, 2 or 3 substituents R⁵ selectedfrom fluorine, chlorine, methyl, hydroxyl, methoxy,methylsulphonylamino, trifluoromethyl and trifluoromethoxy.

1.78 A compound according to Embodiment 1.77 wherein Ar¹ isunsubstituted or substituted with 1, 2 or 3 substituents R⁵ selectedfrom fluorine, chlorine, methyl and methoxy.

1.78A A compound according to Embodiment 1.77A wherein Ar¹ isunsubstituted or substituted with 1, 2 or 3 substituents R⁵ selectedfrom fluorine, chlorine, methylsulphonylamino, methyl and methoxy.

1.79 A compound according to Embodiment 1.78 wherein Ar¹ isunsubstituted or substituted with 1, 2 or 3 substituents R⁵ selectedfrom fluorine, chlorine and methoxy.

1.80 A compound according to any one of Embodiments 1.0 to 1.79 whereinAr¹ is unsubstituted or substituted with one or two substituents R⁵.

1.81 A compound according to Embodiment 1.80 wherein Ar¹ isunsubstituted or substituted with one substituent R⁵.

1.82 A compound according to Embodiment 1.81 wherein Ar¹ isunsubstituted.

1.83 A compound according to Embodiment 1.81 wherein Ar¹ is substitutedwith one substituent R⁵.

1.84 A compound according to Embodiment 1.80 wherein Ar¹ is a phenylring which is unsubstituted or is substituted with one or twosubstituents R⁵ wherein at least one substituent R⁵ is present at themeta- or para-position of the phenyl ring.

1.85 A compound according to Embodiment 1.84 wherein Ar¹ is a phenylring which is substituted with one substituent R⁵ which is present atthe meta-position of the phenyl ring.

1.86 A compound according to Embodiment 1.84 wherein Ar¹ is a phenylring which is substituted with one substituent R⁵ which is present atthe para-position of the phenyl ring.

1.87 A compound according to Embodiment 1.84 wherein Ar¹ is a phenylring which is unsubstituted or is substituted with one substituent R⁵selected from 3-chloro, 4-chloro, 3-fluoro, 4-fluoro, 3-methoxy,4-methoxy, 3-methyl and 4-methyl.

1.88 A compound according to Embodiment 1.87 wherein Ar¹ is a phenylring which is unsubstituted or is substituted with one substituent R⁵selected from 3-chloro, 3-fluoro, 4-fluoro and 3-methoxy.

1.89 A compound according to Embodiment 1.84 wherein Ar¹ is a phenylring which is substituted with two substituents R⁵.

1.90 A compound according to Embodiment 1.89 wherein Ar¹ is a phenylring which is substituted with two substituents R⁵, wherein onesubstituent is present at the para-position of the phenyl ring and theother is present at the meta-substituent of the phenyl ring.

1.91 A compound according to Embodiment 1.90 wherein Ar¹ is3,4-difluorophenyl.

1.91A A compound according to Embodiment 1.82 wherein Ar¹ isunsubstituted phenyl.

1.91B A compound according to Embodiment 1.66 wherein Ar¹ isunsubstituted phenyl or phenyl substituted with one or two substituentsselected from fluorine, chlorine, methoxy, methylsulphonylamino andhydroxyl.

1.91C A compound according to Embodiment 1.66 wherein Ar¹ isunsubstituted phenyl or phenyl substituted with one or two substituentsselected from fluorine, chlorine, methoxy and methylsulphonylamino.

1.91D A compound according to Embodiment 1.66 wherein Ar¹ is selectedfrom unsubstituted phenyl, 3-chlorophenyl, 2-fluorophenyl,3-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 2,6-difluorophenyl,3,4-difluorophenyl, 3-methoxyphenyl, 3-methylsulphonylaminophenyl,2-hydroxyphenyl, 3-hydroxyphenyl and 4-hydroxyphenyl.

1.91E A compound according to Embodiment 1.66 wherein Ar¹ is selectedfrom unsubstituted phenyl, 3-chlorophenyl, 2-fluorophenyl,3-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 2,6-difluorophenyl,3,4-difluorophenyl, 3-methoxyphenyl, 3-methylsulphonylaminophenyl,2-hydroxyphenyl, 3-hydroxyphenyl and 4-hydroxyphenyl

1.92 A compound according to any one of Embodiments 1.0 to 1.91 whereinAr² is selected from 5.6 fused heteroaromatic rings and 6.6 fusedheteroaromatic rings, each containing 1, 2, 3 or 4 heteroatom ringmembers selected from N, O and S and being optionally substituted by 1,2, or 3 substituents R⁷ as defined in Embodiment 1.1.

1.93 A compound according to Embodiment 1.92 wherein the 5.6 fusedheteroaromatic rings and 6.6 fused heteroaromatic rings each contain 1,2, 3 or 4 nitrogen heteroatom ring members.

1.94 A compound according to Embodiment 1.92 or 1.93 wherein Ar² isselected from 5.6 fused heteroaromatic rings, each being optionallysubstituted by 1, 2 or 3 substituents R⁷ as defined in Embodiment 1.1.

1.95 A compound according to Embodiment 1.94 wherein Ar² is selectedfrom pyrimido-imidazole, pyrido-imidazole, pyrimido-pyrrole,pyrido-pyrrole, benzo-imidazole, benzo-pyrrole, pyrimido-pyrazole,pyrido-pyrazole and benzo-pyrazole groups, each being optionallysubstituted by 1, 2 or 3 substituents R⁷ as defined in Embodiment 1.1.

1.95A A compound according to Embodiment 1.95 wherein Ar² is selectedfrom pyrimido-pyrrole, pyrido-pyrrole, pyrimido-pyrazole,pyrido-pyrazole groups and pyrimido-imidazole groups, each optionallysubstituted by 1, 2 or 3 substituents R⁷ as defined in Embodiment 1.1.

1.96 A compound according to Embodiment 1.95 wherein Ar² is selectedfrom pyrimido-pyrrole, pyrido-pyrrole, pyrimido-pyrazole andpyrido-pyrazole groups, each optionally substituted by 1, 2 or 3substituents R⁷ as defined in Embodiment 1.1.

1.97 A compound according to Embodiment 1.96 wherein Ar² is apyrimido-pyrazole group, which is optionally substituted by 1, 2 or 3substituents R⁷ as defined in Embodiment 1.1.

1.98 A compound as defined in any one of Embodiments 1.0 to 1.97 whereinAr² is unsubstituted or is substituted with one or two substituents R⁷selected from oxo, fluorine; chlorine; bromine; C₁₋₄ hydrocarbyloptionally substituted with one or more fluorine atoms; C₁₋₄hydrocarbyloxy optionally substituted with one or more fluorine atoms;hydroxy; cyano; and five and six-membered monocyclic groups containingfrom 0 to 3 heteroatom ring members selected from O, N and S, the fiveand six-membered monocyclic groups being unsubstituted or substitutedwith one or more substituents R⁸ selected from C₁₋₄ hydrocarbyl, C₁₋₄hydrocarbyloxy, cyano, hydroxy, oxo, halogen, amino, mono-C₁₋₄hydrocarbylamino and di-C₁₋₄hydrocarbylamino.

1.99 A compound as defined in Embodiment 1.98 wherein Ar² isunsubstituted or is substituted with one or two substituents R⁷ selectedfrom oxo, fluorine; chlorine; bromine; C₁₋₄ alkyl optionally substitutedwith one or more fluorine atoms; C₁₋₄ alkoxy optionally substituted withone or more fluorine atoms; hydroxy; cyano; and five and six-memberedmonocyclic groups selected from phenyl, pyridyl, pyrimidinyl,pyridazinyl, pyrazinyl, pyrrole, pyrazole, imidazole, thiophene, furan,oxazole and isoxazole, the five and six-membered monocyclic groups eachbeing unsubstituted or substituted with one or more substituents R⁸selected from C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano, hydroxy, fluorine,chlorine, amino, methylamino and dimethylamino.

1.100 A compound as defined in Embodiment 1.99 wherein Ar² isunsubstituted or is substituted with one or two substituents R⁷ selectedfrom oxo, fluorine; chlorine; bromine; C₁₋₄ alkyl optionally substitutedwith one or more fluorine atoms; C₁₋₄ alkoxy optionally substituted withone or more fluorine atoms; hydroxy and cyano.

1.101 A compound as defined in Embodiment 1.100 wherein Ar² isunsubstituted or is substituted with one or two substituents R⁷ selectedfrom oxo, methyl, difluoromethyl, trifluoromethyl, amino, hydroxy andcyano.

1.102 A compound as defined in any one of Embodiments 1.0 to 1.101wherein Ar² is unsubstituted or is mono-substituted.

1.103 A compound as defined in Embodiment 1.102 wherein Ar² isunsubstituted or is mono-substituted with one substituent R⁷ selectedfrom methyl and amino.

1.103AA compound as defined in Embodiment 1.102 wherein Ar² isunsubstituted or is mono-substituted with one substituent R⁷ selectedfrom methyl and cyano.

1.104 A compound as defined in Embodiment 1.103 wherein Ar² isunsubstituted or is substituted with one substituent R⁷ which is methyl.

1.105 A compound as defined in Embodiment 1.104 wherein Ar² isunsubstituted.

1.106 A compound as defined in any one of Embodiments 1.0 to 1.105wherein Ar² is:

where * denotes the point of attachment to the quinazoline ring.

1.107 A compound of the formula (3):

or a salt, tautomer or N-oxide thereof, wherein R¹, R², R³, R⁴, Q¹, Q²and Ar¹ are as defined in any one of Embodiments 1.0 to 1.106.

1.108 A compound of the formula (4):

or a salt, tautomer or N-oxide thereof, wherein R¹, R², R³, R⁴, R⁵, Q¹and Q² are as defined in any one of Embodiments 1.0 to 1.106; and x is0, 1 or 2.

1.109 A compound according to Embodiment 1.108 wherein Q¹ is CH₂ orCH(CH₃), Q² is a bond or CH₂ and R¹ is hydrogen.

1.110 A compound according to Embodiment 1.108 or Embodiment 1.109wherein x is 0 or 1.

1.111 A compound selected from the title compounds of Examples 1 to 43herein.

1.112 A compound according to any one of Embodiments 1.0 to 1.111 whichis in the form of a salt.

1.113 A compound according to Embodiment 1.112 wherein the salt is anacid addition salt.

1.114 A compound according to Embodiment 1.112 or Embodiment 1.113wherein the salt is a pharmaceutically acceptable salt.

1.115 A compound according to any one of Embodiments 1.0 to 1.114 whichis in the form of a solvate.

1.116 A compound according to Embodiment 1.115 wherein the solvate is ahydrate.

Definitions

References to “carbocyclic” and “heterocyclic” groups as used hereinshall, unless the context indicates otherwise, include both aromatic andnon-aromatic ring systems. Thus, for example, the term “carbocyclic andheterocyclic groups” includes within its scope aromatic, non-aromatic,unsaturated, partially saturated and fully saturated carbocyclic andheterocyclic ring systems.

The carbocyclic or heterocyclic groups can be aryl or heteroaryl groups.The aryl or heteroaryl groups can be monocyclic or bicyclic groups, asdefined herein. The term “aryl” as used herein refers to a carbocyclicgroup having aromatic character and the term “heteroaryl” is used hereinto denote a heterocyclic group having aromatic character. Where thecontext permits, the terms “aryl” and “heteroaryl” may embrace bicyclicring systems wherein both rings are aromatic or one ring is non-aromaticand the other is aromatic. In such bicyclic systems containing onearomatic and one non-aromatic group, the group may be attached by thearomatic ring, or by the non-aromatic ring.

The term ‘C-linked’ (for example as in “C-linked 4 to 7 memberedmonocyclic non-aromatic or carbocyclic or heterocyclic group”) refers toa group as herein defined where the point of attachment is through acarbon atom.

In formula (1), Ar¹ is a monocyclic 5 or 6-membered aryl or heteroarylring containing 0, 1 or 2 heteroatom ring members selected from O, N andS. Examples of such rings include but are not limited to pyrrole, furan,thiophene, imidazole, oxazole, isoxazole, thiazole, isothiazole,pyrazole, pyridine, pyrazine, pyridazine, pyrimidine and phenyl groups.

The aryl or heteroaryl ring Ar¹ can be substituted with a substituentthat consists of or includes a 3- to 7-membered carbocyclic orheterocyclic group. The carbocyclic or heterocyclic groups can be arylor heteroaryl groups as defined above, or they can be non-aromaticgroups.

The term “non-aromatic group” refers to unsaturated ring systems withoutaromatic character, partially saturated and fully saturated carbocyclicand heterocyclic ring systems. The terms “unsaturated” and “partiallysaturated” refer to rings wherein the ring structure(s) contains atomssharing more than one valence bond e.g. the ring contains at least onemultiple bond e.g. a C═C N═C bond. The term “saturated” refers to ringswhere there are no multiple bonds between ring atoms. Saturatedcarbocyclic groups include the cycloalkyl groups cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Partially saturatedcarbocyclic groups include the cycloalkenyl groups cyclopentenyl,cyclohexenyl, cycloheptenyl and cyclooctenyl. Non-aromatic heterocyclicgroups include azetidine, pyrrolidine, piperidine, azepane, piperazine,morpholine, thiomorpholine, thiomorpholine S-oxide and S,S-dioxide,pyran (2H-pyran or 4H-pyran), dihydrothiophene, dihydropyran,dihydrofuran, dihydrothiazole, tetrahydrofuran, tetrahydrothiophene,dioxane, tetrahydropyran, imidazoline, imidazolidinone, oxazoline,thiazoline, pyrazoline, pyrazolidine.

In formula (1), Ar² is a bicyclic 8- to 11-membered heteroaryl groupcontaining 1, 2, 3 or 4 heteroatom ring members selected from O, N andS. bicyclic heteroaryl group may be, for example, a group selected froma benzene ring fused to a 5- or 6-membered ring containing 1, 2 or 3ring heteroatoms; a pyridine ring fused to a 5- or 6-membered ringcontaining 1, 2 or 3 ring heteroatoms; a pyrimidine ring fused to a 5-or 6-membered ring containing 1 or 2 ring heteroatoms; a pyrrole ringfused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms;pyrazole ring fused to a 5- or 6-membered ring containing 1 or 2 ringheteroatoms; an imidazole ring fused to a 5- or 6-membered ringcontaining 1 or 2 ring heteroatoms; an oxazole ring fused to a 5- or6-membered ring containing 1 or 2 ring heteroatoms; an isoxazole ringfused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; athiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ringheteroatoms; an isothiazole ring fused to a 5- or 6-membered ringcontaining 1 or 2 ring heteroatoms; a thiophene ring fused to a 5- or6-membered ring containing 1, 2 or 3 ring heteroatoms; a furan ringfused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms;a cyclohexyl ring fused to a 5- or 6-membered ring containing 1, 2 or 3ring heteroatoms; and a cyclopentyl ring fused to a 5- or 6-memberedring containing 1, 2 or 3 ring heteroatoms.

Particular examples of bicyclic heteroaryl groups containing a fivemembered ring fused to another five membered ring include but are notlimited to imidazothiazole (e.g. imidazo[2,1-b]thiazole) andimidazoimidazole (e.g. imidazo[1,2-a]imidazole). Particular examples ofbicyclic heteroaryl groups containing a six membered ring fused to afive membered ring include but are not limited to benzfuran,benzthiophene, benzimidazole, benzoxazole, isobenzoxazole,benzisoxazole, benzthiazole, benzisothiazole, isobenzofuran, indole,isoindole, indolizine, indoline, isoindoline, purine (e.g., adenine,guanine), indazole, pyrazolopyrimidine (e.g. pyrazolo[1,5-a]pyrimidine),triazolopyrimidine (e.g. [1,2,4]triazolo[1,5-a]pyrimidine), benzodioxoleand pyrazolopyridine (e.g. pyrazolo[1,5-a]pyridine) groups. Particularexamples of bicyclic heteroaryl groups containing two fused six memberedrings include but are not limited to quinoline, isoquinoline, chroman,thiochroman, chromene, isochromene, chroman, isochroman, benzodioxan,quinolizine, benzoxazine, benzodiazine, pyridopyridine, quinoxaline,quinazoline, cinnoline, phthalazine, naphthyridine and pteridine groups.

The term “hydrocarbyl” as used herein refers to aliphatic, alicyclic andaromatic groups having an all-carbon backbone and consisting of carbonand hydrogen atoms, except where otherwise stated. Examples ofhydrocarbyl groups include alkyl, cycloalkyl, cycloalkenyl, carbocyclicaryl, alkenyl, alkynyl, cycloalkylalkyl, cycloalkenylalkyl, andcarbocyclic aralkyl, aralkenyl and aralkynyl groups. Such groups can beunsubstituted or, where stated, substituted by one or more substituentsas defined herein. In certain cases, as defined herein, one or more, butnot all, of the carbon atoms of the hydrocarbyl group may be replaced byanother atom or group of atoms.

The term “alkylene” (e.g. as in C₁₋₄ straight chain or branched chainalkylene) as used herein refers to an alkanediyl group, i.e. a divalentsaturated acyclic straight chain or branched chain hydrocarbon group.Examples of straight chain alkylene groups include methylene (CH₂),ethylene (CH₂CH₂) and propylene ((CH₂CH₂CH₂). Examples of branched chainalkylene groups include CH(CH₃), CH₂CH(CH₃)CH₂ and CH₂(CH₃)CH₂CH₂.

Salts

The compounds of the invention as defined in Embodiments 1.0 to 1.111may be presented in the form of salts.

The salts referred to above (and also defined in embodiments 1.112,1.113 and 1.114) are typically acid addition salts.

The salts can be synthesized from the parent compound by conventionalchemical methods such as methods described in Pharmaceutical Salts:Properties, Selection, and Use, P. Heinrich Stahl (Editor), Camille G.Wermuth (Editor), ISBN: 3-90639-026-8, Hardcover, 388 pages, August2002. Generally, such salts can be prepared by reacting the free baseform of the compound with the acid in water or in an organic solvent, orin a mixture of the two; generally, nonaqueous media such as ether,ethyl acetate, ethanol, isopropanol, or acetonitrile are used.

Acid addition salts (as defined in Embodiment 1.113) may be formed witha wide variety of acids, both inorganic and organic. Examples of acidaddition salts include salts formed with an acid selected from the groupconsisting of acetic, 2,2-dichloroacetic, adipic, alginic, ascorbic(e.g. L-ascorbic), L-aspartic, benzenesulphonic, benzoic,4-acetamidobenzoic, butanoic, (+) camphoric, camphor-sulphonic,(+)-(1S)-camphor-10-sulphonic, capric, caproic, caprylic, cinnamic,citric, cyclamic, dodecylsulphuric, ethane-1,2-disulphonic,ethanesulphonic, 2-hydroxyethanesulphonic, formic, fumaric, galactaric,gentisic, glucoheptonic, D-gluconic, glucuronic (e.g. D-glucuronic),glutamic (e.g. L-glutamic), α-oxoglutaric, glycolic, hippuric,hydrobromic, hydrochloric, hydriodic, isethionic, (+)-L-lactic,(±)-DL-lactic, lactobionic, maleic, malic, (−)-L-malic, malonic,(±)-DL-mandelic, methanesulphonic, naphthalene-2-sulphonic,naphthalene-1,5-disulphonic, 1-hydroxy-2-naphthoic, nicotinic, nitric,oleic, orotic, oxalic, palmitic, pamoic, phosphoric, propionic,L-pyroglutamic, salicylic, 4-amino-salicylic, sebacic, stearic,succinic, sulphuric, tannic, (+)-L-tartaric, thiocyanic,p-toluenesulphonic, undecylenic and valeric acids, as well as acylatedamino acids and cation exchange resins.

The salt forms of the compounds of the invention are typicallypharmaceutically acceptable salts, and examples of pharmaceuticallyacceptable salts are discussed in Berge et al., 1977, “PharmaceuticallyAcceptable Salts,” J. Pharm. Sci., Vol. 66, pp. 1-19. However, saltsthat are not pharmaceutically acceptable may also be prepared asintermediate forms which may then be converted into pharmaceuticallyacceptable salts. Such non-pharmaceutically acceptable salts forms,which may be useful, for example, in the purification or separation ofthe compounds of the invention, also form part of the invention.

N-Oxides

Many compounds of the Embodiments 1.0 to 1.116 may form N-oxides. Wherea compound contains several amine functions, one or more than onenitrogen atom may be oxidised to form an N-oxide. Particular examples ofN-oxides are the N-oxides of a tertiary amine or a nitrogen atom of anitrogen-containing heterocycle.

N-Oxides can be formed by treatment of the corresponding amine with anoxidizing agent such as hydrogen peroxide or a per-acid (e.g. aperoxycarboxylic acid), see for example Advanced Organic Chemistry, byJerry March, 4^(th) Edition, Wiley Interscience, pages. Moreparticularly, N-oxides can be made by the procedure of L. W. Deady (Syn.Comm. 1977, 7, 509-514) in which the amine compound is reacted withm-chloroperoxybenzoic acid (MCPBA), for example, in an inert solventsuch as dichloromethane.

Further examples of conditions for forming N-oxides are disclosed in ourearlier application WO2008/139152.

Geometric Isomers and Tautomers

The compounds of the invention may exist in a number of differentgeometric isomeric, and tautomeric forms and references to the compoundsof formula (1) as defined in Embodiments 1.0 to 1.116 include all suchforms. For the avoidance of doubt, where a compound can exist in one ofseveral geometric isomeric or tautomeric forms and only one isspecifically described or shown, all others are nevertheless embraced byformula (1) or subgroups, subsets, preferences and examples thereof.

Optical Isomers

Where compounds of the formula contain one or more chiral centres, andcan exist in the form of two or more optical isomers, references to thecompounds include all optical isomeric forms thereof (e.g. enantiomers,epimers and diastereoisomers), either as individual optical isomers, ormixtures (e.g. racemic mixtures) or two or more optical isomers, unlessthe context requires otherwise.

The optical isomers may be characterised and identified by their opticalactivity (i.e. as + and—isomers, or d and l isomers) or they may becharacterised in terms of their absolute stereochemistry using the “Rand S” nomenclature developed by Cahn, Ingold and Prelog, see AdvancedOrganic Chemistry by Jerry March, 4^(th) Edition, John Wiley & Sons, NewYork, 1992, pages 109-114, and see also Cahn, Ingold & Prelog, Angew.Chem. Int. Ed. Engl., 1966, 5, 385-415.

Optical isomers can be separated by a number of techniques includingchiral chromatography (chromatography on a chiral support) and suchtechniques are well known to the person skilled in the art.

As an alternative to chiral chromatography, optical isomers can beseparated by forming diastereoisomeric salts with chiral acids such as(+)-tartaric acid, (−)-pyroglutamic acid, (−)-di-toluoyl-L-tartaricacid, (+)-mandelic acid, (−)-malic acid, and (−)-camphorsulphonic,separating the diastereoisomers by preferential crystallisation, andthen dissociating the salts to give the individual enantiomer of thefree base.

Where compounds of the invention exist as two or more optical isomericforms, one enantiomer in a pair of enantiomers may exhibit advantagesover the other enantiomer, for example, in terms of biological activity.Thus, in certain circumstances, it may be desirable to use as atherapeutic agent only one of a pair of enantiomers, or only one of aplurality of diastereoisomers. Accordingly, the invention providescompositions containing a compound having one or more chiral centres,wherein at least 55% (e.g. at least 60%, 65%, 70%, 75%, 80%, 85%, 90% or95%) of the compound of the formula (1) is present as a single opticalisomer (e.g. enantiomer or diastereoisomer). In one general embodiment,99% or more (e.g. substantially all) of the total amount of the compoundof the formula (1) may be present as a single optical isomer (e.g.enantiomer or diastereoisomer).

Isotopes

The compounds of the invention as defined in any one of Embodiments 1.0to 1.116 may contain one or more isotopic substitutions, and a referenceto a particular element includes within its scope all isotopes of theelement. For example, a reference to hydrogen includes within its scope¹H, ²H (D), and ³H (T). Similarly, references to carbon and oxygeninclude within their scope respectively ¹²C, ¹³C and ¹⁴C and ¹⁶O and¹⁸O.

The isotopes may be radioactive or non-radioactive. In one embodiment ofthe invention, the compounds contain no radioactive isotopes. Suchcompounds are preferred for therapeutic use. In another embodiment,however, the compound may contain one or more radioisotopes. Compoundscontaining such radioisotopes may be useful in a diagnostic context.

Solvates

Compounds of the formula (1) as defined in any one of Embodiments 1.0 to1.116 may form solvates.

Preferred solvates are solvates formed by the incorporation into thesolid state structure (e.g. crystal structure) of the compounds of theinvention of molecules of a non-toxic pharmaceutically acceptablesolvent (referred to below as the solvating solvent). Examples of suchsolvents include water, alcohols (such as ethanol, isopropanol andbutanol) and dimethylsulphoxide. Solvates can be prepared byrecrystallising the compounds of the invention with a solvent or mixtureof solvents containing the solvating solvent. Whether or not a solvatehas been formed in any given instance can be determined by subjectingcrystals of the compound to analysis using well known and standardtechniques such as thermogravimetric analysis (TGE), differentialscanning calorimetry (DSC) and X-ray crystallography.

The solvates can be stoichiometric or non-stoichiometric solvates.

Particularly preferred solvates are hydrates, and examples of hydratesinclude hemihydrates, monohydrates and dihydrates.

For a more detailed discussion of solvates and the methods used to makeand characterise them, see Bryn et al., Solid-State Chemistry of Drugs,Second Edition, published by SSCI, Inc of West Lafayette, Ind., USA,1999, ISBN 0-967-06710-3.

Prodrugs

The compounds of the formula (1) as defined in any one of Embodiments1.0 to 1.116 may be presented in the form of a pro-drug.

By “prodrugs” is meant for example any compound that is converted invivo into a biologically active compound of the formula (1), as definedin any one of Embodiments 1.0 to 1.116.

For example, some prodrugs are esters of the active compound (e.g., aphysiologically acceptable metabolically labile ester). Duringmetabolism, the ester group (—C(═O)OR) is cleaved to yield the activedrug. Such esters may be formed by esterification, for example, of anyhydroxyl groups present in the parent compound with, where appropriate,prior protection of any other reactive groups present in the parentcompound, followed by deprotection if required.

Also, some prodrugs are activated enzymatically to yield the activecompound, or a compound which, upon further chemical reaction, yieldsthe active compound (for example, as in ADEPT, GDEPT, LIDEPT, etc.). Forexample, the prodrug may be a sugar derivative or other glycosideconjugate, or may be an amino acid ester derivative.

Complexes and Clathrates

Also encompassed by formula (1) or subgroups, subsets, preferences andexamples thereof are complexes (e.g. inclusion complexes or clathrateswith compounds such as cyclodextrins, or complexes with metals) of thecompounds.

Biological Activity

Compounds of the formula (1) as defined in any one of Embodiments 1.0 to1.116 have activity as inhibitors of p70S6 kinase. As such, they may beuseful in preventing or treating disease states and conditions in whichp70S6 kinase or mutant forms thereof play an active part.

For example, it is envisaged that the compounds of Embodiments 1.0 to1.116 will be useful in treating a range of proliferative disorders suchas cancers.

Accordingly, in further embodiments (Embodiments 2.1 to 2.9), theinvention provides:

2.1 A compound of the formula (1) as defined in any one of Embodiments1.0 to 1.116 for use in medicine or therapy.

2.2 A compound of the formula (1) as defined in any one of Embodiments1.0 to 1.116 for use in preventing or treating disease states andconditions mediated by p70S6 kinase or mutant forms thereof.

2.3 A compound of the formula (1) as defined in any one of Embodiments1.0 to 1.116 for use in preventing or treating disease states andconditions characterised by abnormal expression of p70S6 kinase (e.g.over-expression or expression of a mutant form of p70S6 kinase).

2.4 A compound of the formula (1) as defined in any one of Embodiments1.0 to 1.116 for use as an anti-cancer agent.

2.5 The use of a compound of the formula (1) as defined in any one ofEmbodiments 1.0 to 1.116 for the manufacture of a medicament for thetreatment of cancer.

2.6 A method of treating a cancer, which method comprises administeringto a subject in need thereof a therapeutically effective amount of acompound of the formula (1) as defined in any one of Embodiments 1.0 to1.116, optionally together with another anti-cancer agent or radiationtherapy.

2.7 A compound of the formula (1) as defined in any one of Embodiments1.0 to 1.116 for use in enhancing a therapeutic effect of radiationtherapy or chemotherapy in the treatment of a proliferative disease suchas cancer.

2.8 The use of a compound of the formula (1) as defined in any one ofEmbodiments 1.0 to 1.116 for the manufacture of a medicament forenhancing a therapeutic effect of radiation therapy or chemotherapy inthe treatment of a proliferative disease such as cancer.

2.9 A method for the prophylaxis or treatment of a proliferative diseasesuch as cancer, which method comprises administering to a patient incombination with radiotherapy or chemotherapy a compound of the formula(1) as defined in any one of Embodiments 1.0 to 1.116.

Examples of proliferative disorders (e.g. cancers) as defined inEmbodiments 2.4 to 2.9 include, but are not limited to carcinomas, forexample carcinomas of the bladder, breast, colon, kidney, epidermis,liver, lung, oesophagus, gall bladder, ovary, pancreas, stomach, cervix,thyroid, prostate, gastrointestinal system, or skin, hematopoieitictumours such as leukaemia, B-cell lymphoma, T-cell lymphoma, Hodgkin'slymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, or Burkett'slymphoma; hematopoieitic tumours of myeloid lineage, for example acuteand chronic myelogenous leukaemias, myelodysplastic syndrome, orpromyelocytic leukaemia; thyroid follicular cancer; tumours ofmesenchymal origin, for example fibrosarcoma or rhabdomyosarcoma;tumours of the central or peripheral nervous system, for exampleastrocytoma, neuroblastoma, glioma or schwannoma; melanoma; seminoma;teratocarcinoma; osteosarcoma; xeroderma pigmentosum; keratoctanthoma;thyroid follicular cancer; or Kaposi's sarcoma.

One particular subset of cancers against which the compounds ofEmbodiments 1.0 to 1.116 should prove particularly active are cancerswhich are characterised by P70S6 overexpression or elevated expressionof P70S6 or the presence of mutant forms of P70S6 or elevated levels ofactivated (phosphorylated) p70S6K.

The ability of the compounds of the invention to inhibit P70S6 kinasecan be determined by means of the protocols set out in the Examplessection below.

Further particular examples of cancers against which the compounds ofEmbodiments 1.0 to 1.116 should prove particularly active are:

-   -   Breast Cancer (over expression is linked to poor prognosis and        metastasis (see Mol. Can. Ther, 2010, 9, 1180), particularly        triple negative breast cancer    -   Diffuse large B-cell lymphoma: (see Expert Opin Ther Targets.        2009 September; 13(9):1085-93.)    -   Glioblastoma multiforme (associated with increased levels of        P70S6K (see J Clin Oncol. 2005 Aug. 10; 23(23):5294-304))    -   Human colorectal cancer (in which the mtor pathway & p70S6K are        highly activated (see Ann. Surg. Oncol. 2009 September;        16(9):2617-28. Epub 2009 Jun. 11))

Another subset of cancers against which the compounds of Embodiments 1.0to 1.116 should prove particularly active includes:

-   -   breast cancer    -   glioblastoma multiforme;    -   adenocarcinomas of the colon;    -   non-small cell lung cancer;    -   small-cell lung cancer;    -   cisplatin-resistant small-cell lung cancer;    -   ovarian cancer;    -   leukemia;    -   pancreatic cancer;    -   prostate cancer;    -   mammary carcinoma;    -   renal cell carcinoma;    -   multiple myeloma;    -   Kaposi's sarcoma;    -   Hodgkin's lymphoma;    -   lymphangioeiomyomatosis; and    -   non-Hodgkin's lymphoma or sarcoma

A further sub-set of cancers against which the compounds of Embodiments1.0 to 1.116 should prove particularly active includes cancers of thebrain such as:

-   -   brain metastases from Triple-Negative Breast Cancer; and    -   gliomas and glioblastomas.        Triple-Negative Breast Cancer

The majority of breast cancers are hormone-positive breast cancers,wherein the growth of cancer cells is stimulated by exposure tooestrogen and/or progesterone. Patients suffering from such cancers aretypically treated with therapeutic agents that prevent or reduce theformation of oestrogen in the body or prevent oestrogen from binding tothe cell and stimulating growth. Examples of such therapeutive agentsinclude selective estrogen-receptor response modulators (SERMs) such astamoxifen and toremifene; aromatase inhibitors such as anastrozole,exemestane and letrozole; oestrogen-receptor downregulators (ERDs) suchas fulvestrant; and luteinizing hormone-releasing hormone agents (LHRHs)such as goserelin, leuprolide), and triptorelin. The stimulation ofprogesterone on hormone-positive cancer cells is affected by estrogenreceptor activity; therefore, if estrogen exposure is reduced,progesterone sensitivity is often also affected.

Approximately one quarter of breast cancers are HER2-positive breastcancers which are characterised by overexpression of human epidermalgrowth factor receptor 2 (HER2). HER2-positive cancers are typicallytreated with therapeutic agents (e.g. Herceptin) that target thereceptor to slow growth and replication.

There are however some breast cancers that are not oestrogen- orprogesterone-positive and do not overexpress HER2 to a level that wouldcharacterise them as HER2-positive. Such forms of breast cancer arecommonly referred to as triple-negative breast cancers. Patients withtriple-negative breast cancer have fewer treatment options than patientswith either hormone-positive or HER2-positive disease, and hence aregenerally more difficult to treat than oestrogen-positive,progesterone-positive and HER2-positive cancers. Triple negative breastcancers are also recognised as being more likely to spread (metastasize)to the brain. Patients with brain metastases are typically considered tobe incurable with standard treatment approaches.

The compounds of formula (1) as defined in Embodiments 1.0 to 1.116herein may be used in the treatment of triple negative breast cancer andthe treatment of brain metastases arising from triple negative breastcancer. The compounds may also be used in the treatment of brainmetastases arising from other forms of cancer.

Furthermore, the compounds of formula (1) as defined in Embodiments 1.0to 1.116 herein may be used in the prevention or treatment of metastasesin general, for example in the prevention or treatment of metastases inthe brain, lung, liver, pancreas, kidney, bladder and gallbladder.

Accordingly, in further Embodiments 2.10 to 2.18, the inventionprovides:

2.10 A compound as defined in any one of Embodiments 1.0 to 1.116 foruse in the treatment of triple negative breast cancers.

2.11 A compound as defined in any one of Embodiments 1.0 to 1.116 foruse in the prevention or treatment of metastases, for example metastasesin the brain, bones, lung, liver, pancreas, kidney, bladder andgallbladder, e.g. brain metastases arising from triple negative breastcancers.

2.12 A compound as defined in any one of Embodiments 1.0 to 1.116 foruse in the treatment of brain metastases arising from non-brain cancers.

2.13 The use of a compound as defined in any one of Embodiments 1.0 to1.116 for the manufacture of a medicament for the treatment of triplenegative breast cancers.

2.14 The use of a compound as defined in any one of Embodiments 1.0 to1.116 for the manufacture of a medicament for the prevention ortreatment of metastases, for example metastases in the brain, bones,lung, liver, pancreas, kidney, bladder and gallbladder, e.g. brainmetastases arising from triple negative breast cancers.

2.15 The use of a compound as defined in any one of Embodiments 1.0 to1.116 for the manufacture of a medicament for the treatment of brainmetastases arising from non-brain cancers.

2.16 A method of treating a triple negative breast cancer in a subject(e.g. a human subject) in need thereof, which method comprisesadministering to the subject a therapeutically effective amount of acompound as defined in any one of Embodiments 1.0 to 1.116.

2.17 A method of preventing or treating metastases, for examplemetastases in the brain, bones, lung, liver, pancreas, kidney, bladderand gallbladder (e.g. brain metastases arising from triple negativebreast cancers), in a subject (e.g. a human subject) in need thereof,which method comprises administering to the subject a therapeuticallyeffective amount of a compound as defined in any one of Embodiments 1.0to 1.116.

2.18 A method of treating brain metastases arising from non-braincancers in a subject (e.g. a human subject) in need thereof, whichmethod comprises administering to the subject a therapeuticallyeffective amount of a compound as defined in any one of Embodiments 1.0to 1.116.

Gliomas

It is envisaged that the compounds of formula (1) as defined inEmbodiments 1.0 to 1.116 herein will be useful in the treatment ofgliomas on account of their potency as inhibitors of S6K1 (which isknown to have a role in glial transformation) and their ability to reachthe site of action, i.e. the brain.

Gliomas are a common type of primary brain tumour that originate in theglial cells in the brain, and account for about 30% of all primary brainand central nervous system tumours, and about 80% of all malignant braintumours. Gliomas typically arise from three different types of cellsthat are normally found in the brain, namely astrocytes,oligodendrocytes, and ependymal cells. Major types of gliomas includeependymomas (associated with ependymal cells), astrocytomas (associatedwith astrocytes), oligodendrogliomas (associated with oligodendrocytes),brainstem glioma (which develops in the brain stem), optic nerve glioma(which develops in or around the optic nerve) and mixed gliomas (whichcontain cells from different types of glia).

An ependymoma is a type of glioma that develops from ependymal cells,usually in the lining of the ventricles of the brain or in the spinalcord. In children, they are most commonly found near the cerebellum.Ependymomas are rare, accounting for only about 2-3% of primary braintumours. However, they account for about 8-10% of brain tumours inchildren and occur most often in children younger than 10 years of age.

Astrocytomas originate in the star-shaped glial cells (astrocytes) inthe cerebrum. Astrocytomas do not usually spread outside the brain andspinal cord and do not usually affect other organs but they are the mostcommon glioma and can occur in most parts of the brain and occasionallyin the spinal cord. Two broad classes of astrocytoma are generallyrecognised, namely those with narrow zones of infiltration (mostlyinvasive tumours; e.g., pilocytic astrocytoma, subependymal giant cellastrocytoma, pleomorphic xanthoastrocytoma), that often are clearlyoutlined on diagnostic images; and those with diffuse zones ofinfiltration (e.g., high-grade astrocytoma, anaplastic astrocytoma,glioblastoma). Glioblastoma multiforme is a malignant astrocytoma andthe most common primary brain tumour among adult humans.

An oligodendrogliomas is a type of glioma that develops fromoliogodendrocytes, which are the supportive tissue cells of the brain,and are usually found in the cerebrum. About 4% of primary brain tumoursare oliogodendrogliomas and they are most common in young andmiddle-aged adults. Seizures are a very common symptom of these gliomas,as well as headache, weakness, or changes in behavior or sleepiness.

Brain stem gliomas, as the name suggests, are tumours found in the brainstem. Most brain stem tumours cannot be surgically removed because ofthe remote location and delicate and complex function this areacontrols. Brain stem gliomas occur almost exclusively in children,typically in school-age children.

A mixed glioma is a malignant glioma made up of more than one type ofglial cell. This type of glioma may also be referred to as anoligoastrocytoma. Mixed gliomas are often found in the cerebrum, but maymetastasize to other parts of the brain. Only about 1% of primary braintumours are mixed gliomas and they are most commonly found in adult men.

An optic nerve glioma is a type of malignant glioma (brain tumour) foundin the optic chiasm. Optic nerve gliomas often surround the opticnerves, and are frequently found in people who have neurofibromatosis. Aperson suffering from an optic nerve glioma typically experiences lossof vision, and may also suffer from hormone disturbances as the tumoursare often found at the base of the brain where the structuresresponsible for hormonal control are located. Optic nerve gliomas aretypically difficult to treat because of the sensitivity of thesurrounding brain structures.

In addition to being classified according to the type of glial cell fromwhich they originate or the region of the brain in which they develop,gliomas can also be classified according to their “grade”, which is ameasure of the growth potential and aggressiveness of the tumour.

Thus, gliomas are most often referred to as “low-grade” or “high-grade”gliomas, the grade being determined by pathological evaluation of thetumour. Tumours can be further graded according to the World HealthOrganization (WHO) grading system, under which tumours are graded from I(least advanced disease—best prognosis) to IV (most advanceddisease—worst prognosis).

Gliomas can also be classified according to whether they are locatedabove or below the tentorium membrane which tentorium separates thecerebrum (above) region of the brain from the cerebellum (below).Supratentorial gliomas (i.e. tumours located above the tentorium in thecerebrum), are mostly found in adults (70%), whereas infratentorialgliomas (tumours located below the tentorium, in the cerebellum) arefound mostly in children (70%).

A further class of gliomas consists of those tumours found in the ponsof the brainstem. The brainstem has three parts (pons, midbrain andmedulla); the pons controls critical functions such as breathing, makingsurgery on pontine gliomas extremely dangerous.

Accordingly, in further Embodiments 2.19 to 2.34, the inventionprovides:

2.19 A compound as defined in any one of Embodiments 1.0 to 1.116 foruse in the treatment of gliomas and glioblastomas.

2.20 A compound for use according to Embodiment 2.19 wherein the gliomais an ependymoma.

2.21 A compound for use according to Embodiment 2.19 wherein the gliomais an astrocytoma.

2.22 A compound for use according to Embodiment 2.19 wherein the gliomais a glioblastoma.

2.23 A compound for use according to Embodiment 2.19 wherein the gliomais glioblastoma multiforme.

2.24 A compound for use according to Embodiment 2.19 wherein the gliomais an oligodendroglioma.

2.25 A compound for use according to Embodiment 2.19 wherein the gliomais a brainstem glioma.

2.26 A compound for use according to Embodiment 2.19 wherein the gliomais an optic nerve glioma.

2.27 A compound for use according to Embodiment 2.19 wherein the gliomais a mixed glioma.

2.28 A compound for use according to Embodiment 2.19 wherein the gliomais a low-grade glioma.

2.29 A compound for use according to Embodiment 2.19 wherein the gliomais a high-grade glioma.

2.30 A compound for use according to Embodiment 2.19 wherein the gliomais a supratentorial glioma.

2.31 A compound for use according to Embodiment 2.19 wherein the gliomais an infratentorial glioma.

2.32 A compound for use according to Embodiment 2.19 wherein the gliomais a pontine glioma.

2.33 The use of a compound as defined in any one of Embodiments 1.0 to1.116 for the manufacture of a medicament for the treatment of a gliomaas defined in any one of Embodiments 2.19 to 2.32.

2.34 A method of treating a glioma as defined in any one of Embodiments2.19 to 2.32 in a subject in need thereof, which method comprisesadministering to the subject an effective therapeutic amount of acompound as defined in any one of Embodiments 2.19 to 2.32.

Neurodevelopmental Diseases and Neurodegenerative Diseases

As discussed above, P70S6K also has a crucial role in the pathology of anumber of neurodevelopmental diseases and neurodegenerative disordersand diseases and it is envisaged that the inhibition of P70S6K willprovide a means of treating many such diseases. Accordingly, in furtherembodiments 2.35 to 2.48, the invention provides:

2.35 A compound as defined in any one of Embodiments 1.0 to 1.116 foruse in the treatment of a neurodevelopmental disorder.

2.36 A compound for use according to Embodiment 2.35 wherein theneurodevelopmental disorder is Fragile X Syndrome.

2.37 A compound for use according to Embodiment 2.35 wherein theneurodevelopmental disorder is Autism or an Autism Spectrum Disorder.

2.38 A compound for use according to Embodiment 2.35 wherein theneurodevelopmental disorder is Fragile X-associated tremor/ataxiasyndrome (FXTAS).

2.39 A compound for use according to Embodiment 2.35 wherein theneurodevelopmental disorder is Angleman's syndrome.

2.40 A compound for use according to Embodiment 2.35 wherein theneurodevelopmental disorder is Tuberous sclerosis complex.

2.41 A compound for use according to Embodiment 2.35 wherein theneurodevelopmental disorder is MECP2 duplication syndrome.

2.42 A compound for use according to Embodiment 2.35 wherein theneurodevelopmental disorder is Down Syndrome.

2.43 A compound as defined in any one of Embodiments 1.0 to 1.116 foruse in the treatment of a neurodegenerative disease.

2.44 A compound for use according to Embodiment 2.43 wherein theneurodegenerative disease is Alzheimer's disease.

2.45 A compound for use according to Embodiment 2.43 wherein theneurodegenerative disease is Huntington's disease.

2.46 A compound for use according to Embodiment 2.43 wherein theneurodegenerative disease is Parkinson's disease.

2.47 The use of a compound of the formula (1) as defined in any one ofEmbodiments 1.0 to 1.116 for the manufacture of a medicament for thetreatment of a brain disorder, e.g. a brain disorder as defined in anyone of Embodiments 2.35 to 2.46.

2.48 A method of treating a brain disorder (e.g. a brain disorder asdefined in any one of Embodiments 2.35 to 2.46) in a subject (e.g. amammalian subject such as a human), which method comprises administeringto the subject a therapeutically effective amount of a compound of theformula (1), (2), (3) or (4) as defined in any one of Embodiments 1.0 to1.116.

Fragile X syndrome usually manifests first in childhood. A delay inspeech is common and is often the first symptom that brings the child tomedical attention (around the age of two or three). Accordingly, infurther embodiments, the invention provides:

2.48A A compound according to any one of Embodiments 1.0 to 1.116 foruse in the treatment of Fragile X syndrome in a patient under the age of20, for example under the age of 15, or under the age of 12, or underthe age of 10, preferably below the age of 8, and even more preferablyunder the age of 5.

2.48B A method for the treatment of Fragile X syndrome which methodcomprises administering a patient in need thereof a compound as definedin any one of Embodiments 1.0 to 1.116, wherein the patient is under theage of 20, for example under the age of 15, or under the age of 12, orunder the age of 10, preferably below the age of 8, and even morepreferably under the age of 5.

2.48C The use of a compound as defined in any one of Embodiments 1.0 to1.116 for the manufacture of a medicament for the treatment orprophylaxis of Fragile X syndrome in a patient under the age of 20, forexample under the age of 15, or under the age of 12, or under the age of10, preferably below the age of 8, and, even more preferably under theage of 5.

Other Diseases and Conditions in which S6K1 May be Implicated

As discussed above, P70S6K inhibitors may also be useful in thetreatment of PTEN hamartoma syndrome, neurofibromatosis type 1 andlymphangioleiomyomatosis (LAM). Accordingly, in further embodiments(Embodiments 2.49 to 2.52), the invention provides:

2.49 A compound as defined in any one of Embodiments 1.0 to 1.116 foruse in the treatment of a condition which is PTEN hamartoma syndrome.

2.50 A compound as defined in any one of Embodiments 1.0 to 1.116 foruse in the treatment of a condition which is neurofibromatosis type 1.

2.51 A compound as defined in any one of Embodiments 1.0 to 1.116 foruse in the treatment of a condition which is lymphangioleiomyomatosis.

2.52 The use of a compound as defined in any one of Embodiments 1.0 to1.116 for the manufacture of a medicament for the treatment of acondition as defined in any one of Embodiments 2.49 to 2.51.

2.53 A method of treating a condition as defined in any one ofEmbodiments 2.49 to 2.51 in a subject (e.g. a mammalian subject such asa human), which method comprises administering to the subject atherapeutically effective amount of a compound of the formula (1), (2),(3) or (4) as defined in any one of Embodiments 1.0 to 1.116.

Determination of Biological Properties

The ability of the compounds of Embodiments 1.0 to 1.116 to inhibit cellproliferation can also be determined using the protocols set out in theExamples section below.

One advantage of compounds of Embodiments 1.0 to 1.116 is that they areselective kinase inhibitors.

Preferred compounds of Embodiments 1.0 to 1.116 are those having an IC₅₀against p70S6 kinase of less than 5 μM, or less than 1 μM and preferablyless than 0.1 μM.

For example, compounds of Embodiments 1.0 to 1.116 are selectiveinhibitors of p70S6 kinase compared to activity against Akt2 kinase.Preferred compounds of Embodiments 1.0 to 1.116 are at least 5 fold moreactive against p70S6 kinase than they are against Akt2 kinase, and morepreferred compounds of Embodiments 1.0 to 1.116 are at least 10 fold orat least 20 fold more active against p70S6 kinase than they are againstAkt2 kinase. Particularly preferred compounds of Embodiments 1.0 to1.116 are at least 100 fold more active against p70S6 kinase than theyare against Akt2 kinase.

Furthermore, compounds of Embodiments 1.0 to 1.116 are selectiveinhibitors of p70S6 kinase compared to activity against Aurora kinase.Preferred compounds of Embodiments 1.0 to 1.116 are at least 5 fold moreactive against p70S6 kinase than they are against Aurora A and/or Bkinase, and more preferred compounds of Embodiments 1.0 to 1.116 are atleast 10 fold more active against p70S6 kinase than they are againstAurora A and/or B kinase.

Compounds of Embodiments 1.0 to 1.116 having greater selectivity forp70S6 kinase versus Aurora A and/or Aurora B kinase and/or Akt kinaseare expected to exhibit improved side effect profiles in relation toside effects arising from Aurora kinase and Akt kinase inhibition. Forexample, in the case of inhibition of Aurora kinases, neutropenia is awell known side effect in the clinic.

Accordingly, in further embodiments (Embodiments 2.54 to 2.57), theinvention provides:

2.54 A compound according to any one of Embodiments 1.0 to 1.116 havingan IC₅₀ against p70S6 kinase of less than 5 μM.

2.55 A compound according to any one of Embodiments 1.0 to 1.116 havingan IC₅₀ against p70S6 kinase of or less than 1 μM.

2.56 A compound according to any one of Embodiments 1.0 to 1.116 havingan IC₅₀ against p70S6 kinase of less than 0.1 μM.

2.57 A compound according to any one of Embodiments 2.54 to 2.56 for usein a therapy, treatment, method or use according to any one ofEmbodiments 2.1 to 2.52.

Many compounds defined in Embodiments 1.0 to 1.116 have good brainpenetration and therefore are useful in treating brain disorders inwhich inhibition of p70S6 kinase is therapeutically effective.

The brain penetrating ability of the compounds of Embodiments 1.0 to1.116 can be determined by means of an in vivo cassette mouse modelwhich is an industry-standard means of assessing brain penetration ofsmall molecules (see for example “In vitro permeability analysis,pharmacokinetic and brain distribution study in mice of imperatorin,isoimperatorin and cnidilin in Radix Angelicae Dahuricae”, Fitoterapia,Volume 85, March 2013, Pages 144-153).

Methods for the Preparation of Compounds of the Invention

The invention also provides methods for the preparation of a compound ofthe formula (1).

Accordingly, in another embodiment (Embodiment 3.1), the inventionprovides a method for preparing a compound as defined in any one ofEmbodiments 1.0 to 1.116 wherein Y is R³ and Z is Ar², which methodcomprises:

(a) the reaction of a compound of the formula (8):

or a protected form thereof, wherein Hal is a halogen such as bromine,with a boronic acid or boronate reagent of the formula Ar²—Bor where Boris a boronate or boronic acid residue, in the presence of a palladiumcatalyst; and thereafter optionally removing any protecting grouppresent; or(b) the reaction of a compound of the formula (9):

or a protected form thereof, with a compound of the formula LG-Q²-R¹where LG is a leaving group such as a halogen; and thereafter optionallyremoving any protecting group present.

In another embodiment (Embodiment 3.2), the invention provides a methodfor preparing a compound as defined in any one of Embodiments 1.0 to1.116 wherein Y is Ar² and Z is R³, which method comprises:

(a) the reaction of a compound of the formula (10):

or a protected form thereof, wherein Hal is a halogen such as bromine,with a boronic acid or boronate reagent of the formula Ar²—Bor where Boris a boronate or boronic acid residue, in the presence of a palladiumcatalyst; and thereafter optionally removing any protecting grouppresent; or(b) the reaction of a compound of the formula (11):

or a protected form thereof, with a compound of the formula LG-Q²-R¹where LG is a leaving group such as a halogen; and thereafter optionallyremoving any protecting group present.

Reaction (a) in Embodiments 3.1 and 3.2 above may be carried out underSuzuki coupling conditions, in the presence of a palladium catalyst suchas bis(tri-t-butylphosphine)palladium (0) and a base (e.g. a carbonatesuch as potassium carbonate or caesium carbonate). The reaction may becarried out in a polar solvent such as dimethyl formamide (DMF) ordioxane, and the reaction mixture is typically subjected to heating, forexample to a temperature in excess of 100° C.

Reaction (b) in Embodiments 3.1 and 3.2 above is typically carried outat room temperature in a polar solvent such as dimethyl sulphoxide ordimethyl formamide in the presence of a non-nucleophilic base such as analkali metal hydride (e.g. sodium hydride).

Illustrative reaction schemes for the preparation of compounds of theformula (1) are set out below.

In Scheme 1, when R², R³ and R⁴ are hydrogen the starting material isthe 6-bromo-2-chloro-quinazoline (12) which is commercially available.The 6-bromo-2-chloro-quinazoline (12) is reacted with the aryl- orheteroarylalkylamine H₂N-Q¹-Ar¹ in a polar solvent such asdimethylsulphoxide, typically at room temperature or optionally withmild heating, to give the intermediate compound (13). The compound (13)is reacted with sodium hydride in dimethylformamide at a reducedtemperature of around 0° C. and a compound of formula (14), wherein LG¹is a suitable leaving group (e.g. halogen, methanesulphonate ortosylate), is then added to the resulting reaction mixture. The reactionmixture may then be heated to a mild temperature of around 50° C. togive the bromo-intermediate (15).

Alternatively, the bromo-intermediate (15) can be synthesised directlyfrom the 6-bromo-2-chloro-quinazoline starting material (12) by reactingwith amine NH(Q¹Ar¹)(Q²R¹) in a polar solvent such asdimethylsulphoxide, typically at room temperature or optionally withmild heating.

The bromo-intermediate (15) is then reacted with the heteroaryl boronate(16) in a polar solvent such as dioxane in the presence ofbis(tri-tert-butylphosphine)palladium (0) and caesum or potassiumcarbonate and optionally in the presence of potassium iodide underSuzuki reaction conditions to give the compound of formula (1) or aprotected derivative thereof. The heteroaryl group Ar² may be present inthe boronate compound (16) in a protected form. For example, when Ar²contains an NH group, a protecting group such as a Boc(tert-butoxycarbonyl) group may be attached to the nitrogen atom,replacing the hydrogen atom. After the reaction between the boronatecompound (16) and the intermediate (15), a deprotection step may berequired in order to give the compound of formula (1). In the case of aBoc protecting group, this can be removed by treatment with an acid suchas hydrochloric acid.

Boronates and boronic acids of the formula Ar²—Bor are widely availablecommercially or can be prepared for example as described in the reviewarticle by N. Miyaura and A. Suzuki, Chem. Rev. 1995, 95, 2457. Thus,boronates can be prepared by reacting the corresponding bromo-compoundwith an alkyl lithium such as butyl lithium and then reacting with aborate ester. The resulting boronate ester derivative can, if desired,be hydrolysed to give the corresponding boronic acid.

Compounds of the formula (1) wherein Q² is a bond and R¹ is a cyclicgroup Cy¹ can be prepared by the sequence of reactions shown in Scheme2.

In Scheme 2, the 6-bromo-2-chloro-quinazoline (12) is reacted with thecarbocyclyl or heterocyclyl amine Cy¹-NH₂ in a polar solvent such asdimethylsulphoxide, typically at room temperature or optionally withmild heating, to give the intermediate compound (17) which is thentreated with compound (18), wherein LG¹ is a suitable leaving group(e.g. halogen, methanesulphonate or tosylate), under standard alkylationconditions to give the bromo-compound (19). The bromo-compound (19) isthen reacted with the heteroaryl boronate (16) under the Suzuki reactionconditions described above to give the compound of formula (20) whichcorresponds to a compound of the formula (1) in which Q² is a bond andR¹ is a cyclic group Cy¹. Alternatively, the bromo-compound (19) isreacted with bis borane pinacol ester to give the boronate (19a) whichis then reacted with a heteroaryl bromide Ar²—Br under Suzuki couplingconditions to give compound (20).

In cases where it is not possible to isolate a suitable reagent Ar²-Borfor use in the Suzuki reaction, then the reactivity of the Suzukireaction can be reversed as illustrated in Scheme 3 below.

In Scheme 3 the bromide (15) is converted to a boronate ester viacoupling with bispinacolate diborane in the presence of potassiumacetate using a palladium catalyst such as[1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II), complexwith dichloromethane. A polar solvent such as DMSO is preferred and thereaction mixture is heated at 80° C. under an atmosphere of nitrogen orargon to enable the reaction to take place. The resulting boronate esteris then reacted with a halogen-substituted aromatic or heteroaromaticgroup under Suzuki reaction conditions already described herein.

Compounds of formula (1) wherein Z is Ar² and Y is R³ can be prepared asdescribed herein using the 7-bromo-2-chloro-quinazoline regioisomer asthe starting material.

Once formed, one compound of the formula (1), or a protected derivativethereof, can be converted into another compound of the formula (1) bymethods well known to the skilled person. Examples of syntheticprocedures for converting one functional group into another functionalgroup are set out in standard texts such as Advanced Organic Chemistry,by Jerry March, 4^(th) edition, 119, Wiley Interscience, New York;Fiesers' Reagents for Organic Synthesis, Volumes 1-17, John Wiley,edited by Mary Fieser (ISBN: 0-471-58283-2); and Organic Syntheses,Volumes 1-8, John Wiley, edited by Jeremiah P. Freeman (ISBN:0-471-31192-8)).

In many of the reactions described above, it may be necessary to protectone or more groups to prevent reaction from taking place at anundesirable location on the molecule. Examples of protecting groups, andmethods of protecting and deprotecting functional groups, can be foundin Protective Groups in Organic Synthesis (T. Green and P. Wuts; 3rdEdition; John Wiley and Sons, 1999).

Compounds made by the foregoing methods may be isolated and purified byany of a variety of methods well known to those skilled in the art andexamples of such methods include recrystallisation and chromatographictechniques such as column chromatography (e.g. flash chromatography) andHPLC.

Pharmaceutical Formulations

While it is possible for the active compound to be administered alone,it is preferable to present it as a pharmaceutical composition (e.g.formulation).

Accordingly, in another embodiment (Embodiment 4.1) of the invention,there is provided a pharmaceutical composition comprising at least onecompound of the formula (1) as defined in any one of Embodiments 1.0 to1.116 together with a pharmaceutically acceptable excipient.

The pharmaceutically acceptable excipient can be, for example, a carrier(e.g. a solid, liquid or semi-solid carrier), a diluent or bulkingagent, a granulating agent, coating agent, binding agent, disintegrant,lubricating agent, preservative, antioxidant, buffering agent,suspending agent, thickening agent, flavouring agent, sweetener, tastemasking agent or any other excipient conventionally used inpharmaceutical compositions. Examples of excipients for various types ofpharmaceutical compositions are set out in more detail below.

The pharmaceutical compositions can be in any form suitable for oral,parenteral, topical, intranasal, ophthalmic, otic, rectal,intra-vaginal, or transdermal administration. Where the compositions areintended for parenteral administration, they can be formulated forintravenous, intramuscular, intraperitoneal, subcutaneous administrationor for direct delivery into a target organ or tissue by injection,infusion or other means of delivery. The delivery can be by bolusinjection, short term infusion or longer term infusion and can be viapassive delivery or through the utilisation of a suitable infusion pump.

Pharmaceutical formulations adapted for parenteral administrationinclude aqueous and non-aqueous sterile injection solutions which maycontain anti-oxidants, buffers, bacteriostats, co-solvents, organicsolvent mixtures, cyclodextrin complexation agents, emulsifying agents(for forming and stabilizing emulsion formulations), liposome componentsfor forming liposomes, gellable polymers for forming polymeric gels,lyophilisation protectants and combinations of agents for, interalia,stabilising the active ingredient in a soluble form and rendering theformulation isotonic with the blood of the intended recipient.Pharmaceutical formulations for parenteral administration may also takethe form of aqueous and non-aqueous sterile suspensions which mayinclude suspending agents and thickening agents (R. G. Strickly,Solubilizing Excipients in oral and injectable formulations,Pharmaceutical Research, Vol 21(2) 2004, p 201-230).

A drug molecule that is ionizable can be solubilized to the desiredconcentration by pH adjustment if the drug's pK_(a) is sufficiently awayfrom the formulation pH value. The acceptable range is pH 2-12 forintravenous and intramuscular administration, but subcutaneously therange is pH 2.7-9.0. The solution pH is controlled by either the saltform of the drug, strong acids/bases such as hydrochloric acid or sodiumhydroxide, or by solutions of buffers which include but are not limitedto buffering solutions formed from glycine, citrate, acetate, maleate,succinate, histidine, phosphate, tris(hydroxymethyl)-aminomethane(TRIS), or carbonate.

The combination of an aqueous solution and a water-soluble organicsolvent/surfactant (i.e., a co-solvent) is often used in injectableformulations. The water-soluble organic solvents and surfactants used ininjectable formulations include but are not limited to propylene glycol,ethanol, polyethylene glycol 300, polyethylene glycol 400, glycerin,dimethylacetamide (DMA), N-methyl-2-pyrrolidone (NMP; Pharmasolve),dimethylsulphoxide (DMSO), Solutol HS 15, Cremophor EL, Cremophor RH 60,and polysorbate 80. Such formulations can usually be, but are notalways, diluted prior to injection.

Propylene glycol, PEG 300, ethanol, Cremophor EL, Cremophor RH 60, andpolysorbate 80 are the entirely organic water-miscible solvents andsurfactants used in commercially available injectable formulations andcan be used in combinations with each other. The resulting organicformulations are usually diluted at least 2-fold prior to IV bolus or IVinfusion.

Alternatively, increased water solubility can be achieved throughmolecular complexation with cyclodextrins.

The formulations may be presented in unit-dose or multi-dose containers,for example sealed ampoules and vials, and may be stored in afreeze-dried (lyophilised) condition requiring only the addition of thesterile liquid carrier, for example water for injections, immediatelyprior to use.

The pharmaceutical formulation can be prepared by lyophilising acompound of Formula (1) or acid addition salt thereof. Lyophilisationrefers to the procedure of freeze-drying a composition. Freeze-dryingand lyophilisation are therefore used herein as synonyms. A typicalprocess is to solubilise the compound and the resulting formulation isclarified, sterile filtered and aseptically transferred to containersappropriate for lyophilisation (e.g. vials). In the case of vials, theyare partially stoppered with lyo-stoppers. The formulation can be cooledto freezing and subjected to lyophilisation under standard conditionsand then hermetically capped forming a stable, dry lyophile formulation.The composition will typically have a low residual water content, e.g.less than 5% e.g. less than 1% by weight based on weight of thelyophile.

The lyophilisation formulation may contain other excipients for example,thickening agents, dispersing agents, buffers, antioxidants,preservatives, and tonicity adjusters. Typical buffers includephosphate, acetate, citrate and glycine. Examples of antioxidantsinclude ascorbic acid, sodium bisulphite, sodium metabisulphite,monothioglycerol, thiourea, butylated hydroxytoluene, butylated hydroxylanisole, and ethylenediaminetetraacetic acid salts. Preservatives mayinclude benzoic acid and its salts, sorbic acid and its salts, alkylesters of para-hydroxybenzoic acid, phenol, chlorobutanol, benzylalcohol, thimerosal, benzalkonium chloride and cetylpyridinium chloride.The buffers mentioned previously, as well as dextrose and sodiumchloride, can be used for tonicity adjustment if necessary.

Bulking agents are generally used in lyophilisation technology forfacilitating the process and/or providing bulk and/or mechanicalintegrity to the lyophilized cake. Bulking agent means a freely watersoluble, solid particulate diluent that when co-lyophilised with thecompound or salt thereof, provides a physically stable lyophilized cake,a more optimal freeze-drying process and rapid and completereconstitution. The bulking agent may also be utilised to make thesolution isotonic.

The water-soluble bulking agent can be any of the pharmaceuticallyacceptable inert solid materials typically used for lyophilisation. Suchbulking agents include, for example, sugars such as glucose, maltose,sucrose, and lactose; polyalcohols such as sorbitol or mannitol; aminoacids such as glycine; polymers such as polyvinylpyrrolidine; andpolysaccharides such as dextran.

The ratio of the weight of the bulking agent to the weight of activecompound is typically within the range from about 1 to about 5, forexample of about 1 to about 3, e.g. in the range of about 1 to 2.

Alternatively, they can be provided in a solution form which may beconcentrated and sealed in a suitable vial. Sterilisation of dosageforms may be via filtration or by autoclaving of the vials and theircontents at appropriate stages of the formulation process. The suppliedformulation may require further dilution or preparation before deliveryfor example dilution into suitable sterile infusion packs.

Extemporaneous injection solutions and suspensions may be prepared fromsterile powders, granules and tablets.

In one preferred embodiment of the invention, the pharmaceuticalcomposition is in a form suitable for i.v. administration, for exampleby injection or infusion.

In another preferred embodiment, the pharmaceutical composition is in aform suitable for sub-cutaneous (s.c.) administration.

Pharmaceutical dosage forms suitable for oral administration includetablets, capsules, caplets, pills, lozenges, syrups, solutions, powders,granules, elixirs and suspensions, sublingual tablets, wafers or patchesand buccal patches.

Pharmaceutical compositions containing compounds of the formula (I) canbe formulated in accordance with known techniques, see for example,Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton,Pa., USA.

Thus, tablet compositions can contain a unit dosage of active compoundtogether with an inert diluent or carrier such as a sugar or sugaralcohol, eg; lactose, sucrose, sorbitol or mannitol; and/or a non-sugarderived diluent such as sodium carbonate, calcium phosphate, calciumcarbonate, or a cellulose or derivative thereof such as methylcellulose, ethyl cellulose, hydroxypropyl methyl cellulose, and starchessuch as corn starch. Tablets may also contain such standard ingredientsas binding and granulating agents such as polyvinylpyrrolidone,disintegrants (e.g. swellable crosslinked polymers such as crosslinkedcarboxymethylcellulose), lubricating agents (e.g. stearates),preservatives (e.g. parabens), antioxidants (e.g. BHT), buffering agents(for example phosphate or citrate buffers), and effervescent agents suchas citrate/bicarbonate mixtures. Such excipients are well known and donot need to be discussed in detail here.

Capsule formulations may be of the hard gelatin or soft gelatin varietyand can contain the active component in solid, semi-solid, or liquidform. Gelatin capsules can be formed from animal gelatin or synthetic orplant derived equivalents thereof.

The solid dosage forms (eg: tablets, capsules etc.) can be coated orun-coated, but typically have a coating, for example a protective filmcoating (e.g. a wax or varnish) or a release controlling coating. Thecoating (e.g. a Eudragit™ type polymer) can be designed to release theactive component at a desired location within the gastro-intestinaltract. Thus, the coating can be selected so as to degrade under certainpH conditions within the gastrointestinal tract, thereby selectivelyrelease the compound in the stomach or in the ileum or duodenum.

Instead of, or in addition to, a coating, the drug can be presented in asolid matrix comprising a release controlling agent, for example arelease delaying agent which may be adapted to selectively release thecompound under conditions of varying acidity or alkalinity in thegastrointestinal tract. Alternatively, the matrix material or releaseretarding coating can take the form of an erodible polymer (e.g. amaleic anhydride polymer) which is substantially continuously eroded asthe dosage form passes through the gastrointestinal tract. As a furtheralternative, the active compound can be formulated in a delivery systemthat provides osmotic control of the release of the compound.

Osmotic release and other delayed release or sustained releaseformulations may be prepared in accordance with methods well known tothose skilled in the art.

The compound of formula (1), as defined in any one of Embodiments 1.0 to1.116, or a prodrug thereof, may be formulated with a carrier andadministered in the form of nanoparticles. Nanoparticles offer thepossibility of direct penetration into the cell. Nanoparticle drugdelivery systems are described in “Nanoparticle Technology for DrugDelivery”, edited by Ram B Gupta and Uday B. Kompella, InformaHealthcare, ISBN 9781574448573, published 13 Mar. 2006. Nanoparticlesfor drug delivery are also described in J. Control. Release, 2003, 91(1-2), 167-172, and in Sinha et al., Mol. Cancer Ther. August 1, (2006)5, 1909.

The pharmaceutical formulations may be presented to a patient in“patient packs” containing an entire course of treatment in a singlepackage, usually a blister pack. Patient packs have an advantage overtraditional prescriptions, where a pharmacist divides a patient's supplyof a pharmaceutical from a bulk supply, in that the patient always hasaccess to the package insert contained in the patient pack, normallymissing in patient prescriptions. The inclusion of a package insert hasbeen shown to improve patient compliance with the physician'sinstructions.

Compositions for topical use include ointments, creams, sprays, patches,gels, liquid drops and inserts (for example intraocular inserts). Suchcompositions can be formulated in accordance with known methods.

Compositions for parenteral administration are typically presented assterile aqueous or oily solutions or fine suspensions, or may beprovided in finely divided sterile powder form for making upextemporaneously with sterile water for injection.

Examples of formulations for rectal or intra-vaginal administrationinclude pessaries and suppositories which may be, for example, formedfrom a shaped moldable or waxy material containing the active compound.

Compositions for administration by inhalation may take the form ofinhalable powder compositions or liquid or powder sprays, and can beadministrated in standard form using powder inhaler devices or aerosoldispensing devices. Such devices are well known. For administration byinhalation, the powdered formulations typically comprise the activecompound together with an inert solid powdered diluent such as lactose.

The compounds of Embodiments 1.0 to 1.116 will generally be presented inunit dosage form and, as such, will typically contain sufficientcompound to provide a desired level of biological activity. For example,a formulation may contain from 1 nanogram to 2 grams of activeingredient, e.g. from 1 nanogram to 2 milligrams of active ingredient.Within this range, particular sub-ranges of compound are 0.1 milligramsto 2 grams of active ingredient (more usually from 10 milligrams to 1gram, e.g. 50 milligrams to 500 milligrams), or 1 microgram to 20milligrams (for example 1 microgram to 10 milligrams, e.g. 0.1milligrams to 2 milligrams of active ingredient).

For oral compositions, a unit dosage form may contain from 1 milligramto 2 grams, more typically 10 milligrams to 1 gram, for example 50milligrams to 1 gram, e.g. 100 milligrams to 1 gram, of active compound.

The active compound will be administered to a patient in need thereof(for example a human or animal patient) in an amount sufficient toachieve the desired therapeutic effect.

Methods of Treatment

It is envisaged that the compounds of Embodiments 1.0 to 1.116 will beuseful either as sole chemotherapeutic agents or, more usually, incombination therapy with chemotherapeutic agents or radiation therapy inthe prophylaxis or treatment of a range of proliferative disease statesor conditions. Examples of such disease states and conditions are setout above.

Particular examples of chemotherapeutic agents that may beco-administered with the compounds of Embodiments 1.0 to 1.116 include:

-   -   Topoisomerase I inhibitors    -   Antimetabolites    -   Tubulin targeting agents    -   DNA binder and topoisomerase II inhibitors    -   EGFR inhibitors (e.g. Gefitinib—see Biochemical Pharmacology 78        2009 460-468)    -   mTOR inhibitors (e.g. Everolimus)    -   PI3K pathway inhibitors (e.g. PI3K, PDK1)    -   Akt inhibitors    -   Alkylating Agents (e.g. temozolomide, cyclophosphamide)    -   Monoclonal Antibodies (e.g. antibodies targeting CTLA-4, PD-1,        PD-L1, CD52 or CD20)    -   Anti-Hormones    -   Signal Transduction Inhibitors    -   Proteasome Inhibitors    -   DNA methyl transferases    -   Cytokines and retinoids    -   Hypoxia triggered DNA damaging agents (e.g. Tirapazamine)    -   Aromatase inhibitors    -   Anti Her2 antibodies, (see for example        http://www.wipo.int/pctdb/en/wo.jsp?wo=2007056118),    -   Inhibitors of angiogenesis    -   HDAC inhibitors    -   MEK inhibitors    -   B-Raf inhibitors    -   ERK inhibitors    -   HER2 small molecule inhibitors (e.g. lapatinib)    -   Bcr-Abl tyrosine-kinase inhibitors (e.g. imatinib)    -   CDK4/6 inhibitor e.g. Ibrance    -   VEGFR inhibitors    -   IGFR-1 inhibitors    -   Inhibitors of the Hedgehog signalling pathway

Further examples of chemotherapeutic agents that may be co-administeredwith a compound as defined in any one Embodiments 1.0 to 1.116 include:

-   -   Torc 1 inhibitors    -   PI3K pathway inhibitors (e.g. PI3K, PDK1)    -   EGFR inhibitors (e.g. Gefitinib—refer to: Everolimus restores        gefitinib sensitivity in resistant non-small cell lung cancer        cell lines, Biochemical Pharmacology 78 2009 460-468)    -   Taxanes (e.g. paclitaxel, docetaxel, cabazitaxel)    -   Platinum agents (e.g. cisplatin, carboplatin, oxaliplatin)    -   Anthracyclines (e.g. Doxorubicin)    -   Inhibitors of Bcl-2 family proteins e.g. ABT263 (navitoclax), a        Bcl-2/Bcl-extra large (Bcl-xL) inhibitor

One particular combination comprises a compound according to any one ofEmbodiments 1.0 to 1.116 together with an EGFR inhibitor such asGefitinib or Erlotinib or with an mTOR inhibitor such as Everolimus.

The compounds may also be administered in conjunction with radiotherapy.

The compounds may be administered over a prolonged term to maintainbeneficial therapeutic effects or may be administered for a short periodonly. Alternatively they may be administered in a pulsatile orcontinuous manner.

The compounds of the invention will be administered in an effectiveamount, i.e. an amount which is effective to bring about the desiredtherapeutic effect. For example, the “effective amount” can be aquantity of compound which, when administered to a subject sufferingfrom cancer, slows tumour growth, ameliorates the symptoms of thedisease and/or increases longevity.

The amount of P70S6 inhibitor compound of the invention administered tothe subject will depend on the type and severity of the disease orcondition and on the characteristics of the subject, such as generalhealth, age, sex, body weight and tolerance to drugs. The skilled personwill be able to determine appropriate dosages depending on these andother factors.

The compounds are generally administered to a subject in need of suchadministration, for example a human or animal patient, preferably ahuman.

A typical daily dose of the compound of any of Embodiments 1.0 to 1.116can be in the range from 100 picograms to 100 milligrams per kilogram ofbody weight, more typically 5 nanograms to 25 milligrams per kilogram ofbodyweight, and more usually 10 nanograms to 15 milligrams per kilogramof bodyweight (e.g. 10 nanograms to 10 milligrams, and more typically 1microgram per kilogram to 20 milligrams per kilogram, for example 1microgram to 10 milligrams per kilogram) although higher or lower dosesmay be administered where required. The compound can be administered ona daily basis or on a repeat basis every 2, or 3, or 4, or 5, or 6, or7, or 10 or 14, or 21, or 28 days for example.

In one particular dosing schedule, a patient will be given an infusionof a compound for periods of one hour daily for up to ten days inparticular up to five days for one week, and the treatment repeated at adesired interval such as two to four weeks, in particular every threeweeks.

More particularly, a patient may be given an infusion of a compound forperiods of one hour daily for 5 days and the treatment repeated everythree weeks.

In another particular dosing schedule, a patient is given an infusionover 30 minutes to 1 hour followed by maintenance infusions of variableduration, for example 1 to 5 hours, e.g. 3 hours.

In a further particular dosing schedule, a patient is given a continuousinfusion for a period of 12 hours to 5 days, an in particular acontinuous infusion of 24 hours to 72 hours.

Ultimately, however, the quantity of compound administered and the typeof composition used will be commensurate with the nature of the diseaseor physiological condition being treated and will be at the discretionof the physician.

Methods of Diagnosis

Prior to administration of a compound of any one of Embodiments 1.0 to1.116, a patient may be screened to determine whether a disease orcondition from which the patient is or may be suffering is one whichwould be susceptible to treatment with a compound having activityagainst p70S6 kinase.

For example, a biological sample taken from a patient may be analysed todetermine whether a condition or disease, such as cancer, that thepatient is or may be suffering from is one which is characterised by agenetic abnormality or abnormal protein expression which leads toup-regulation of p70S6 kinase or to sensitisation of a pathway to normalp70S6 kinase activity or to over-expression of phosphorylated p70S6kinase. The term up-regulation includes elevated expression orover-expression, including gene amplification (i.e. multiple genecopies) and increased expression by a transcriptional effect, andhyperactivity and activation, including activation by mutations. Thus,the patient may be subjected to a diagnostic test to detect a markercharacteristic of up-regulation of p70S6 kinase. The term diagnosisincludes screening. By marker we include genetic markers including, forexample, the measurement of DNA composition to identify mutations ofp70S6. The term marker also includes markers which are characteristic ofup-regulation of p70S6, including enzyme activity, enzyme levels, enzymestate (e.g. phosphorylated or not) and mRNA levels of the aforementionedproteins.

Tumours with upregulation of p70S6 kinase may be particularly sensitiveto p70S6 inhibitors. Tumours may preferentially be screened forupregulation of p70S6. Thus, the patient may be subjected to adiagnostic test to detect a marker characteristic of up-regulation ofp70S6. The diagnostic tests are typically conducted on a biologicalsample selected from tumour biopsy samples, blood samples (isolation andenrichment of shed tumour cells), stool biopsies, sputum, chromosomeanalysis, pleural fluid, peritoneal fluid,

Methods of identification and analysis of mutations and up-regulation ofproteins are known to a person skilled in the art. Screening methodscould include, but are not limited to, standard methods such asreverse-transcriptase polymerase chain reaction (RT-PCR) or in-situhybridisation.

In screening by RT-PCR, the level of mRNA in the tumour is assessed bycreating a cDNA copy of the mRNA followed by amplification of the cDNAby PCR. Methods of PCR amplification, the selection of primers, andconditions for amplification, are known to a person skilled in the art.Nucleic acid manipulations and PCR are carried out by standard methods,as described for example in Ausubel, F. M. et al., eds. CurrentProtocols in Molecular Biology, 2004, John Wiley & Sons Inc., or Innis,M. A. et-al., eds. PCR Protocols: a guide to methods and applications,1990, Academic Press, San Diego. Reactions and manipulations involvingnucleic acid techniques are also described in Sambrook et al., 2001,3^(rd) Ed, Molecular Cloning: A Laboratory Manual, Cold Spring HarborLaboratory Press. Alternatively a commercially available kit for RT-PCR(for example Roche Molecular Biochemicals) may be used, or methodologyas set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531;5,192,659, 5,272,057, 5,882,864, and 6,218,529 and incorporated hereinby reference.

An example of an in-situ hybridisation technique for assessing mRNAexpression would be fluorescence in-situ hybridisation (FISH) (seeAngerer, 1987 Meth. Enzymol., 152: 649).

Generally, in situ hybridization comprises the following major steps:(1) fixation of tissue to be analyzed; (2) pre-hybridization treatmentof the sample to increase accessibility of target nucleic acid, and toreduce nonspecific binding; (3) hybridization of the mixture of nucleicacids to the nucleic acid in the biological structure or tissue; (4)post-hybridization washes to remove nucleic acid fragments not bound inthe hybridization, and (5) detection of the hybridized nucleic acidfragments. The probes used in such applications are typically labeled,for example, with radioisotopes or fluorescent reporters. Preferredprobes are sufficiently long, for example, from about 50, 100, or 200nucleotides to about 1000 or more nucleotides, to enable specifichybridization with the target nucleic acid(s) under stringentconditions. Standard methods for carrying out FISH are described inAusubel, F. M. et al., eds. Current Protocols in Molecular Biology,2004, John Wiley & Sons Inc and Fluorescence In Situ Hybridization:Technical Overview by John M. S. Bartlett in Molecular Diagnosis ofCancer, Methods and Protocols, 2nd ed.; ISBN: 1-59259-760-2; March 2004,pps. 077-088; Series: Methods in Molecular Medicine.

Alternatively, the protein products expressed from the mRNAs may beassayed by immunohistochemistry of tumour samples, solid phaseimmunoassay with microtiter plates, Western blotting, 2-dimensionalSDS-polyacrylamide gel electrophoresis, ELISA, flow cytometry and othermethods known in the art for detection of specific proteins. Detectionmethods would include the use of site specific antibodies. The skilledperson will recognize that all such well-known techniques for detectionof up-regulation of p70S6 kinase could be applicable in the presentcase.

Accordingly, in another embodiment of the invention (Embodiment 5.1),there is provided a method for the diagnosis and treatment of a diseasestate or condition mediated by p70S6 kinase which method comprises (i)screening a patient to determine whether a disease or condition fromwhich the patient is or may be suffering is one which would besusceptible to treatment with a compound having activity against p70S6kinase; and (ii) where it is indicated that the disease or conditionfrom which the patient is thus susceptible, thereafter administering tothe patient a compound as defined in any one of Embodiments 1.0 to1.116.

In another embodiment (Embodiment 5.2), there is provided the use of acompound as defined in any one of Embodiments 1.0 to 1.116 for themanufacture of a medicament for the treatment or prophylaxis of adisease state or condition in a patient who has been screened and hasbeen determined as suffering from, or being at risk of suffering from, adisease or condition which would be susceptible to treatment with acompound having activity against p70S6.

In a further embodiment (Embodiment 5.3), there is provided a compoundas defined in any one of Embodiments 1.0 to 1.116 for use in thetreatment or prophylaxis of a disease state or condition in a patientwho has been screened and has been determined as suffering from, orbeing at risk of suffering from, a disease or condition which would besusceptible to treatment with a compound having activity against p70S6.

In another embodiment of the invention (Embodiment 5.4), there isprovided a method for the diagnosis and treatment of a disease state orcondition characterised by up-regulation of p70S6 kinase or the presenceof a mutated form of p70S6, which method comprises (i) screening apatient to determine whether a disease or condition from which thepatient is or may be suffering is one which would be susceptible totreatment with a compound having activity against p70S6 kinase; and (ii)where it is indicated that the disease or condition from which thepatient is thus susceptible, thereafter administering to the patient acompound as defined in any one of Embodiments 1.0 to 1.116.

In a further embodiment (Embodiment 5.5), there is provided a method forthe treatment of a disease state or condition characterised byup-regulation of p70S6 kinase or the presence of a mutated form ofp70S6, which method comprises administering a therapeutically effectiveamount of a compound as defined in any one of Embodiments 1.0 to 1.116to a patient who has been screened and has been determined as sufferingfrom, or being at risk of suffering from, a disease or condition whichwould be susceptible to treatment with a compound having activityagainst p70S6.

In another embodiment (Embodiment 5.6), there is provided the use of acompound as defined in any one of Embodiments 1.0 to 1.116 for themanufacture of a medicament for the treatment or prophylaxis of adisease, condition of disorder as defined in any one of Embodiments 2.1to 2.43 in a patient who has been screened and has been determined assuffering from, or being at risk of suffering, from a said disease,condition or disorder which would be susceptible to treatment with acompound having activity against p70S6.

In a further embodiment (Embodiment 5.7), there is provided a compoundas defined in any one of Embodiments 1.0 to 1.116 for use in thetreatment or prophylaxis of a disease or brain disorder in a patient whohas been screened and has been determined as suffering from, or being atrisk of suffering from, a disease, condition of disorder as defined inany one of Embodiments 2.1 to 2.43 which would be susceptible totreatment with a compound having activity against p70S6.

Triple-negative breast cancers are characterised in that the cancer doesnot express the genes for estrogen receptor (ER), progesterone receptor(PR) or HER2. The presence of ER and PR can be determined by standardimmuno-histochemical staining methods (see for example, Narod et al,Triple-Negative Breast Cancer: Clinical Features and Patterns ofRecurrence, Clin Cancer Res Aug. 1, 2007 13; 4429). Alternatively, it ispossible to assess gene expression of these proteins by methods such asQuantitative real-time polymerase chain reaction (QRT-PCR) withcommercially available PCR assays (see Jozefczuk et al, Quantitativereal-time PCR-based analysis of gene expression, Methods Enzymol. 2011;500:99-109).

Overexpression of the HER2 protein can be evaluated using the CB11monoclonal antibody in representative paraffin sections of each tumourusing the peroxidase-antiperoxidase technique for immunohistochemicalassay. A tumour is defined as exhibiting HER2 positivity when strongcomplete membrane staining is observed in at least 10% of tumour cells(Narod et al, Clin Cancer Res Aug. 1, 2007 13; 4429).

Accordingly, in another embodiment of the invention (Embodiment 5.8),there is provided a method for the diagnosis and treatment of a canceras defined in any one of Embodiments 2.10 to 2.18, which methodcomprises (i) screening a patient to determine whether a cancer fromwhich the patient is or may be suffering is one which does not expressestrogen receptor, progesterone receptor and/or HER2; and (ii) where itis indicated that the cancer which the patient is thus susceptible to,thereafter administering to the patient a compound as defined in any oneof Embodiments 1.0 to 1.116.

In another embodiment (Embodiment 5.9), there is provided the use of acompound as defined in any one of Embodiments 1.0 to 1.116 for themanufacture of a medicament for the treatment or prophylaxis of a canceras defined in any one of Embodiments 2.10 to 2.18 in a patient who hasbeen screened and has been determined as suffering from, or being atrisk of suffering, from a cancer which does not express estrogenreceptor, progesterone receptor and/or HER2.

In a further embodiment (Embodiment 5.10), there is provided a compoundas defined in any one of Embodiments 1.0 to 1.116 for use in thetreatment or prophylaxis of a cancer as defined in any one ofEmbodiments 2.10 to 2.18 in a patient who has been screened and has beendetermined as suffering from, or being at risk of suffering, from acancer which does not express estrogen receptor, progesterone receptorand/or HER2.

Fragile X syndrome occurs as a result of a mutation of the fragile Xmental retardation 1 gene (FMR1). In individuals affected by FXS, theFMR1 gene contains over 45, more commonly over 55 and in some cases over200 repeats of the CGG codon compared to between 5 and 44 times, morecommonly either 29 or 30 times, in unaffected individuals. This mutationresults in a failure to express fragile X mental retardation proteinFMRP leading to excessive production of an array of proteins normallycontrolled by FMRP. As FXS is a genetic disease, diagnosis of FXS can bereadily accomplished by running a genetic test from a blood or skinsample of the patient in question. FXS patients will not express or havemuch lower FMR1 mRNA levels than unaffected individuals. The levels ofFMR1 mRNA levels may be quantified using real-time PCR, assays for whichare commercially available. In addition, the size of the CGG repeat canbe determined by isolating genomic DNA by salting out followed by PCR.See, for example, Kumari et al. (HUMAN MUTATION, Vol. 35, No. 12,1485-1494, 2014) for laboratory methods to obtain this data. Thus,biomarkers that enable FXS to be identified in a patient include FMR1mRNA levels and the presence of oversized CGG repeats in a patient'sgenomic DNA.

Accordingly, in another embodiment of the invention (Embodiment 5.11),there is provided a method for the diagnosis and treatment of Fragile Xsyndrome, which method comprises (i) screening a patient for one or morebiomarkers indicative of Fragile X syndrome; and (ii) where such abiomarker is detected, thereafter administering to the patient acompound as defined in any one of Embodiments 1.0 to 1.116.

In another embodiment (Embodiment 5.12), there is provided the use of acompound as defined in any one of Embodiments 1.0 to 1.116 for themanufacture of a medicament for the treatment or prophylaxis of FragileX syndrome in a patient who has been screened for and found to harbourone or more biomarkers indicative of Fragile X syndrome.

In a further embodiment (Embodiment 5.13), there is provided a compoundas defined in any one of Embodiments 1.0 to 1.116 for use in thetreatment or prophylaxis of Fragile X syndrome in a patient who has beenscreened for and found to harbour one or more biomarkers indicative ofFragile X syndrome.

In another embodiment of the invention (Embodiment 5.14), there isprovided a method for the diagnosis and treatment of Fragile X syndrome,which method comprises (i) screening a patient to determine whether theyhave levels of FMR1 mRNA indicative of Fragile X syndrome; and (ii)where it is indicated that they do have such levels of FMR1 mRNA,thereafter administering to the patient a compound as defined in any oneof Embodiments 1.0 to 1.116.

In another embodiment (Embodiment 5.15), there is provided the use of acompound as defined in any one of Embodiments 1.0 to 1.116 for themanufacture of a medicament for the treatment or prophylaxis of FragileX syndrome in a patient who has been screened and has been determined ashaving levels of FMR1 mRNA indicative of Fragile X syndrome.

In a further embodiment (Embodiment 5.16), there is provided a compoundas defined in any one of Embodiments 1.0 to 1.116 for use in thetreatment or prophylaxis of Fragile X syndrome in a patient who has beenscreened and has been determined as having levels of FMR1 mRNAindicative of Fragile X syndrome.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates results obtained from in an in vivo model of triplenegative breast cancer as described in Example 44 herein, and inparticular shows the percentage of mice free of tumour against thenumber of days after implantation of the tumour when treated with 100mg/kg of Example 1 or the vehicle.

FIG. 2 shows the tumour volume against the number of days followingtumour implantation when treated with 100 mg/kg of Example 1 or thevehicle, in the in vivo model of triple negative breast cancer asdescribed in Example 44 herein.

FIG. 3 shows the weights of the livers of the subject mice in Example44.

FIG. 4 shows the tumour weights of the subject mice in Example 44.

EXAMPLES Examples 1 to 43

The compounds of Examples 1 to 43 in Table 1 below are illustrative ofthe invention.

Example 1

Example 2

Example 3

Example 4

Example 5

Example 6

Example 7

Example 8

Example 9

Example 10

Example 11

Example 12

Example 13

Example 14

Example 15

Example 16

Example 17

Example 18

Example 19

Example 20

Example 21

Example 22

Example 23

Example 24

Example 25

Example 26

Example 27

Example 28

Example 29

Example 30

Example 31

Example 32

Example 33

Example 34

Example 35

Example 36

Example 37

Example 38

Example 39

Example 40

Example 41

Example 42

Example 43Analytical Data

¹H NMR spectra were recorded on a Bruker 400 machine.

LCMS Methods:

LCMS analysis was carried using the following method(s):

LCMS Method 1

Parameter Information LCMS equipment Waters Alliance 2690 Column flow(mL/min) 1.2 Eluent solvents (A) 0.1% Ammonia in water; (mobile phase)(B) 100% methanol Column supplier Waters Column name X BRIDGE C18 columnColumn length (mm) 100 Column internal diameter (mm) 4.6 Column particlesize (micron) 5Elution Gradient:

Time (min) % A % B 0.0 90 10 1.00 90 10 5.00 0 100 7.00 0 100 7.50 90 108.00 90 10LCMS Method 2

LC-MS was carried out using a Waters Acquity H class device withSingleQda-Mass Detector using Positive/negative electrospray ionisation.The column used was as follows: Waters Acquity BEH C18 (50×2.1 mm) 1.7micron. Column flow rate: 0.55 mL/min. Solvent system used: mobile phase(A) 5 mm Ammonium Acetate+0.1% Formic acid (FA) in water and (B) 0.1% FAin Acetonitrile according to the following gradient:

Time (min) A % B % 0.01 95 5 0.4 95 5 0.8 65 35 1.2 45 55 2.5 0 100 3.30 100 3.31 95 5 4.00 95 5LCMS Method 3

Parameter Information LCMS equipment Waters Alliance 2690 Column flow(mL/min) 1.2 Eluent solvents (A) 10 nM Ammonium bicarbonate (mobilephase) in water; (B) 100% methanol Column supplier Waters Column name XBRIDGE C18 column Column length (mm) 100 Column internal diameter (mm)4.6 Column particle size (micron) 5Elution Gradient:

Time (min) % A % B 0.0 90 10 1.00 90 10 5.00 0 100 7.00 0 100 7.50 90 108.00 90 10LCMS Method 4

Parameter Information LCMS equipment Waters Alliance 2690 Column flow(mL/min) 1.2 Eluent solvents (A) % triflouroacetic acid in water;(mobile phase) (B) 100% methanol Column supplier Waters Column name XBRIDGE C18 column Column length (mm) 100 Column internal diameter (mm)4.6 Column particle size (micron) 5Elution Gradient:

Time (min) % A % B 0.01 90 10 3.00 10 90 6.00 0 100 7.00 0 100 7.01 9010 10.00 90 10LCMS Method 5

Parameter Information LCMS equipment Waters ACQUITY UPLC System Columnflow (mL/min) 0.8 Eluent solvents (A) 0.1% formic acid in water; (mobilephase) (B) 100% acetonitrile Column supplier Waters Column name BEH C18column Column length (mm) 50 Column internal diameter (mm) 2.1 Columnparticle size (micron) 1.7Elution Gradient:

Time (min) % A % B 0.00 90 10 0.75 90 10 2.80 10 90 4.50 00 100 4.60 00100 4.70 90 10 6.00 90 10LCMS Method 6

Parameter Information LCMS equipment Waters Alliance 2690 Column flow(mL/min) 1.2 Eluent solvents (A) 10 nM Ammonium bicarbonate (mobilephase) in water; (B) 100% methanol Column supplier Waters Column name XBRIDGE C18 column Column length (mm) 50 Column internal diameter (mm)4.6 Column particle size (micron) 3.5Elution Gradient:

Time (min) % A % B 0.00 90 10 1.00 90 10 4.00 0 100 6.00 0 100 6.50 9010 7.00 90 10Chiral HPLC Methods:

Chiral HPLC analysis was carried out using the following methods:

Chiral HPLC Method 1

Chiral HPLC was carried out using a Waters Super-critical FluidChromatography (SFC) Investigator analytical HPLC device with PDADetector. Flow rate: 4.0 ml/min. Injection volume: 10 uL. Analyticalcolumn used: Chiralpak IB (250*4.6 mm) 5 micron particle size. Solventsystem used: mobile phase (A) liquid carbon dioxide (B) 100% methanolaccording to the following gradient:

Time (min) A % B % 0 95 5 5 50 50 10 50 50Chiral HPLC Method 2

Parameter Information Chiral HPLC equipment SHIMADZU-2010 CHT Columnflow (mL/min) 1.0 Eluent solvents (A) 0.1% DEA in hexane; (mobile phase)(B) 0.1% DEA in ethanol Column supplier Daicel Column name Chiralpak IAColumn length (mm) 250 Column internal diameter (mm) 4.6 Column particlesize (micron) 5

An isocratic elution was used:

% A % B 60 40Chiral HPLC Method 3

Chiral HPLC was carried out using a Waters Super-critical FluidChromatography (SFC) Investigator analytical HPLC device with PDADetector. Flow rate: 4.0 ml/min. Injection volume: 35 uL. Analyticalcolumn used: Chiralpak IB (250*4.6 mm) 5 micron particle size. Solventsystem used: mobile phase (A) liquid carbon dioxide (B) 100% methanolaccording to the following gradient:

Time (min) A % B % 0 90 10 2 90 10 5 50 50 10 50 50Chiral HPLC Method 4

Chiral HPLC was carried out using a Waters Super-critical FluidChromatography (SFC) Investigator analytical HPLC device with PDADetector. Flow rate: 4.0 ml/min. Injection volume: 20 uL. Analyticalcolumn used: Chiralpak IB (250*4.6 mm) 5 micron particle size. Solventsystem used: mobile phase (A) liquid carbon dioxide (B) 50:50isopropanol:acetonitrile according to the following gradient:

Time (min) A % B % 0 95 5 5 50 50 10 50 50Chiral HPLC Method 5

Parameter Information Chiral HPLC equipment SHIMADZU-2010 CHT Columnflow (mL/min) 1.0 Eluent solvents (A) 0.1% DEA in hexane; (mobile phase)(B) 0.1% DEA in ethanol Column supplier Daicel Column name Chiralpak IAColumn length (mm) 250 Column internal diameter (mm) 4.6 Column particlesize (micron) 5

An isocratic elution was used:

% A % B 50 50Chiral HPLC Method 6

Parameter Information Chiral HPLC equipment SHIMADZU-2010 CHT Columnflow (mL/min) 1.0 Eluent solvents (A) 0.1% diethylamine (DEA) in (mobilephase) hexane; (B) ethanol Column supplier Daicel Column name ChiralpakIA Column length (mm) 250 Column internal diameter (mm) 4.6 Columnparticle size (micron) 5

An isocratic elution was used:

% A % B 50 50Chiral HPLC Method 7

Parameter Information Chiral HPLC equipment SHIMADZU-2010 CHT Columnflow (mL/min) 1.0 Eluent solvents (A) 0.1% DEA in hexane; (mobile phase)(B) 0.1% DEA in IPA Column supplier Daicel Column name Chiralpak IAColumn length (mm) 250 Column internal diameter (mm) 4.6 Column particlesize (micron) 5

An isocratic elution was used:

% A % B 25 75Chiral HPLC Method 8

Parameter Information Chiral HPLC equipment SHIMADZU-2010 CHT Columnflow (mL/min) 1.0 Eluent solvents (A) 0.1% DEA in water; (mobile phase)(B) 0.1% DEA in acetonitrile Column supplier Daicel Column nameChiralpak IA Column length (mm) 250 Column internal diameter (mm) 4.6Column particle size (micron) 5Elution Gradient:

Time (min) % A % B 0.01 90 10 9.00 10 90 11.00 0 100 20.00 0 100 20.0190 10 27.00 90 10Chiral HPLC Method 9

Parameter Information Chiral HPLC equipment SHIMADZU-2010 CHT Columnflow (mL/min) 1.0 Eluent solvents (A) 10 mM NH₄HCO₃ in water (mobilephase) (B) 100% acetonitrile Column supplier Daicel Column nameChiralpak IA Column length (mm) 250 Column internal diameter (mm) 4.6Column particle size (micron) 5Elution Gradient:

Time (min) % A % B 0.01 90 10 9.00 10 90 11.00 0 100 20.00 0 100 20.0190 10 27.00 90 10Chiral HPLC Method 10

Parameter Information Chiral HPLC equipment Agilent 1200 series PDAColumn flow (mL/min) 1.0 Eluent solvents (A) 0.1% DEA in hexane; (mobilephase) (B) 100% IPA Column supplier Daicel Column name Chiralpak IBColumn length (mm) 250 Column internal diameter (mm) 4.6 Column particlesize (micron) 5Elution Gradient:

Time (min) % A % B 0.00 90 10 5.00 90 10 10.00 70 30 15.00 70 30 25.0040 60 30.00 15 85 35.00 15 85 35.01 90 10 40.00 90 10Chiral HPLC Method 11

The same method was used as for Chiral method 10 except that ethanol wasused as solvent B

Chiral HPLC Method 12

Parameter Information Chiral HPLC equipment Agilent 1200 series PDAColumn flow (mL/min) 1.0 Eluent solvents (mobile phase) (A) 0.1% DEA inheptanes; (B) 100% IPA Column supplier Daicel Column name Chiralpak IAColumn length (mm) 250 Column internal diameter (mm) 4.6 Column particlesize (micron) 5

An isocratic elution was used:

Time (min) % A % B 50.00 90 10Preparative HPLC Methods:Preparative HPLC Method 1

Purification was carried out using a Waters PHP-01 Preparative HPLCsystem using an X Bridge C18 (250 mm length×19 mm internal diameter)column with 5 micron particle size and a flow rate of 15 mL/min. Solventsystem used: mobile phases (A) 0.1% ammonia in 100% water and (B) 100%acetonitrile using the following gradient:

Time (min) % A % B 0.01 70 30 14.00 20 80 14.01 0 100 16.00 0 100 16.0170 30 17.00 70 30Preparative HPLC Method 2

Purification was carried out using a Waters PHP-01 Preparative HPLCsystem using an X Bridge C18 (250 mm length×30 mm internal diameter)column with 5 micron particle size and a flow rate of 30 mL/min. Solventsystem used: mobile phases (A) 0.1% ammonia in 100% water and (B) 100%acetonitrile using the following gradient:

Time (min) % A % B 0.01 75 25 16.00 20 80 16.01 0 100 17.00 0 100 17.0175 25 18.00 75 25Preparative HPLC Method 3

Parameter Information chiral HPLC equipment Waters PHP-01 (2487) Columnflow (mL/min) 22 Eluent solvents (A) 10 mM NH₄HCO₃ in water (mobilephase) (B) acetonitrile:methanol:isopropyl alcohol (65:25:10) Columnsupplier Waters Column name X BRIDGE C18 column Column length (mm) 250Column internal diameter (mm) 30 Column particle size (micron) 5Elution Gradient:

Time (min) % A % B 0.01 70 30 6.00 54 46 6.01 54 46 23.00 54 46 23.01 0100 25.00 0 100 25.01 70 30 26.00 70 30Preparative HPLC Method 4

Parameter Information chiral HPLC equipment Waters PHP-01 (2487) Columnflow (mL/min) 22 Eluent solvents (A) 10 mM NH₄HCO₃ in water (mobilephase) (B) acetonitrile:methanol:isopropyl alcohol (65:25:10) Elutiongradient See below Column supplier Waters Column name Grace AlltechDenali C18 Reversed Phase Column Column length (mm) 250 Column internaldiameter (mm) 25 Column particle size (micron) 5Elution Gradient:

Time (min) A B 0.01 65 35 7.00 65 35 26.00 45 55 26.01 0 100 27.00 0 10027.01 65 35 28.00 65 35Preparative HPLC Method 5

Parameter Information chiral HPLC equipment Waters PHP-01 (2487) Columnflow (mL/min) 22 Eluent solvents (A) 10 mM NH₄HCO₃ in water (mobilephase) (B) 100% acetonitrile Elution gradient See below Column supplierWaters Column name Grace Alltech Denali C18 Reversed Phase Column Columnlength (mm) 250 Column internal diameter (mm) 25 Column particle size(micron) 5Elution Gradient:

Time (min) A B 0.01 70 30 3.00 50 50 22.00 50 50 22.01 0 100 23.00 0 10023.01 70 30 24.00 70 30Preparative HPLC Method 6

The same method was used as for Preparative HPLC method 5 except thatthe following elution gradient was used:

Time (min) % A % B 0.01 90 10 3.00 53 47 22.00 50 50 22.01 0 100 23.00 0100 23.01 90 10 24.00 90 10Preparative HPLC Method 7

The same method was used as for Preparative HPLC method 5 except thatthe following elution gradient was used:

Time (min) % A % B 0.01 90 10 3.00 63 37 16.00 58 42 16.01 0 100 17.00 0100 17.01 90 10 18.00 90 10

Int A is commercially available and can also be synthesized by methodsdescribed in the literature (Jain, Rama et al, PCT InternationalApplication WO2009153313)

Where X═CH or N and where R=protecting group such as THP

Compound 4 may be isolated as the free base or a salt form, e.g.monohydrochloride salt, depending on the method of isolation used.

Where X═CH or N and where R=protecting group such as THP

Compound 5 may be isolated as the free base or a salt form e.g.monohydrochloride salt depending on the method of isolation used.

Where X═CH or N and where R=protecting group such as THP

Compound 5 may be isolated as the free base or a salt form, e.g.monohydrochloride salt, depending on the method of isolation used.

Synthesis of Intermediates Intermediate A: 6-Bromo-2-chloro-quinazoline

A suspension of 6-Bromo-quinazolin-2-ol (2 g, 8.89 mmol) in POCl₃ (20mL) was stirred at 110° C. for 5 h. After completion of the reaction,the reaction mixture was concentrated in vacuo and the residue wasslowly poured into ice, resulting in a solid precipitate. The solid wasfiltered, washed with water followed by hexanes and then dried in vacuoto afford the title product (1.5 g, 69%).

6-Bromo-quinazolin-2-ol is commercially available and can also besynthesized by methods described in the literature (Jain, Rama et al,PCT Int. Appl., 2009153313)

Intermediate B:4-Chloro-1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine

Step 1: 4-Chloro-1H-pyrazolo[3,4-d]pyrimidine

1H-Pyrazolo [3,4-d]pyrimidin-4-ol (5.0 g, 36.7 mmol) was dissolved inPOCl₃ (61.2 mL, 100.67 g, 657 mmol) at room temperature under nitrogen.N,N-diisopropyl ethylamine (10.2 mL, 58.5 mmol) was added into thereaction mixture and the resulting mixture was refluxed at 110° C. for 4hrs. After 4 hrs, POCl₃ was distilled off under vacuum at 40° C. toobtain a blackish red thick gum. The thick gum was poured into ice coldwater (25 mL) and extracted by DCM (25 mL×3). The organic layer wasconcentrated to 25 mL. The product was used as crude for the next step.

Step 2: 4-Chloro-1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine

To a solution of 4-chloro-1H-pyrazolo[3,4-d]pyrimidine (2 g, 12.9 mmol)and D-10-Camphor sulphonic acid (0.324 g, 1.39 mmol) in anhydrous ethylacetate (20 mL) was slowly added 3,4-dihydropyrane (6 mL, 5.53 g, 65.8mmol) at room temperature. The reaction mixture was then allowed to stirat room temperature for 24 h. After completion of reaction, as judged byTLC, the reaction mixture was concentrated in vacuo and purified byflash column chromatography on silica gel eluting with 10% ethyl acetatein hexanes to afford the title product (1.92 g, 62%).

Intermediate C: N′-Benzyl-N,N-dimethyl-ethane-1,2-diamine

To a stirred solution of Benzaldehyde (1.0 g, 9.42 mmol) in methanol (20mL) was added N,N dimethyl ethylene diamine (0.83 g, 9.42 mmol) andglacial acetic acid (1.13 g, 1.18 mmol) at RT under nitrogen. Themixture was stirred at RT for 2 h. To the reaction mixture was addedsodium triacetoxyborohydride (5.99 g, 2.83 mmol) at 0° C. and thereaction mixture was stirred for 18 h at RT under nitrogen. The reactionmixture was concentrated in vacuo. Then to the crude was added 20 ml 1NHCl and the aqueous was extracted with ethyl acetate (20 mL). Theaqueous layer was separated off, basified to pH 8 with solid NaHCO₃ andextracted with DCM (7×30 mL). The DCM layer was separated off, driedover Na₂SO₄ and concentrated in vacuo to afford title product (1.0 g,60%).

Intermediate D: (R)-3-Aminomethyl-morpholine-4-carboxylic AcidTert-Butyl Ester

Step 1:(R)-3-(1,3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-morpholine-4-carboxylicAcid Tert-Butyl Ester

To a solution of (R)-4-Boc-3-hydroxymethylmorpholine (1.5 g, 6.90 mmol)in THF (7.5 mL) was added phthalimide (1.21 g, 8.22 mmol) andtriphenylphosphine (5.43 g, 20.70 mmol) at RT. To the reaction mixturewas added a solution of Diisopropylazodicarboxylate (DIAD) (4.18 g,0.0207 mol) in THF (7.5 mL) dropwise and the reaction mixture wasstirred at RT for 30 min. The reaction mixture was poured into water andextracted with ethyl acetate (3×50 mL). The organic layer was thenwashed with brine (1×30 mL) as well as water (1×30 mL), dried overanhydrous sodium sulphate and concentrated in vacuo. The residue wasfurther purified by column chromatography on silica gel, eluting with16% ethyl acetate in hexane to afford an oil (4.3 g, >100%).

Step 2: (R)-3-Aminomethyl-morpholine-4-carboxylic Acid Tert-Butyl Ester

To a solution of(R)-3-(1,3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-morpholine-4-carboxylicacid tert-butyl ester (4.3 g, 12.4 mmol) in ethanol (26 mL) and toluene(26 mL) was added hydrazine hydrate (99% in water, 1.19 g, 23.53 mmol)at RT. The reaction mixture was refluxed for 30 min, concentrated invacuo, and the residue was poured into ice-water and extracted withethyl acetate (3×100 mL). The organic layers were combined and washedwith brine, separated off and dried over sodium sulphate, thenconcentrated in vacuo to afford crude product. The crude product wasfurther purified by flash column chromatography on silica gel, elutingwith 4% methanol in chloroform to afford the title product (1.63 g,61%).

Intermediate E: (S)-3-Aminomethyl-morpholine-4-carboxylic AcidTert-Butyl Ester

Intermediate E was prepared from (S)-4-Boc-3-hydroxymethylmorpholineusing the same method as described for intermediate D.

Intermediate F: 6-Chloro-9-(tetrahydro-pyran-2-yl)-9H-purine

Intermediate F is commercially available (CAS No.: 7306-68-5).

Intermediate G:4-Chloro-3-methyl-1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4d]pyrimidine

To a suspension of 4-chloro-3-methyl-1H-pyrazolo[3,4-d]pyrimidine (0.5g, 2.97 mmol) in ethyl acetate (21 mL) was sequentially added D-10camphor sulfonic acid (0.07 g, 0.301 mmol) and 3,4-dihydropyran (1.24 g,14.7 mmol) at RT. The reaction mixture was stirred for 24 h at RT andwas then concentrated in vacuo prior to purification by flash columnchromatography on silica, eluting with 8% ethyl acetate in hexane toafford title product (0.59 g, 79%).

Intermediate H:N-{3-[(6-Bromo-quinazolin-2-ylamino)-methyl]-phenyl}-methanesulfonamide

Step 1: (6-Bromo-quinazolin-2-yl)-(3-nitro-benzyl)-amine

To a stirred solution of 6-bromo-2-chloro-quinazoline (0.6 g, 2.46 mmol)in DMSO (6 mL) was added 3-nitrobenzylamine hydrochloride (0.56 g, 2.97mmol) and DIPEA (1.28 g, 1.73 mL, 9.89 mmol) at RT. The resultingmixture was heated at 80° C. for 12 h. The reaction mixture was pouredinto cold water and extracted with ethyl acetate (2×50 mL). The organiclayer was washed with brine (20 mL) then water (20 mL), separated off,dried over anhydrous sodium sulphate and concentrated in vacuo to affordcrude product. The crude product was purified by flash columnchromatography on silica gel, eluting with 18% ethyl acetate in hexaneto afford the title product (0.97 g, >100%).

Step 2: (3-Amino-benzyl)-(6-bromo-quinazolin-2-yl)-amine

To a stirred solution of(6-Bromo-quinazolin-2-yl)-(3-nitro-benzyl)-amine (0.97 g, 2.70 mmol) inmethanol (10 mL) was added glacial acetic acid (0.30 g, 5.0 mmol) andIron powder (100 mesh) (0.30 g, 5.4 mmol) at RT. The resulting mixturewas heated at 60° C. for 4 h. The reaction mixture was poured into coldwater and extracted with ethyl acetate (2×50 mL). The organic layer waswashed with brine (20 mL) then water (20 mL), separated off, dried overanhydrous sodium sulphate and concentrated in vacuo to afford crudeproduct which was used directly in the next step.

Step 3:N-{3-[(6-Bromo-quinazolin-2-ylamino)-methyl]-phenyl}-methanesulfonamide

To a stirred solution of(3-Amino-benzyl)-(6-bromo-quinazolin-2-yl)-amine (0.85 g, 2.58 mmol) inDCM (13 mL) was added 2,6-lutidine (0.30 g, 0.33 mL, 2.80 mmol) andmethane sulphonyl chloride (0.29 g, 0.196 mL, 2.53 mmol) at 00° C. Theresulting mixture was then stirred for 6 h at RT. The reaction mixturewas poured into cold water and extracted with ethyl acetate (2×50 mL).The organic layer was washed with brine (20 mL) then water (20 mL),separated off, dried over anhydrous sodium sulphate and concentrated invacuo to afford crude product. The crude product was purified by flashcolumn chromatography on silica gel, eluting with 40% ethyl acetate inhexane to afford the title product (0.6 g, 57%).

Intermediate I:N-{3-[(R)-1-(6-Bromo-quinazolin-2-ylamino)-ethyl]-phenyl}-methanesulfonamide

The title compound was prepared using the same method as described forintermediate H, with the exception that (R)-1-(3-nitrophenyl)ethylaminehydrochloride (0.70 g, 3.45 mmol) was used instead of 3-nitrobenzylaminehydrochloride in step 1. Yield of final step: 0.7 g (57%).

Synthetic scheme A is illustrated with reference to Example 1 below.

Example 1((R)-1-Phenyl-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

Step 1: (6-Bromo-quinazolin-2-yl)-((R)-1-phenyl-ethyl)-amine

To a solution of 6-Bromo-2-chloro-quinazoline (10 g, 41.07 mmol) in DMSO(100 mL) was added (R)-(+)-1-phenylethylamine (6.0 g, 49.51 mmol) andDIPEA (21.4 g, 28.84 mL, 166 mmol). The resulting mixture was heated at80° C. for 12 h. The reaction mixture was poured into cold waterresulting in a solid precipitate. The solid was collected in vacuo andwashed with cold water (3×100 mL) to afford title product which was usedin the next step without purification (13.2 g, 98%).

Step 2:((R)-1-Phenyl-ethyl)-[6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-quinazolin-2-yl]-amine

To a stirred solution of(6-Bromo-quinazolin-2-yl)-((R)-1-phenyl-ethyl)-amine (13.2 g, 40.22 mol)in 1, 4-dioxane (149 mL) was added bis(pinacolato)diborane (17.4 g,68.52 mmol) followed by potassium acetate (11.8 g, 120.2 mmol) undernitrogen at RT. Nitrogen gas was bubbled through the resulting mixturefor 30 min. To the reaction mixture was then added 1,1-bis(diphenylphosphino)ferrocene palladium(II)dichloridedichloromethane complex (1.6 g, 1.96 mmol). The reaction mixture wasthen heated at 80° C. for 3 h. The reaction mixture was poured intowater and extracted with ethyl acetate (3×200 mL). The organic layerswere combined and washed with brine (100 mL) followed by water (100 mL),then separated off and dried over anhydrous sodium sulphate. The organiclayer was concentrated in vacuo then purified by flash columnchromatography on silica eluting with 15% ethyl acetate in hexanes toafford title product which was used in the next step without furtherpurification (19.9 g, >100%).

Step 3:((R)-1-Phenyl-ethyl)-{6-[1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-quinazolin-2-yl}-amine

To a solution of((R)-1-Phenyl-ethyl)-[6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-quinazolin-2-yl]-amine(19.9 g, 67.89 mmol) in a mixture of THF: water (267 mL, 4:1 ratio) wasadded Intermediate B (19.4 g, 81.28 mmol) followed by Cs₂CO₃ (88.3 g,271.01 mmol) under nitrogen at RT. Nitrogen gas was bubbled through theresulting mixture for 45 min and to the reaction mixture was then addedtetrakis(triphenylphosphine)palladium (0) (7.84 g, 6.78 mmol). Thereaction mixture was then heated at 80° C. for 4 h under nitrogen. Thereaction mixture was poured into water and extracted with ethyl acetate(2×300 mL). The organic layers were combined and washed with water (100mL), separated off then dried over anhydrous sodium sulphate. Theorganic layer was concentrated in vacuo then purified by flash columnchromatography on silica eluting with 45% ethyl acetate in hexanes toafford title product (15 g, 49%).

Step 4:((R)-1-Phenyl-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

To a stirred solution of((R)-1-Phenyl-ethyl)-{6-[1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-quinazolin-2-yl}-amine(15.0 g, 33.2 mol) in a mixture of methanol (36 mL) and 1,4-dioxane (150mL) was added 4N HCl in 1,4-dioxane (41.5 mL) under nitrogen at RT. Thereaction mixture was further stirred for 3 h at RT.

The reaction mixture was filtered in vacuo, and the filtered solid waswashed with ethyl acetate (3×50 mL) then hexane (3×50 mL) to afford theHCl salt. The solid was added to water (100 mL) and the resultingmixture was basified to pH 8.3 using saturated aqueous NaHCO₃ solution.The resulting suspension was stirred for 30 min at RT then filtered invacuo. The solid was re-suspended in water on a Büchner funnel and theresulting slurry was stirred for 10 mins and then filtered in vacuo. Theslurrying in water process was repeated a further seven times. Theresulting filtered solid was dried in vacuo to afford the title product(9.0 g, 74%).

Optionally, it is possible to retain the title compound as the HCl saltby omitting the final basification procedure.

Example 2((R)-1-(3-Chloro-phenyl)-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

The title product was prepared from intermediate A (0.4 g, 1.64 mmol)using the same method as described for Example 1 with the followingexceptions: (a) (R)-1-(3-chloro-phenyl)-ethylamine was used instead of(R)-1-phenyl-ethylamine in Step 1 (b) in step 4, the following methodwas used:N—((R)-1-(3-chlorophenyl)ethyl)-6-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)quinazolin-2-amine(0.12 g, 0.247 mmol) was dissolved in methanol (1 mL) and 4 N HCl indioxane (3 mL) was added at RT. After stirring at RT for 4 h, the solidprecipitate thus formed was filtered and washed with ethyl acetate toafford title product as the monohydrochloride salt (0.050 g, 46%).

Example 3((R)-1-(3-Fluoro-phenyl)-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

The title product was prepared from intermediate A (0.4 g, 1.64 mmol)using the same method as described for Example 1 with the followingexceptions: (a) (R)-1-(3-fluoro-phenyl)-ethylamine was used instead of(R)-1-phenyl-ethylamine in step 1 (b) in step 4, the method describedfor example 2 was used resulting in the compound being isolated as themonohydrochloride salt (0.040 g, 68%).

Example 4((R)-1-(4-Fluoro-phenyl)-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

The title product was prepared from intermediate A (0.35 g, 1.43 mmol)using the same method as described for Example 1 with the followingexceptions: (a) (R)-1-(4-fluoro-phenyl)-ethylamine was used instead of(R)-1-phenyl-ethylamine in step 1 (b) in step 4, following concentrationof the reaction mixture in vacuo, the crude product was purified bypreparative HPLC purification to afford the title product (0.020 g,22%).

Example 5((S)-2-Hydroxy-1-phenyl-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

The title product was prepared from intermediate A (0.4 g, 1.64 mmol)using the same method as described for Example 1 with the followingexceptions: (a) (S)-2-phenylglycinol was used instead of(R)-1-phenyl-ethylamine in step 1 (b) in step 4, following concentrationof the reaction mixture in vacuo, the crude product was purified bypreparative HPLC purification to afford the free base. To a solution offree base in ethyl acetate (1 ml) at 10° C. was added 4N HCl in dioxane(0.05 ml) followed by stirring at RT for 30 min. After 30 min, thereaction mixture was concentrated in vacuo and triturated with ethylacetate to afford the title product as the monohydrochloride salt (0.050g, 37%).

Example 6(4-Fluorobenzyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-methylamine

The title product was prepared from intermediate A (0.4 g, 1.64 mmol)using the same method as described for Example 1 with the followingexceptions: (a) N-(4-fluorobenzyl)-N-methylamine was used instead of(R)-1-phenyl-ethylamine in step 1 (b) in step 4, following concentrationof the reaction mixture in vacuo, the product was triturated withmethanol and ethyl acetate to afford the title product as themonohydrochloride salt (0.080 g, 59%).

Example 7Benzyl-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-methylamine

The title product was prepared from intermediate A (0.6 g, 2.46 mmol)using the same method as described for Example 1 with the followingexceptions: (a) N-benzyl-N-methylamine was used instead of(R)-1-phenyl-ethylamine in step 1 (b) in step 4, the method of example 6was applied. The title product was isolated as the monohydrochloridesalt (0.080 g, 60%).

Example 8((R)-1-Phenyl-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-methylamine

The title product was prepared from intermediate A and by followingscheme B and the method described below.

Step 1: (6-Bromo-quinazolin-2-yl)-((R)-1-phenyl-ethyl)-amine

As described in step 1 of Example 1

Step 2: (6-Bromo-quinazolin-2-yl)-methyl-((R)-1-phenyl-ethyl)-amine

To a suspension of NaH (60% in mineral oil) (0.082 g, 2.05 mmol) in DMF(5 mL) at 0° C. under nitrogen was added a solution of(6-Bromo-quinazolin-2-yl)-((R)-1-phenyl-ethyl)-amine (0.45 g, 1.37 mmol)in DMF (5 mL). The reaction mixture was stirred at 0° C. for 30 minutes.MeI (0.233 g, 1.64 mmol) was added and the reaction mixture was stirredat RT for 2 h. The reaction mixture was then diluted with water (30 mL)and extracted with ethyl acetate (2×30 mL). The combined organic layerswere separated off, dried over anhydrous sodium sulphate, theconcentrated in vacuo to afford crude product. The crude product waspurified by flash column chromatography on silica gel eluting with 5-8%ethyl acetate in hexanes to afford the title product (0.45 g, 96%).

Step 3:Methyl-((R)-1-phenyl-ethyl)-[6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-quinazolin-2-yl]-amine

(6-Bromo-quinazolin-2-yl)-methyl-((R)-1-phenyl-ethyl)-amine (0.45 g,1.31 mmol) was subjected to the conditions of step 2, Example 1 toafford the title product (0.25 g, 49%).

Step 4:Methyl-((R)-1-phenyl-ethyl)-{6-[1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-quinazolin-2-yl}-amine

Methyl-((R)-1-phenyl-ethyl)-[6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-quinazolin-2-yl]-amine(0.25 g, 0.64 mmol) was subjected to the conditions of step 3, Example 1to afford the title product (0.1 g, 34%).

Step 5:((R)-1-Phenyl-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-methylamine

To a solution ofMethyl-((R)-1-phenyl-ethyl)-{6-[1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-quinazolin-2-yl}-amine(0.1 g, 0.21 mmol) in methanol (3 mL) was added 4N HCl in dioxane (2 mL)at RT and the reaction mixture was stirred at RT for 5 h. During thereaction a solid precipitated out; the solid was thus filtered in vacuoand washed with ethyl acetate then dried in vacuo to afford the titleproduct (0.080 g, 91%).

The compound is isolated as the monohydrochloride salt.

Example 9(4-Fluorobenzyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

The title product was prepared from intermediate A (1.2 g, 4.96 mmol)using the same method as described for Example 1 with the followingexceptions: (a) 4-fluorobenzylamine was used instead of(R)-1-phenyl-ethylamine in step 1 (b) in step 4, following treatmentwith 4N HCl in dioxane (6.0 mL) and stirring for 3 h, the reactionmixture was concentrated in vacuo, poured into water and the resultingreaction mixture was basified up to pH 8 using saturated bicarbonate(aq) solution. The resulting suspension was filtered in vacuo to affordtitle product. Yield of final step: 0.105 g (48%).

Example 10(3-Fluorobenzyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

The title product was prepared from intermediate A (1.0 g, 4.13 mmol)using the same method as described for Example 1 with the followingexceptions: (a) 3-fluorobenzylamine was used instead of(R)-1-phenyl-ethylamine in step 1 (b) in step 4, the method of isolationdescribed in example 9 was used but additionally the filtered productwas suspended in ethyl acetate (5 mL) for 15 min at RT, followed byfiltration in vacuo. Yield of final step: 0.112 g (34%).

Example 11(3-Chlorobenzyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

The title product was prepared from intermediate A (0.60 g, 2.48 mmol)using the same method as described for Example 1 with the followingexceptions: (a) 3-chlorobenzylamine was used instead of(R)-1-phenyl-ethylamine in step 1 (b) in step 4, the method of isolationdescribed in example 9 was used but additionally the filtered productwas further purified by preparative HPLC purification using preparativeHPLC method 1. Yield of final step: 0.036 g (17%).

Example 12((R)-1-Phenyl-ethyl)-[7-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

The title product was prepared using the same method as described forExample 1 with the following exceptions: (a) 7-bromo-quinazolin-2-ol(1.2 g, 4.96 mmol) was used instead of 6-bromo-quinazolin-2-ol in thesynthesis of Int. A (b) in step 4, reaction time was 1 h. The method ofisolation described in example 9 was used but the filtered solid wasfurthermore purified by flash column chromatography, eluting with 3%methanol in chloroform, followed by preparative HPLC purification usingpreparative HPLC method 2. Yield of final step: 0.022 g (17%).

7-Bromo-quinazolin-2-ol can be purchased from various commercialsources, as indicated by availability on Scifinder databases, or can beprepared via the route described in International patent applicationWO2007117607.

Example 13((R)-1-Phenyl-ethyl)-[6-(1H-pyrazolo[3,4-b]pyridin-4-yl)-quinazolin-2-yl]-amine

The title product was prepared from((R)-1-Phenyl-ethyl)-[6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-quinazolin-2-yl]-amine(0.3 g, 0.799 mmol) using the same method as described for Example 1with the following exceptions: (a) in step 3,4-chloro-1H-pyrazolo[3,4-b]pyridine was used instead of intermediate B.Furthermore, in step 3, a solvent mixture of DMF: water was used (4:1, 5mL) and heating took place at 130° C. in a microwave reactor. Step 4 wasa HCl salt formation step: to a suspension of((R)-1-Phenyl-ethyl)-[6-(1H-pyrazolo[3,4-b]pyridin-4-yl)-quinazolin-2-yl]-amine(0.080 g, 0.218 mmol) in ethyl acetate (0.8 mL) was added 4N HCl indioxane (0.08 mL) at 10° C. and the reaction mixture was stirred at thesame temperature for 40 min. The reaction mixture was then concentratedin vacuo and triturated with ethyl acetate to afford the title productas the monohydrochloride salt (0.070 g, 80%)

4-Chloro-1H-pyrazolo[3,4-b]pyridine can be purchased from variouscommercial sources.

Example 14((R)-1-Phenyl-ethyl)-[6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

The title product was prepared from((R)-1-Phenyl-ethyl)-[6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-quinazolin-2-yl]-amine(0.35 g, 0.933 mmol) using the same method as described for Example 1with the following exceptions: (a) 4-chloro-7H-pyrrolo[2,3-d]pyrimidinewas used in step 3 instead of intermediate B (b) a HCl salt formationstep was included, the method for which is described in example 13 Thecompound is isolated as the monohydrochloride salt (0.055 g, 83%).

4-Chloro-7H-pyrrolo[2,3-d]pyrimidine can be purchased from variouscommercial sources.

Example 15((R)-1-Phenyl-ethyl)-[6-(1H-pyrrolo[2,3-b]pyridin-4-yl)-quinazolin-2-yl]-amine

The title product was prepared from((R)-1-Phenyl-ethyl)-[6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-quinazolin-2-yl]-amine(0.20 g, 0.533 mmol) using the same method as described for Example 1with the following exceptions: (a) in step 3,4-bromo-1H-pyrrolo[2,3-b]pyridine was used instead of intermediate B,potassium carbonate was used instead of cesium carbonate, and dioxane:water (4:1) was used as solvent rather than THF: water (b) a HCl saltformation step was included, the method for which is described inexample 13. The compound is isolated as the monohydrochloride salt(0.070 g, 80%).

4-Bromo-1H-pyrrolo[2,3-b]pyridine can be purchased from variouscommercial sources.

Example 16N-Benzyl-N′,N′-dimethyl-N-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-ethane-1,2-diamine

The title compound can be prepared via Synthetic Scheme A, following themethod of example 1, using N′-Benzyl-N,N-dimethyl-ethane-1,2-diamine(intermediate C) in step 1.

In step 4, the following method was followed:

Step 4

To a stirred solution ofN-Benzyl-N′,N′-dimethyl-N-{6-[1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-quinazolin-2-yl}-ethane-1,2-diamine(0.40 g, 0.79 mmol) in 1,4-dioxane (4 mL) was added 4N HCl in1,4-dioxane (0.25 mL, 1.0 mmol) under nitrogen at RT. The reactionmixture was further stirred for 4 h at RT. An additional aliquot of 4NHCl in 1,4-dioxane (0.25 mL, 1.0 mol) was added and the reaction mixturewas stirred for 3 h at RT. The reaction mixture was then concentrated invacuo to afford crude product which was added to water. The resultingmixture was basified with saturated NaHCO₃ (aq) solution to pH 8. Theresulting mixture was extracted by ethyl acetate and then concentratedin vacuo. The residue was purified by flash chromatography on silicagel, eluting with 2.5% methanol in chloroform to afford a crude yellowsolid which was further triturated using diethyl ether. The solidrecovered from trituration (0.086 g, 0.189 mmol) was dissolved in1,4-dioxane (0.8 mL) at room temperature and 4M HCl in 1,4-dioxane (0.06mL, 0.24 mmol) was added. The reaction mixture was stirred for 30minutes at RT, after which the reaction mixture was concentrated invacuo and triturated with diethyl ether (1 mL) to afford title productas the monohydrochloride salt (0.067 g, 19% overall yield).

Example 17Benzyl-(R)-1-morpholin-3-ylmethyl-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

The title compound was prepared according to Synthetic Scheme C.

Step 1: (tert-butyl(R)-3-(((6-bromoquinazolin-2-yl)amino)methyl)morpholine-4-carboxylate)

To a stirred solution of Int A (1.4 g, 5.75 mmol) in DMSO (14 mL) wasadded Int D (1.5 g, 6.93 mmol) and DIPEA (3.0 g, 4.04 mL, 23.21 mmol) atRT. The resulting mixture was heated at 80° C. for 18 h. The reactionmixture was poured into ice-cold water and extracted with ethyl acetate(3×50 mL). The organic layer was then washed with brine (50 mL) as wellas water (50 mL), separated off, dried over anhydrous sodium sulphateand concentrated in vacuo to afford crude product. The crude product waspurified by flash column chromatography on silica gel, eluting with 25%ethyl acetate in hexane to afford the title product (1.58 g, 65%).

Step 2: (tert-butyl(R)-3-((benzyl(6-bromoquinazolin-2-yl)amino)methyl)morpholine-4-carboxylate)

To a suspension of sodium hydride (0.74 g, 18.5 mmol) in dry DMF (22 mL)was added a solution of (tert-butyl(R)-3-(((6-bromoquinazolin-2-yl)amino)methyl)morpholine-4-carboxylate)(1.58 g, 3.73 mmol) in DMF (22 mL) at 00° C. under nitrogen. Thereaction mixture was stirred for 30 min at 00° C. and then brought to RTbefore benzyl bromide (1.92 g, 11.23 mmol) was added. The reactionmixture was stirred at 00° C. for 30 min. The reaction mixture waspoured into ice-water and extracted with ethyl acetate (3×50 mL). Theorganic layers were separated, combined and then washed with brine (50mL) followed by water (50 mL), dried over sodium sulphate andconcentrated in vacuo. The crude residue was purified by flash columnchromatography on silica gel, eluting with 10% ethyl acetate in hexaneto afford the title product (1.8 g, 94%).

Step 3: (tert-butyl(R)-3-((benzyl(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-yl)amino)methyl)morpholine-4-carboxylate)

(Tert-butyl(R)-3-((benzyl(6-bromoquinazolin-2-yl)amino)methyl)morpholine-4-carboxylate)(1.8 g, 3.51 mmol) was subjected to the same conditions as described forexample 1, step 2 to afford title product. Yield: 2.3 g (>100%).

Step 4: (tert-butyl(3R)-3-((benzyl(6-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)quinazolin-2-yl)amino)methyl)morpholine-4-carboxylate)

(Tert-butyl(R)-3-((benzyl(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-yl)amino)methyl)morpholine-4-carboxylate)(2.30 g, 4.10 mmol) was subjected to the same conditions as describedfor example 1, step 3 to afford title product (1.2 g, 46%).

Step 5:((R)—N-benzyl-N-(morpholin-3-ylmethyl)-6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)quinazolin-2-amine)

(Tert-butyl(3R)-3-((benzyl(6-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)quinazolin-2-yl)amino)methyl)morpholine-4-carboxylate)(1.2 g, 1.88 mmol) was subjected to the same conditions as described forexample 1, step 4 and purified as follows: after completion of thereaction, the reaction mixture was filtered in vacuo and the resultingfiltered solid was washed with ethyl acetate (3×50 mL) and hexane (3×50mL). The solid was further triturated in acetone, then filtered in vacuoto afford the title product as a monohydrochloride salt (0.48 g, 52%).

Example 18Benzyl-(S)-1-morpholin-3-ylmethyl-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

The title compound was prepared from Int A (1.3 g, 5.34 mmol) viaSynthetic Scheme C above using the same method as for Example 17 withthe following exceptions: (a) in step 1, intermediate E,(S)-3-Aminomethyl-morpholine-4-carboxylic acid tert-butyl ester(prepared by an analogous procedure to intermediate D) was used insteadof (R)-3-Aminomethyl-morpholine-4-carboxylic acid tert-butyl ester (b)in step 5 the acetone trituration was omitted. The compound is isolatedas the monohydrochloride salt. Yield of final step: 0.63 g (67%).

Example 19[(R)-1-(3,4-Difluoro-phenyl)-ethyl]-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amineStep 1: ((R)-6-bromo-N-(1-(3,4-difluorophenyl)ethyl)quinazolin-2-amine)

To a stirred solution of Intermediate A (0.5 g, 2.05 mol) in DMSO (5 mL)was added (R)-1-(3,4-difluorophenyl)ethylamine (0.39 g, 2.48 mmol) andDIPEA (1.08 g, 1.46 mL, 8.4 mmol) at room temperature. The resultingmixture was heated at 80° C. for 12 h. The reaction mixture was pouredinto ice water resulting in a precipitate. The solid was filtered off invacuo and washed with cold water to afford the title product (0.7 g,94%).

Step 2:((R)—N-(1-(3,4-difluorophenyl)ethyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-amine)

To a stirred solution of((R)-6-bromo-N-(1-(3,4-difluorophenyl)ethyl)quinazolin-2-amine) (0.70 g,1.92 mmol) in 1,4-dioxane (8 mL) was added bis(pinacolato)diborane (0.84g, 3.31 mmol) followed by potassium acetate (0.57 g, 5.80 mmol) undernitrogen at RT. The resulting mixture was purged by bubbling nitrogenthrough for 30 minutes. To the reaction mixture was added 1,1-bis(diphenylphosphino)ferrocene palladium(II)dichloridedichloromethane complex (0.08 g, 0.098 mmol). The reaction mixture wasthen heated at 80° C. for 2 h. The reaction mixture was poured intowater and extracted with ethyl acetate (2×40 mL). The combined organiclayers were washed with brine (20 mL) then water (20 mL), separated offand dried over anhydrous sodium sulphate prior to concentration invacuo. The crude residue was purified by flash column chromatography onsilica gel, eluting with 7% ethyl acetate in hexane to afford the titleproduct (0.94 g.>100%).

Step 3:(N—((R)-1-(3,4-difluorophenyl)ethyl)-6-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)quinazolin-2-amine)

To a stirred solution of((R)—N-(1-(3,4-difluorophenyl)ethyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-amine)(0.94 g, 2.29 mmol) in a mixture of THF: water (12.5 mL, 4:1) was addedIntermediate B (0.65 g, 2.72 mmol) followed by Cs₂C03 (2.97 g, 9.12mmol) under nitrogen at RT. The mixture was purged by bubbling nitrogengas through for 45 min, and to the resulting mixture was addedTetrakis(triphenylphosphine)palladium(0) (0.26 g, 0.225 mmol) at RT. Thereaction mixture was then heated at 80° C. for 3 h. The resultingreaction mixture was poured into water and the product was extractedusing ethyl acetate (2×30 mL). The combined organic layers were washedwith brine (20 mL) then water (20 mL), separated off and dried overanhydrous sodium sulphate, then concentrated in vacuo to afford crudeproduct. The crude was purified by flash column chromatography on silicagel, eluting with 45% ethyl acetate in hexane to afford title product(0.6 g, 54%).

Step 4:((R)—N-(1-(3,4-difluorophenyl)ethyl)-6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)quinazolin-2-amine)

To a stirred solution of(N—((R)-1-(3,4-difluorophenyl)ethyl)-6-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)quinazolin-2-amine)(0.6 g, 1.23 mmol) in a mixture of methanol (1.4 mL) and 1,4-dioxane (6mL) was added 4N HCl in 1,4-dioxane (6 mL) under nitrogen at RT. Thereaction mixture was further stirred for 1 h at RT, at which point aprecipitate had formed which was filtered off in vacuo and washed withethyl acetate (3×30 mL) followed by hexane (3×30 mL). The solid was thenadded to water (10 mL) and the resulting mixture was basified up to pH 8using saturated NaHCO₃ solution, with stirring for 30 min. The reactionmixture was filtered in vacuo, washing with water, to afford the titleproduct (0.27 g, 54%).

Example 20((R)-1-Phenyl-ethyl)-[6-(9H-purin-6-yl)-quinazolin-2-yl]-amine

The title product was prepared from intermediate A (10 g, 41.1 mmol)using the same method as described for Example 19 with the followingexceptions: (a) in step 1, (R)-1-phenyl-ethylamine was used instead of(R)-1-(3,4-difluorophenyl)ethylamine (b) in step 3, intermediate F,6-chloro-9-(tetrahydro-pyran-2-yl)-9H-purine, was used instead ofintermediate B. Yield of final step: 0.26 g (46%).

Example 21Benzyl-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

The title product was prepared from intermediate A (0.5 g, 2.05 mmol)using the same method as described for Example 19 except that in step 1,benzylamine was used instead of (R)-1-(3,4-difluorophenyl)ethylamine.Yield of final step: 0.2 g (40%).

Example 22[6-(3-Methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-((R)-1-phenyl-ethyl)-amine

The title product was prepared from intermediate A (10 g, 41.1 mmol)using the same method as described for Example 19 with the followingexceptions: (a) in step 1, (R)-1-phenyl-ethylamine was used instead of(R)-1-(3,4-difluorophenyl)ethylamine (b) in step 3, intermediate G,4-chloro-3-methyl-1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine,was used instead of intermediate B (c) in step 4, preparative HPLC(using preparative HPLC method 3) was used as final step to purify titleproduct. Yield of final step: 0.12 g (24%).

Example 23(3-Methoxy-benzyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

The title product was prepared from intermediate A (0.5 g, 2.05 mmol)using the same method as described for Example 19 except that in step 1,3-methoxy benzylamine was used instead of(R)-1-(3,4-difluorophenyl)ethylamine. Yield of final step: 0.27 g (59%).

Example 242-Fluoro-benzyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

The title product was prepared from intermediate A (0.4 g, 1.64 mmol)using the same method as described for Example 19 except that in step 1,2-fluorobenzylamine was used instead of(R)-1-(3,4-difluorophenyl)ethylamine. Yield of final step: 0.17 g (46%).

Example 25(3,4-Difluoro-benzyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

The title product was prepared from intermediate A (0.5 g, 2.05 mmol)using the same method as described for Example 19 except that in step 1,3,4-difluorobenzylamine was used instead of(R)-1-(3,4-difluorophenyl)ethylamine. Yield of final step: 0.34 g (78%).

Example 26N-(3-{[6-(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-methyl}-phenyl)-methanesulfonamide

Intermediate H (0.6 g, 1.47 mmol) was subjected to the conditions ofsteps 2-4 of Example 19 followed by purification by preparative HPLCmethod 4 to afford the title product (0.05 g, 11%).

Example 27[(R)-1-(3-Methoxy-phenyl)-ethyl]-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

The title product was prepared from intermediate A (0.6 g, 2.46 mmol)using the same method as described for Example 19 except that in step 1,(R)-(+)-1-(3-methoxyphenyl)ethylamine was used instead of(R)-1-(3,4-difluorophenyl)ethylamine.

Yield of final step: 0.4 g (59%).

Example 28[(R)-1-(2-Fluoro-phenyl)-ethyl]-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

The title product was prepared from intermediate A (0.5 g, 2.05 mmol)using the same method as described for Example 19 with the followingexceptions: (a) in step 1, (R)-1-(2-fluorophenyl)ethylamine was usedinstead of (R)-1-(3,4-difluorophenyl)ethylamine (b) in step 4, a finalacetone trituration was applied. Yield of final step: 0.3 g (42%).

Example 29((S)-1-Phenyl-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

The title product was prepared from intermediate A (2.5 g, 10.3 mmol)using the same method as described for Example 19 with the followingexceptions: (a) (S)-(−)-α-methyl benzyl amine was used instead of(R)-1-(3,4-difluorophenyl)ethylamine in step 1 (b) in step 4, a finalethyl acetate trituration was applied. Yield of final step: 0.56 g(47%).

Example 30N-(3-{(R)-1-[6-(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-ethyl}-phenyl)-methanesulfonamide

Intermediate I (1.0 g, 1.47 mmol) was subjected to the conditions ofsteps 2-4 of Example 19 to afford the title product. Yield of finalstep: 0.22 g (39%).

Example 31(R)-3-Phenyl-3-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-propan-1-ol

The title product was prepared from intermediate A (0.5 g, 2.05 mmol)using the same method as described for Example 19 with the exceptionthat in step 1, (R)-3-Amino-3-phenyl-propan-1-ol was used instead of(R)-1-(3,4-difluorophenyl)ethylamine. Yield of final step: 0.14 g (38%).

Example 32[(R)-1-(2,4-Difluoro-phenyl)-ethyl]-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

The title product was prepared from intermediate A (0.5 g, 2.05 mmol)using the same method as described for Example 19 with the exceptionthat (R)-1-(2,4-Difluoro-phenyl)-ethylamine hydrochloride was used instep 1 instead of (R)-1-(3,4-difluorophenyl)ethylamine. Yield of finalstep: 0.205 g (56%).

Example 33[(R)-1-(2,6-Difluoro-phenyl)-ethyl]-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine

The title product was prepared from intermediate A (0.5 g, 2.05 mmol)using the same method as described for Example 19 with the exceptionthat (R)-1-(2,6-difluorophenyl)ethanamine hydrochloride was used in step1 instead of (R)-1-(3,4-difluorophenyl)ethylamine. Yield of final step:0.235 g (47%).

Example 344-[2-((R)-1-Phenyl-ethylamino)-quinazolin-6-yl]-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile

The title product was prepared from intermediate A (1.0 g, 4.11 mmol)using the same method as described for Example 19 with the followingexceptions: (a) (R)-1-phenyl-ethylamine was used in step 1 instead of(R)-1-(3,4-difluorophenyl)ethylamine; (b) step 3 was carried out asdescribed below; and (c) Step 4 was omitted.4-Chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile is commerciallyavailable. Yield of final step: 0.142 g (19%).

Step 3:4-[2-((R)-1-Phenyl-ethylamino)-quinazolin-6-yl]-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile

To a stirred solution of4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile (0.35 g, 1.96 mmol)and((R)-1-Phenyl-ethyl)-[6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-quinazolin-2-yl]-amine(0.75 g, 2.00 mmol) in DMF (7 mL) was added 1M aqueous NaHCO₃ solution(5.9 mL, 5.9 mmol) under a nitrogen atmosphere at RT. The reactionmixture was purged with nitrogen gas for 30 minutes and then to thereaction mixture was added dichlorobis(triphenylphosphine)palladium(II)(0.07 g, 0.0997 mmol) at RT. The resulting reaction mixture was thenheated at 80° C. for 18 h. The reaction mixture was poured into waterand extracted with ethyl acetate (2×20 mL). The organic layers werecombined and washed with brine (20 mL), then separated off, dried overanhydrous sodium sulphate and concentrated in vacuo to afford crudetitle product. The crude was purified by flash column chromatography onsilica gel, eluting with 60% ethyl acetate in hexane to afford titleproduct which was then further purified by preparative HPLC using method5.

Example 352-{(R)-1-[6-(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-ethyl}-phenol

The title product was prepared from intermediate A (0.8 g, 3.29 mmol)using the same method as described for Example 19 with the followingexceptions: (1) 2-((R)-1-Amino-ethyl)-phenol was used in step 1 insteadof (R)-1-(3,4-difluorophenyl)ethylamine; and (2) In step 4 the reactionmixture was not filtered immediately but was first basified up to pH 8using aqueous saturated NaHCO₃ solution. The aqueous phase was extractedwith EtOAc (2×20 mL). The organic layers were combined and concentratedin vacuo to afford crude title product which was purified by flashcolumn chromatography on silica gel, eluting with 4% methanol inchloroform to afford title product which was then further purified bypreparative HPLC using method 6. Yield of final step: 0.032 g (12%).

Example 363-{(R)-1-[6-(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-ethyl}-phenol

The title product was prepared from intermediate A (0.8 g, 3.29 mmol)using the same method as described for Example 19 with the exceptionthat 3-((R)-1-amino-ethyl)-phenol was used in step 1 instead of(R)-1-(3,4-difluorophenyl)ethylamine. Yield of final step: 0.126 g(16%).

Example 374-{(R)-1-[6-(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-ethyl}-phenol

The title product was prepared from intermediate A (0.8 g, 3.29 mmol)using the same method as described for Example 19 with the followingexceptions: (1) 4-((R)-1-Amino-ethyl)-phenol was used in step 1 insteadof (R)-1-(3,4-difluorophenyl)ethylamine (2) In step 4 the reactionmixture was not filtered immediately but was first basified up to pH 8using aqueous saturated NaHCO₃ solution, and was then filtered in vacuo.The isolated solid was then purified by preparative HPLC using method 6to afford title product. Yield of final step: 0.1 g (20%).

Example 38(S)-2-(2-Fluoro-phenyl)-2-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-ethanol

The title product was prepared from intermediate A (0.6 g, 2.46 mmol)using the same method as described for Example 19 with the exceptionthat (S)-2-Amino-2-(2-fluoro-phenyl)-ethanol was used in step 1 insteadof (R)-1-(3,4-difluorophenyl)ethylamine.

Example 39(S)-2-(3-Fluoro-phenyl)-2-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-ethanol

The title product was prepared from intermediate A (0.8 g, 3.29 mmol)using the same method as described for Example 19 with the exceptionthat (S)-2-amino-2-(3-fluoro-phenyl)-ethanol was used in step 1 insteadof (R)-1-(3,4-difluorophenyl)ethylamine.

Example 40(S)-2-(4-Fluoro-phenyl)-2-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-ethanol

The title product was prepared from intermediate A (0.8 g, 3.29 mmol)using the same method as described for Example 19 with the exceptionthat (S)-2-amino-2-(4-fluoro-phenyl)-ethanol was used in step 1 insteadof (R)-1-(3,4-difluorophenyl)ethylamine.

Example 41(R)-3-(2-Fluoro-phenyl)-3-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-propan-1-ol

The title product was prepared from intermediate A (0.8 g, 3.29 mmol)using the same method as described for Example 19 with the exceptionthat (R)-3-amino-3-(2-fluoro-phenyl)-propan-1-ol was used in step 1instead of (R)-1-(3,4-difluorophenyl)ethylamine. Yield of final step:0.144 g (34%).

Example 42(R)-3-(3-Fluoro-phenyl)-3-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-propan-1-ol

The title product was prepared from intermediate A (0.8 g, 3.29 mmol)using the same method as described for Example 19 with the exceptionthat (R)-3-amino-3-(3-fluoro-phenyl)-propan-1-ol was used in step 1instead of (R)-1-(3,4-difluorophenyl)ethylamine. Yield of final step:0.1 g (24%).

Example 43(R)-3-(4-Fluoro-phenyl)-3-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-propan-1-ol

The title product was prepared from intermediate A (0.6 g, 2.46 mmol)using the same method as described for Example 19 with the followingexceptions: (1) (R)-3-amino-3-(4-fluoro-phenyl)-propan-1-ol was used instep 1 instead of (R)-1-(3,4-difluorophenyl)ethylamine; and (2) in step4 the reaction mixture was concentrated in vacuo, added into water andthe resulting reaction mixture was basified up to pH 8 using aqueoussaturated NaHCO₃ solution. The mixture was stirred for 30 min at RT andwas then filtered in vacuo washing with water (3×30 mL) followed byhexane (2×15 mL). The crude material was purified by preparative HPLCusing method 7. Yield of final step: 0.203 g (31%).

Chiral Chiral Example Synthetic HPLC RT LC RT HPLC LCMS No. Name scheme¹H NMR (min) (min) MS method method 1 ((R)-1-Phenyl-ethyl)-[6- A 1H NMR(DMSO-d6) δ 34.981 6.148 368.3 2 3 (1H-pyrazolo[3,4- 14.39-14.10 (br s,1H), (MH+) d]pyrimidin-4-yl)- 9.44 (1H, s), 9.04 (s,quinazolin-2-yl]-amine 1H), 8.90 (s, 2H), 8.74- 8.55 (m, 2H), 7.68 (d,1H), 7.49 (m, 2H), 7.32 (t, 2H), 7.22 (t, 1H), 5.46-5.33 (m, 1H), 1.52(3H, d). 2 ((R)-1-(3-Chloro-phenyl)- A 1H NMR (DMSO-d6) δ 6.29 2.289402.3 1 2 ethyl)-[6-(1H- 14.29 (br s, 1H), 9.48 (MH+)pyrazolo[3,4-d]pyrimidin- (br s, 1H), 9.06 (s, 1H),4-yl)-quinazolin-2-yl]- 8.94 (br s, 1H), 8.85 amine (br s, 1H), 8.70 (m,monohydrochloride 1H), 7.73 (d, 1H), 7.58 (s, 1H), 7.47 (s, 1H), 7.38(t, 1H), 7.29 (d, 1H), 5.44 (br m, 1H) 1.54 (d, 3H). 3((R)-1-(3-Fluoro-phenyl)- A 1H NMR (DMSO-d6) δ 5.82 2.176 386.3 1 2ethyl)-[6-(1H- 14.37 (br s, 1H), 9.50 (MH+) pyrazolo[3,4-d]pyrimidin-(br s, 1H), 9.06 (s, 1H), 4-yl)-quinazolin-2-yl]- 8.99-8.84 (m, 3H),amine 8.69 (br m, 1H), 7.74 monohydrochloride (d, 1H), 7.41-7.29 (m,3H), 7.04 (m, 1H), 5.47 (m, 1H), 1.55 (d, 3H). 4((R)-1-(4-Fluoro-phenyl)- A 1H NMR (DMSO-d6) δ 5.75 2.150 386.2 1 2ethyl)-[6-(1H- 14.21 (br s, 1H), 9.39 (MH+) pyrazolo[3,4-d]pyrimidin-(s, 1H), 9.03 (s, 1H), 4-yl)-quinazolin-2-yl]- 8.89 (s, 1H), 8.85 (d,amine 1H), 8.63 (d, 1H), 8.36 (d, 1H), 7.57 (d, 1H), 7.55-7.45 (br m,2H), 7.14 (t, 2H), 5.32 (br m, 1H), 1.51 (d, 3H). 5((S)-2-Hydroxy-1-phenyl- A 1H NMR (DMSO-d6) δ 10.52 2.534 384.2 1 2ethyl)-[6-(1H- 14.22 (s, 1H), 9.40 (s, (MH+) pyrazolo[3,4-d]pyrimidin-1H), 9.03 (s, 1H), 8.88 4-yl)-quinazolin-2-yl]- (d, 2H), 8.64 (br d,amine 1H), 8.23 (br s, 1H), monohydrochloride 7.58 (br d, 1H), 7.47 (brm, 2H), 7.32 (t, 2H), 7.22 (t, 1H), 5.28 (br m, 1H), 3.70 (m, 2H). 6(4-Fluorobenzyl)-[6-(1H- A 1H NMR (DMSO-d6) δ N/A 2.371 386.3 N/A 2pyrazolo[3,4-d]pyrimidin- 14.30 (br s, 1H), 9.60 (MH+)4-yl)-quinazolin-2-yl]- (s, 1H), 9.08 (s, 1H), methylamine 9.02 (d, 1H),8.96 (s, monohydrochloride 1H), 8.76 (br m, 1H), 7.96 (br m, 1H), 7.40(br m, 2H), 7.19 (t, 2H) 5.09 (s, 2H), 3.30 (s, 3H). 7 Benzyl-[6-(1H- A1H NMR (DMSO-d6) δ N/A 2.373 368.3 N/A 2 pyrazolo[3,4-d]pyrimidin- 14.35(br s, 1H), 9.60 (MH+) 4-yl)-quinazolin-2-yl]- (s, 1H), 9.09 (s, 1H),methylamine 9.02 (s, 1H), 8.96 (s, monohydrochloride 1H), 8.82-8.70 (brm, 1H), 7.95 (br m, 1H), 7.39-7.27 (m, 5H), 5.12 (s, 2H), 3.31 (s, 3H).8 ((R)-1-Phenyl-ethyl)-[6- B 1H NMR (DMSO-d6) δ 7.33 2.492 382.3 1 2(1H-pyrazolo[3,4- 14.13 (br s, 1H), 9.59 (MH+) d]pyrimidin-4-yl)- (s,1H), 9.07 (s, 1H), quinazolin-2-yl]- 9.01 (s, 1H), 8.96 (s, methylamine1H), 8.74 (d, 1H), 7.82 monohydrochloride (br s, 1H), 7.37 (m, 4H), 7.32(m, 1H), 6.48 (m, 1H), 3.01 (s, 3H), 1.64 (d, 3H). 9(4-Fluorobenzyl)-[6-(1H- A 1H NMR (DMSO-d6) δ N/A 6.057  372.17 N/A 1pyrazolo[3,4-d]pyrimidin- 14.22 (s, 1H), 9.41 (s, (MH+)4-yl)-quinazolin-2-yl]- 1H), 9.04 (s, 1H), 8.91 amine (d, 2H), 8.66 (dd,1H), 8.37 (br s, 1H), 7.63 (d, 1H), 7.45 (br s, 2H), 7.16 (t, 2H), 4.64(br d, 2H). 10 (3-Fluorobenzyl)-[6-(1H- A 1H NMR (DMSO-d6) δ N/A 6.118 372.14 N/A 1 pyrazolo[3,4-d]pyrimidin- 14.23 (s, 1H), 9.43 (s, (MH+)4-yl)-quinazolin-2-yl]- 1H), 9.04 (s, 1H), 8.90 amine (d, 2H), 8.65 (d,1H), 8.40 (br s, 1H), 7.63 (d, 1H), 7.37 (q, 1H), 7.29-7.13 (m, 2H),7.05 (t, 1H), 4.68 (d, 2H) 11 (3-Chlorobenzyl)-[6-(1H- A 1H NMR(DMSO-d6) δ N/A 6.162 388.1 N/A 1 pyrazolo[3,4-d]pyrimidin- 9.45 (s,1H), 9.04 (s, (MH+) 4-yl)-quinazolin-2-yl]- 1H), 8.89 (d, 2H), 8.65amine (d, 1H), 8.35 (br s, 1H), 7.61 (d, 1H), 7.49-7.38 (m, 2H), 7.29(m, 2H), 4.71 (d, 2H). 12 ((R)-1-Phenyl-ethyl)-[7- A 1H NMR (DMSO-d6) δND 4.760 368.2 1 (1H-pyrazolo[3,4- 14.30 (br s, 1H), 9.26 (MH+)d]pyrimidin-4-yl)- (s, 1H), 9.11 (s, 1H), quinazolin-2-yl]-amine 8.70(s, 1H), 8.23 (s, 1H), 8.17 (br s, 1H), 8.09-7.99 (m, 2H), 7.49 (br s,2H), 7.31 (br m, 2H), 7.20 (d, 1H), 5.33 (m, 1H), 1.51 (d, 3H). 13((R)-1-Phenyl-ethyl)-[6- A 1H NMR (DMSO-d6) δ 7.53 2.191  367.30 3 2(1H-pyrazolo[3,4- 13.90 (br s, 1H), 9.60- (MH+)b]pyridin-4-yl)-quinazolin- 9.43 (br s, 1H), 8.63 2-yl]-amine (d, 1H),8.55 (br s, monohydrochloride 1H), 8.51 (s, 1H), 8.35 (br s, 1H), 7.95(br s, 1H), 7.55 (br s, 2H), 7.48 (d, 1H), 7.36 (t, 2H), 7.26 (t, 1H),5.60 (br s, 1H), 1.58 (d, 3H). 14 ((R)-1-Phenyl-ethyl)-[6- A 1H NMR(DMSO-d6) δ 5.81 2.110 367.3 4 2 (7H-pyrrolo[2,3- 13.10-12.81 (br s,1H), (MH+) d]pyrimidin-4-yl)- 9.58-9.45 (br s, 1H),quinazolin-2-yl]-amine 9.01 (s, 1H), 8.75 (br monohydrochloride s, 1H),8.52 (br s, 1H), 7.92 (s, 1H), 7.79 (br s, 1H), 7.52 (br m, 2H) 7.33 (t,2H), 7.23 (m, 2H), 5.47 (br s, 1H), 1.55 (d, 3H). 15((R)-1-Phenyl-ethyl)-[6- A 1H NMR (DMSO-d6) δ 7.64 2.225 366.3 3 2(1H-pyrrolo[2,3-b]pyridin- 9.46-9.42 (br s, 1H), (MH+)4-yl)-quinazolin-2-yl]- 8.46 (d, 2H), 8.28 (br amine s, 1H), 7.95 (br s,1H), monohydrochloride 7.76 (t, 1H), 7.57-7.45 (m, 3H), 7.35 (t, 2H),7.26 (t, 1H), 6.91 (br s, 1H), 5.59 (br s, 1H), 1.58 (d, 3H). 16N-Benzyl-N′,N′-dimethyl- A 1H NMR (DMSO-d6) δ N/A 4.318 425.3 N/A 4N-[6-(1H-pyrazolo[3,4- 10.44 (br s, 1H), 9.58 (MH+) d]pyrimidin-4-yl)-(s, 1H), 9.09 (s, 1H), quinazolin-2-yl]-ethane- 9.00 (s, 1H), 8.95 (s,1,2-diamine 1H), 8.73 (d, 1H), 7.78 monohydrochloride (br m, 1H),7.45-7.27 (m, 5H), 5.10 (s, 2H), 4.08 (m, 2H), 3.40 (m, 2H), 2.88 (s,6H). 17 Benzyl-(R)-1-morpholin- C 1H NMR (DMSO-d6) δ 16.272 5.285 453.35 1 3-ylmethyl-[6-(1H- 14.27 (br s, 1H), 9.94 (MH+)pyrazolo[3,4-d]pyrimidin- (br m, 1H), 9.59 (br s,4-yl)-quinazolin-2-yl]- 2H), 9.07 (s, 1H), 9.00 amine (br s, 1H), 8.95(s, 1H), monohydrochloride 8.72 (d, 1H), 7.81 (br d, 1H), 7.41-7.23 (m,5H), 5.25 (m, 1H), 5.01 (d, 1H), 4.04-3.65 (m, 7H), 3.30 (br m, 1H),3.11-2.99 (m, 1H). 18 Benzyl-(S)-1-morpholin- C 1H NMR (DMSO-d6) δ13.719 5.246 453.4 5 1 3-ylmethyl-[6-(1H- 14.36 (br s, 1H), 9.89 (MH+)pyrazolo[3,4-d]pyrimidin- (br m, 1H), 9.59 (br s,4-yl)-quinazolin-2-yl]- 2H), 9.07 (s, 1H), 9.00 amine (br s, 1H), 8.98(s, 1H), monohydrochloride 8.72 (d, 1H), 7.81 (br d, 1H), 7.42-7.25 (m,5H), 5.25 (m, 1H), 5.01 (d, 1H), 4.04-3.65 (m, 7H), 3.30 (br m, 1H),3.11-2.99 (m, 1H). 19 [(R)-1-(3,4-Difluoro- A 1H NMR (DMSO-d6) δ 27.6316.195 404.3 6 1 phenyl)-ethyl]-[6-(1H- 14.30 (br s, 1H), 9.48 (MH+)pyrazolo[3,4-d]pyrimidin- (s, 1H), 9.05 (s, 1H), 4-yl)-quinazolin-2-yl]-8.91 (s, 2H), 8.82 (br amine s, 1H), 8.70 (m, 1H), 7.76 (m, 1H), 7.55(m, 1H), 7.43-7.31 (m, 2H), 5.43 (br m, 1H), 1.53 (d, 3H). 20((R)-1-Phenyl-ethyl)-[6- A 1H NMR (DMSO-d6) δ 7.958 4.824 368.2 2 1(9H-purin-6-yl)- 13.69 (br s, 1H), 9.39- (MH+) quinazolin-2-yl]-amine9.30 (m, 2H), 9.13 (br d, 1H), 8.95 (s, 1H), 8.68 (s, 1H), 8.37 (br s,1H), 7.65-7.54 (m, 1H), 7.49-7.44 (m, 2H), 7.34-7.30 (t, 2H), 7.21 (t,1H), 5.34 (m, 1H), 1.51 (d, 3H). 21 Benzyl-[6-(1H- A 1H NMR (DMSO-d6) δN/A 5.221 354.2 N/A 1 pyrazolo[3,4-d]pyrimidin- 14.24 (br s, 1H), 9.43(MH+) 4-yl)-quinazolin-2-yl]- (s, 1H), 9.04 (s, 1H), amine 8.91 (s, 2H),8.66 (d, 1H), 8.50 (br s, 1H), 7.65 (d, 1H), 7.41-7.30 (m, 4H), 7.23 (t,1H), 4.70 (s, 2H). 22 [6-(3-Methyl-1H- A 1H NMR (DMSO-d6) δ 23.211 6.055382.5 6 1 pyrazolo[3,4-d]pyrimidin- 13.82 (s, 1H), 9.31 (s, (MH+)4-yl)-quinazolin-2-yl]-((R)- 1H), 8.96 (s, 1H), 8.32-1-phenyl-ethyl)-amine 8.25 (m, 2H), 8.13 (br d, 1H), 7.56 (d, 1H),7.51-7.43 (m, 2H), 7.33 (t, 2H), 7.20 (t, 1H), 5.34 (m, 1H), 2.42 (s,3H), 1.51 (d, 3H). 23 (3-Methoxy-benzyl)-[6- A 1H NMR (DMSO-d6) δ N/A5.161 384.0 N/A 1 (1H-pyrazolo[3,4- 14.23 (br s, 1H), 9.44 (MH+)d]pyrimidin-4-yl)- (s, 1H), 9.04 (s, 1H), quinazolin-2-yl]-amine 8.92(s, 2H), 8.69 (br d, 1H), 8.60 (br s, 1H), 7.69 (d, 1H), 7.23 (t, 1H),7.02-6.93 (m, 2H), 6.80 (dd, 1H), 4.68 (m, 2H), 3.73 (s, 3H). 24(2-Fluoro-benzyl)-[6-(1H- A 1H NMR (DMSO-d6) δ N/A 5.260 372.1 N/A 1pyrazolo[3,4-d]pyrimidin- 14.21 (s, 1H), 9.43 (s, (MH+)4-yl)-quinazolin-2-yl]- 1H), 9.03 (s, 1H), 8.90 amine (d, 2H), 8.66 (d,1H), 8.37-8.25 (br s, 1H), 7.63 (d, 1H), 7.45 (br s, 1H), 7.30 (m, 1H),7.22-7.13 (m, 2H), 4.72 (m, 2H). 25 (3,4-Difluoro-benzyl)-[6- A 1H NMR(DMSO-d6) δ N/A 5.277 390.0 N/A 1 (1H-pyrazolo[3,4- 14.50-14.12 (br s,1H), (MH+) d]pyrimidin-4-yl)- 9.47 (s, 1H), 9.05 (s,quinazolin-2-yl]-amine 1H,), 9.00-8.90 (m, 2H), 8.89-8.61 (m, 2H), 7.74(d, 1H), 7.51-7.36 (m, 2H), 7.28 (m, 1H), 4.70 (s, 2H). 26 N-(3-{[6-(1H-A 1H NMR (DMSO-d6) δ N/A 5.256 447.2 N/A 1 Pyrazolo[3,4-d]pyrimidin-9.41 (s, 1H), 9.03 (s, (MH+) 4-yl)-quinazolin-2- 1H), 8.92 (s, 1H), 8.89ylamino]-methyl}-phenyl)- (s, 1H), 8.66 (d, 1H), methanesulfonamide8.39-8.29 (br s, 1H), 7.62 (d, 1H), 7.31-7.24 (m, 2H), 7.15-7.03 (m,2H), 4.63 (m, 2H), 2.94 (s, 3H). 27 [(R)-1-(3-Methoxy- A 1H NMR(DMSO-d6) δ 36.866 5.278 398.3 7 1 phenyl)-ethyl]-[6-(1H- 9.60-9.43 (brs, 1H), (MH+) pyrazolo[3,4-d]pyrimidin- 9.05 (s, 1H), 8.98-8.904-yl)-quinazolin-2-yl]- (m, 2H), 8.79-8.65 (m, amine 2H), 7.80-7.69 (brs, 1H), 7.26 (t, 1H), 7.14- 7.00 (m, 2H), 6.80 (dd, 1H), 5.41 (m, 1H),3.74 (s, 3H), 1.53 (d, 3H). 28 [(R)-1-(2-Fluoro-phenyl)- A 1H NMR(DMSO-d6) δ 16.652 6.180 386.3 5 1 ethyl]-[6-(1H- 14.50-13.95 (br s,1H), (MH+) pyrazolo[3,4-d]pyrimidin- 9.60-9.46 (m, 1H),4-yl)-quinazolin-2-yl]- 9.05 (s, 1H), 8.95-8.89 amine (m, 2H), 8.90-8.72(br s, 1H,), 8.66 (m, 1H), 7.81-7.64 (m, 1H), 7.56 (t, 1H), 7.30 (m,1H), 7.19 (q, 2H), 5.64 (br s, 1H), 1.55 (d, 3H). 29((S)-1-Phenyl-ethyl)-[6- A 1H NMR (DMSO-d6) δ 59.026 5.379 368.3 2 1(1H- 14.28-14.05 (br s, 1H), (MH+) pyrazolo[3,4d]pyrimidin- 9.44 (s,1H), 9.04 (s, 4-yl)-quinazolin-2-yl]- 1H), 8.91 (s, 1H), 8.90 amine (s,1H), 8.71-8.60 (br m, 2H), 7.66 (d, 1H), 7.49 (m, 2H), 7.33 (t, 2H),7.22 (t, 1H), 5.39 (br m, 1H), 1.52 (d, 3H). 30 N-(3-{(R)-1-[6-(1H- A 1HNMR (DMSO-d6) δ 5.295 5.433 461.3 8 1 Pyrazolo[3,4-d]pyrimidin- 14.24(br s, 1H), 9.72 (MH+) 4-yl)-quinazolin-2- (d, 1H), 9.42 (s, 1H),ylamino]-ethyl}-phenyl)- 9.03 (s, 1H), 8.90 (d, methanesulfonamide 1H),8.89 (s, 1H), 8.65 (br m, 1H), 8.52 (broad s, 1H), 7.62 (br d, 1H),7.36-7.19 (m, 3H), 7.05 (dd, 1H), 5.30 (br m, 1H), 2.97 (s, 3H), 1.53(d, 3H). 31 (R)-3-Phenyl-3-[6-(1H- A 1H NMR (DMSO-d6) δ 10.657 5.618398.4 9 1 pyrazolo[3,4-d]pyrimidin- 14.41-14.05 (br s, 1H), (MH+)4-yl)-quinazolin-2- 9.51-9.42 (m, 1H), ylamino]-propan-1-ol 9.04 (s,1H), 8.901 (s, 2H), 8.80-8.68 (m, 2H), 7.66 (br d, 1H), 7.49 (d, 2H),7.33 (t, 2H), 7.21 (t, 1H), 5.51- 5.32 (m, 1H), 3.49 (m, 2H), 2.15-1.90(m, 2H). 32 [(R)-1-(2,4-Difluoro- A 1H NMR (DMSO-d6) δ 14.217 2.376404.2 10 5 phenyl)-ethyl]- 14.60-13.95 (br s, 1H), (MH+)[6-(1H-pyrazolo[3,4- 9.46 (s, 1H), 9.05 (s, d]pyrimidin-4-yl)- 1H), 8.91(s, 2H), 8.81- quinazolin-2-yl]-amine 8.60 (br m, 2H), 7.78- 7.54 (m,2H), 7.26 (t, 1H), 7.08 (t, 1H), 5.60 (br s, 1H), 1.54 (d, 3H). 33[(R)-1-(2,6-Difluoro- A 1H NMR (DMSO-d6) δ 13.680 2.382 404.3 10 5phenyl)-ethyl]- 14.21 (br s, 1H), 9.39 (MH+) [6-(1H-pyrazolo[3,4- (s,1H), 9.03 (s, 1H), d]pyrimidin-4-yl)- 8.89 (s, 1H), 8.87 (s,quinazolin-2-yl]-amine 1H), 8.63 (d, 1H), 8.31 (d, 1H), 7.51 (d, 1H),7.30 (t, 1H), 7.03 (t, 2H), 5.53 (br m, 1H), 1.62 (d, 3H). 344-[2-((R)-1-Phenyl- A 1H NMR (DMSO-d6) δ 17.847 4.556 392.4 10 6ethylamino)-quinazolin-6- 13.42 (br s, 1H), 9.24 (MH+)yl]-7H-pyrrolo[2,3- (s, 1H), 9.00 (s, 1H), d]pyrimidine-5- 8.69 (s, 1H),8.39 (d, carbonitrile 1H), 8.29 (d, 1H), 8.19 (d, 1H), 7.65-7.42 (m,3H), 7.32 (d, 2H), 7.21 (t, 1H), 5.32 (t, 1H), 1.51 (d, 3H). 352-{(R)-1-[6-(1H- A 1H NMR (DMSO-d6) δ 20.227 2.046 384.2 10 5Pyrazolo[3,4-d]pyrimidin- 14.19 (br s, 1H), 9.83 (MH+)4-yl)-quinazolin-2- (br s, 1H), 9.39 (s, 1H), ylamino]-ethyl}-phenol9.03 (s, 1H), 8.91 (s, 1H) 8.88 (s, 1H), 8.63 (d, 1H), 8.28-8.12 (br m,1H), 7.57 (d, 1H), 7.33 (d, 1H), 7.02 (d, 1H), 6.81 (d, 1H), 6.75 (br s,1H), 5.55 (br s, 1H), 1.45 (d, 3H). 36 3-{(R)-1-[6-(1H- A 1H NMR(DMSO-d6) δ 17.963 1.879 383.9 10 5 Pyrazolo[3,4-d]pyrimidin- 14.20 (brs, 1H), 9.40 (MH+) 4-yl)-quinazolin-2- (s, 1H), 9.30 (s, 1H),ylamino]-ethyl}-phenol 9.03 (s, 1H), 8.91 (s, 1H), 8.87 (s, 1H), 8.63(d, 1H), 8.30 (d, 1H), 7.58 (d, 1H), 7.10 (t, 1H), 6.89 (m, 2H), 6.59(d, 1H), 5.27 (quint, 1H), 1.49 (d, 3H). 37 4-{(R)-1-[6-(1H- A 1H NMR(DMSO-d6) δ 16.037 4.253 384.3 11 6 Pyrazolo[3,4-d]pyrimidin- 14.21 (brs, 1H), 9.39 (MH+) 4-yl)-quinazolin-2- (s, 1H), 9.23 (s, 1H),ylamino]-ethyl}-phenol 9.02 (s, 1H), 8.91 (s, 1H), 8.87 (d, 1H), 8.63(d, 1H), 8.21 (d, 1H), 7.58 (d, 1H), 7.27 (d, 2H), 6.69 (d, 2H),5.31-5.21 (m, 1H), 1.490 (d, 3H). 38 (S)-2-(2-Fluoro-phenyl)-2- A 1.884401.8 5 [6-(1H-pyrazolo[3,4- (MH+) d]pyrimidin-4-yl)-quinazolin-2-ylamino]- ethanol 39 (S)-2-(3-Fluoro-phenyl)-2- A 1.915402.3 5 [6-(1H-pyrazolo[3,4- (MH+) d]pyrimidin-4-yl)-quinazolin-2-ylamino]- ethanol 40 (S)-2-(4-Fluoro-phenyl)-2- A 1.875401.9 5 [6-(1H-pyrazolo[3,4- (MH+) d]pyrimidin-4-yl)-quinazolin-2-ylamino]- ethanol 41 (R)-3-(2-Fluoro-phenyl)- A 1H NMR(DMSO-d6) δ 30.320 1.940 416.2 12 5 3-[6-(1H-pyrazolo[3,4- 14.21 (br s,1H), 9.39 (MH+) d]pyrimidin-4-yl)- (s, 1H), 9.03 (s, 1H),quinazolin-2-ylamino]- 8.91 (s, 1H), 8.87 (d, propan-1-ol 1H), 8.63 (d,1H), 8.38 (d, 1H), 7.62-7.50 (m, 2H), 7.25 (q, 1H), 7.18 (q, 2H),5.71-5.55 (m, 1H), 4.62 (t, 1H), 3.52 (m, 2H), 2.13-1.89 (m, 2H). 42(R)-3-(3-Fluoro-phenyl)- A 1H NMR (DMSO-d6) δ 28.297 1.897 416.2 12 53-[6-(1H-pyrazolo[3,4- 14.21 (br s, 1H), 9.40 (MH+) d]pyrimidin-4-yl)-(s, 1H), 9.03 (s, 1H), quinazolin-2-ylamino]- 8.90 (s, 1H), 8.88 (d,propan-1-ol 1H), 8.63 (d, 1H), 8.38 (d, 1H), 7.61 (d, 1H), 7.40-7.20 (m,3H), 7.01 (t, 1H), 5.36 (m, 1H), 4.62 (br s, 1H), 3.55-3.35 (m, 2H),2.15-1.85 (m, 2H). 43 (R)-3-(4-Fluoro-phenyl)- A 1H NMR (DMSO-d6) δ28.763 1.947 416.3 12 5 3-[6-(1H-pyrazolo[3,4- 14.22 (br s, 1H), 9.39(MH+) d]pyrimidin-4-yl)- (s, 1H), 9.03 (s, 1H), quinazolin-2-ylamino]-8.91 (s, 1H), 8.88 (d, propan-1-ol 1H), 8.63 (d, 1H), 8.38 (d, 1H), 7.57(d, 1H), 7.51-7.49 (m, 2H), 7.16 (t, 2H), 5.45-5.29 (m, 1H), 4.61 (t,1H), 3.52-3.39 (m, 2H), 2.15-1.85 (m, 2H). N/A = not applicable

Example 44

Biological Activity

(a) Determination of p70S6 Inhibitory Activity

The ability of compounds of the invention to inhibit P70S6 kinase may bedetermined using the protocol below.

Buffer Composition:

20 mM MOPS, 1 mM EDTA, 0.01% Brij-35, 5% Glycerol, 0.1%b-mercaptoethanol, 1 mg/mL BSA

Method:

p70S6K (h) kinase assay

In a final reaction volume of 25 μL, p70S6K (h) (5-10 mU) is incubatedwith 8 mM MOPS pH 7.0, 0.2 mM EDTA, 100 μM KKRNRTLTV, 10 mM Mg acetateand [γ-33P-ATP](specific activity approx. 500 cpm/pmol, concentration asrequired). The reaction is initiated by the addition of the MgATP mix.After incubation for 40 minutes at room temperature, the reaction isstopped by the addition of 5 μL of a 3% phosphoric acid solution. 10 μLof the reaction mixture is then spotted onto a P30 filtermat and washedthree times for 5 minutes in 75 mM phosphoric acid and once in methanolprior to drying and scintillation counting.

(b) Evaluation of Brain and Plasma Concentrations in an In Vivo CassetteMouse Model

The compounds of this invention were evaluated in an in vivo cassettemouse model to determine brain and plasma concentrations following oraldosing. This is an industry-standard and recognised means to assessbrain penetration of small molecules (for recent literature article,refer to: in vitro permeability analysis, pharmacokinetic and braindistribution study in mice of imperatorin, isoimperatorin and cnidilinin Radix Angelicae Dahuricae, Fitoterapia, Volume 85, March 2013, Pages144-153). It is also recognised that higher brain concentrations (andhigher ratios of brain: plasma concentration) lead to greater exposurein the brain—this is clearly advantageous if the brain is the site ofaction.

Experimental Method:

For a single cassette study, male CD-1 mice were used (n=3 pertimepoint, three timepoints: 1.0 hr, 3.0 hr and 8.0 hr).

5 compounds were dosed PO per cassette (dose level 2.5 mg/kg percompound, dose conc. 0.25 mg/ml, dose volume 10.0 ml/kg).

Formulation used to solubilize compounds: 10% DMSO/90%hydroxypropyl-β-cyclodextrin (20% w/v aqueous)

Sampling was terminal and plasma and brain matrices were generated. Toprepare plasma samples, protein was precipitated using acetonitrile. Toprepare brain samples, homogenisation and protein precipitation wasperformed with acetonitrile. Samples were analysed using HPLC-TOF MSusing electrospray ionisation.

The brain and plasma concentrations and brain-plasma ratios observed forthe compounds tested are set out in the table below.

(d) Plasma (d) Brain (d) Compound p70S6K1 conc. at conc. at Brain:PlasmaExample IC₅₀ 3 hours 3 hours ratio at No. (μM) (μM) (μM) 3 hours 1 0.0130.58 1.60 2.7 2 0.030 3 0.021 0.46 1.68 3.7 4 0.022 0.68 1.51 2.2 50.024 6 0.147 7 0.033 8 0.108 9 0.055 10 0.018 0.50 0.84 1.7 11 0.14512 >3 13 0.043 14 0.057 15 0.097 16 0.106 17 0.110 18 0.025 19 0.0100.60 2.42 4.0 20 0.167 21 0.071 22 0.131 23 0.118 24 0.204 25 0.049 260.067 27 0.041 28 0.015 0.42 1.07 2.6 29 >3 30 0.023 31 0.010 33 0.02834 0.346 35 0.020

In summary, the compounds of the invention demonstrate potent inhibitionof p70S6K1. The compounds tested exhibit favourable brain and plasmaconcentrations in mice following oral dosing, with brain concentrationsin excess of plasma, leading to high brain: plasma ratios. It isgenerally considered that a brain: plasma ratio of >0.5 is favourablefor treatment of diseases of the brain.

(c) Evaluation of Efficacy of Compounds in Counter-Acting TumourInitiation and Metastasis in an In Vivo Model of Triple Negative BreastCancer (TNBC)

It is known that S6K1 has a crucial role in the recurrence of TNBCcancers following surgery, mainly through the activity of S6K1 inpromoting survival of cancer cells in the host via phosphorylation andactivation of the anti-apoptotic protein Bcl2 and of Gli1 (Belletti2014). In addition, S6K1 promotes metastasis of TNBC cells (Akar 2010,Hung 2014).

In order to test the efficacy of an inhibitor of S6K1 in an in vivomodel of tumour initiation and metastasis, the following experiment wasestablished:

A total of 22 female athymic nude mice (Hsd: Athymic Nude-Foxn1^(nu))were purchased from Harlan (UK) and acclimatised for 7 days prior tostudy commencement. Animals were housed in IVC cages (5 per cage) withindividual mice identified by ear punch. All animals were allowed freeaccess to a standard certified commercial diet and sanitised waterduring the study. The holding room was maintained under standardconditions: 20-24° C., 40-70% humidity and a 12h light/dark cycle.

On day −1, animals were randomly assigned to treatment groups asindicated in the table below, and drug treatment commenced. On day 0,MDA-MB-231 cells (1×10⁶ in matrigel) were implanted into the secondmammary fat pad.

The dosing route was PO and the formulation was as follows: 10% DMSO/90%hydroxypropyl-β-cyclodextrin (20% w/v aqueous).

Treatment Groups:

Dosing Dosing Dosing period Group n Treatment Dose route schedule (days)1 8 Vehicle only — p.o. QD 21 2 8 Example 1 100 mg/kg p.o. BID 21(mono-HCl salt)

During the experiment, the following outcome measures were assessed:

(1) Time to palpation of tumour (latency) (2) tumour volume (3) tumourand organ weights as a measure of metastasis (4) visual appearance ofmetastatic nodules in the lungs.

Outcomes:

(1) Time to Palpation of Tumour

The compound of Example 1 delays time until appearance (palpation) oftumour and also decreases the rate of incidence (see FIG. 1) compared tocontrol.

(2) Tumour Volume

Example 1 induces a significant reduction in volume of tumours (FIG. 2)compared to control.

The liver and tumour weights were taken at day 21. Treatment with thecompound of Example 1 led to a reduction in weight of liver compared tothe vehicle treated group which may indicate a reduction in metastaticlesions for the treatment group (see FIG. 3). In addition, the tumoursfrom the treated animals weighed significantly less (see FIG. 4).

(3) Visual Appearance of Metastatic Nodules in the Lungs

At necroscopy the lungs of the vehicle and treated animals were examinedfor presence of metastatic nodules:

No. mice Mean no. bearing of lung Group visible lung nodules no.Treatment Dose mets nodules per animal 1 Vehicle only — 3/4 (75%) 2.3 2Example 1 100 mg/kg 0/5 (0%)  0 (mono-HCl salt) BID x 21

This shows that example 1 is effective in reducing the metastatic burdenin the lungs of the mouse arising as spontaneous metastasis from a TNBCprimary tumour.

Taken together this indicates that Example 1, an S6K1 inhibitor, iseffective in (a) preventing tumour initiation (b) limiting the growth oftumours that do present and (c) preventing metastasis to the lungarising from the primary tumour.

(d) Evaluation of Compounds in the Audiogenic Seizure Assay, an In VivoModel of Fragile X Syndrome (FXS)

Seizures occur in conjunction with FXS and autism in up to one-quarterof children with these disorders (Berry-Kravis E (2002) Epilepsy infragile X syndrome. Dev. Med. Child Neurol. 44(11):724-728). Increasedsusceptibility to sound-induced seizures, called audiogenic seizures(AGS), is a robust and reliable phenotype in FXS mice (Fmr1 KO) thatdoes not occur in VVT mice. The audiogenic seizure assay (AGS) is awell-documented mouse model of FXS (Audiogenic seizures susceptibilityin transgenic mice with fragile X syndrome, Epilepsia. 2000 January;41(1):19-23). In such a model it is possible to dose compounds toobserve effects on susceptibility of the mice to audiogenic seizures.The following AGS experiment was set up to test the efficacy ofcompounds of this application:

The following experiment design was used:

Group Mice n treatment Dosing 1 FXS (Fmr1 KO) 10 vehicle QD x 7 PO 2 FXS(Fmr1 KO) 10 Example 1 QD x 7 PO (mono-HCl salt), 50 mg/kg

Strain of FXS mouse used: FVB background

Vehicle used: 10% DMSO/90% hydroxypropyl-β-cyclodextrin (20% w/vaqueous)

Animals were assessed in AGS following 7 consecutive days of dosing.

Method:

The experimental chamber consisted of a plastic cage of dimensions25×25×47 cm in which a doorbell (Electrical bell Heath Zenith, model172C-A) had been mounted on the cage roof.

Mice were taken from their housing room one by one and transferred intothe experimental chamber and allowed to explore the novel environment(basal noise ˜65 dB) for a period of 30 seconds after which point thebell was rung (124 dB) for a period of 60 seconds.

The resulting motor responses were classified using a scale modifiedfrom the one originally described by Jobe et al. (1973): no response(NR: pause or continuous exploration), wild running (WR), seizure (S) orrespiratory arrest and/or death (RA). The motor response rate is definedas the percentage of animals per group responding to the stimulus.

Results:

Motor Response Group NR WR S RA rate (%) 1 1 9 7 5 9/10 (90%) 2 9 1 0 01/10 (10%)

The data show that the incidence of audiogenic seizures and severity ofresponse were both reduced by administration of Example 1.

Example 45

Pharmaceutical Formulations

(i) Tablet Formulation

A tablet composition containing a compound of the formula (1) as definedin any one of Embodiments 1.0 to 1.116 may be prepared by mixing 50 mgof the compound with 197 mg of lactose (BP) as diluent, and 3 mgmagnesium stearate as a lubricant and compressing to form a tablet inknown manner.

(ii) Capsule Formulation

A capsule formulation is prepared by mixing 100 mg of a compound of theformula (1) as defined in any one of Embodiments 1.0 to 1.116 with 100mg lactose and filling the resulting mixture into standard opaque hardgelatin capsules.

(iii) Injectable Formulation I

A parenteral composition for administration by injection can be preparedby dissolving a compound of the formula (1) as defined in any one ofEmbodiments 1.0 to 1.116 in water containing 10% propylene glycol togive a concentration of active compound of 1.5% by weight. The solutionis then sterilised by filtration, filled into an ampoule and sealed.

(iv) Injectable Formulation II

A parenteral composition for injection is prepared by dissolving inwater a compound of the formula (1) as defined in any one of Embodiments1.0 to 1.116 (2 mg/ml) and mannitol (50 mg/ml), sterile filtering thesolution and filling into sealable 1 ml vials or ampoules.

v) Injectable Formulation III

A formulation for i.v. delivery by injection or infusion can be preparedby dissolving the compound of formula (1) as defined in any one ofEmbodiments 1.0 to 1.116 (e.g. in a salt form) in water at 20 mg/ml. Thevial is then sealed and sterilised by autoclaving.

vi) Injectable Formulation IV

A formulation for i.v. delivery by injection or infusion can be preparedby dissolving the compound of formula (1) as defined in any one ofEmbodiments 1.0 to 1.116 (e.g. in a salt form) in water containing abuffer (e.g. 0.2 M acetate pH 4.6) at 20 mg/ml. The vial is then sealedand sterilised by autoclaving.

(vii) Subcutaneous Injection Formulation

A composition for sub-cutaneous administration is prepared by mixing acompound of the formula (1) as defined in any one of Embodiments 1.0 to1.116 with pharmaceutical grade corn oil to give a concentration of 5mg/ml. The composition is sterilised and filled into a suitablecontainer.

viii) Lyophilised Formulation

Aliquots of formulated compound of formula (1) as defined in any one ofEmbodiments 1.0 to 1.116 are put into 50 ml vials and lyophilized.During lyophilisation, the compositions are frozen using a one-stepfreezing protocol at (−45° C.). The temperature is raised to −10° C. forannealing, then lowered to freezing at −45° C., followed by primarydrying at +25° C. for approximately 3400 minutes, followed by asecondary drying with increased steps if temperature to 50° C. Thepressure during primary and secondary drying is set at 80 millitor.

EQUIVALENTS

The foregoing examples are presented for the purpose of illustrating theinvention and should not be construed as imposing any limitation on thescope of the invention. It will readily be apparent that numerousmodifications and alterations may be made to the specific embodiments ofthe invention described above and illustrated in the examples withoutdeparting from the principles underlying the invention. All suchmodifications and alterations are intended to be embraced by thisapplication.

The invention claimed is:
 1. A compound of the formula (1):

or a salt, tautomer or N-oxide thereof; wherein: one of Y and Z is R³and the other is Ar²; Q¹ is a C₁₋₈ alkylene group optionally substitutedby one or two substituents selected from hydroxy and C₁₋₄hydrocarbyloxy, provided that when a hydroxy substituent is present,there are at least two carbon atoms between the hydroxy substituent andthe nitrogen atom to which Q² is attached; and wherein a carbon atom ofthe C₁₋₈ alkylene group may optionally be replaced by acyclopropane-1,1-diyl or cyclobutane-1,1-diyl group provided that thetotal number of carbon atoms in an alkylene group containing such areplacement does not exceed 8; Q² is a bond or a C₁₋₈ alkylene groupoptionally substituted by one or two substituents selected from hydroxyand C₁₋₄ hydrocarbyloxy, provided that when a hydroxy substituent ispresent, there are at least two carbon atoms between the hydroxysubstituent and the nitrogen atom to which Q² is attached; R¹ isselected from hydrogen, NR^(x)R^(y) and a group Cy¹; R^(x) and R^(y) arethe same or different and each is selected from hydrogen, C₁₋₄hydrocarbyl or hydroxy-C₁₋₄ hydrocarbyl; or NR^(x)R^(y) forms a 4 to7-membered heterocyclic ring containing a total of 1 or 2 heteroatomring members of which one is N and the other is selected from N, O and Sand oxidised forms thereof, the heterocyclic ring being optionallysubstituted with one or two substituents selected from C₁₋₄ hydrocarbyl,oxo, amino, mono-C₁₋₄ hydrocarbylamino, di-C₁₋₄hydrocarbylamino,fluorine and hydroxy, provided that there are at least two carbon atomsin line between the amino, mono-C₁₋₄ hydrocarbylamino,di-C₁₋₄hydrocarbylamino and hydroxy substituents when present and thenitrogen atom of the NR^(x)R^(y) group; Cy¹ is a C-linked 3 to 7membered monocyclic non-aromatic carbocyclic or heterocyclic groupcontaining 0, 1 or 2 heteroatom ring members selected from N, O and Sand oxidised forms of S, and being optionally substituted with one ortwo substituents selected from C₁₋₃ hydrocarbyl, fluorine, oxo andhydroxy; R² and R⁴ are the same or different and each is selected fromhydrogen, fluorine, chlorine, C₁₋₂ alkyl and C₁₋₂ alkoxy, wherein eachC₁₋₂ alkyl and C₁₋₂ alkoxy is optionally substituted with two or morefluorine atoms; R³ is selected from hydrogen, fluorine, chlorine, C₁₋₂alkyl and C₁₋₂ alkoxy, wherein each C₁₋₂ alkyl and C₁₋₂ alkoxy isoptionally substituted with two or more fluorine atoms; Ar¹ is amonocyclic 5 or 6-membered aryl or heteroaryl ring containing 0, 1 or 2heteroatom ring members selected from O, N and S, the aryl or heteroarylbeing optionally substituted with 1, 2 or 3 substituents R⁵ which arethe same or different and are selected from halogen, cyano and a groupR^(a)-R^(b); R^(a) is a bond, O, CO, X³C(X⁴), C(X⁴)X³, X³C(X⁴)X³, S, SO,SO₂, NR^(c), SO₂NR^(c) or NR^(c)SO₂; R^(b) is: hydrogen; a carbocyclicor heterocyclic group having from 3 to 7 ring members, of which 0, 1, 2or 3 are heteroatom ring members selected from O, N and S and oxidisedforms of S, the carbocyclic or heterocyclic group being optionallysubstituted with one or more substituents R⁶; or an acyclic C₁₋₈hydrocarbon group optionally substituted with one or more substituentsselected from hydroxy; oxo; halogen; cyano; carboxy; amino; mono- ordi-C₁₋₄ alkylamino; and carbocyclic and heterocyclic groups having from3 to 7 ring members, of which 0, 1, 2 or 3 are heteroatom ring membersselected from O, N and S and oxidised forms of S, the carbocyclic orheterocyclic group being optionally substituted with one or moresubstituents R⁶; wherein one or two but not all of the carbon atoms ofthe acyclic C₁₋₈ hydrocarbon group may optionally be replaced by O, S,SO, SO₂, NR^(c), X³C(X⁴), C(X⁴)X³ or X³C(X⁴)X³; R⁶ is selected from thesubstituents R⁵ except that R⁶ does not consist of or contain acarbocyclic or heterocyclic group; X³ is O, S or NR^(c); and X⁴ is ═O,═S or ═NR^(c); and R^(c) is hydrogen or C₁₋₄ hydrocarbyl; Ar² is abicyclic 8 to 11-membered heteroaryl group containing 1, 2, 3 or 4heteroatom ring members selected from O, N and S and being optionallysubstituted with 1, 2 or 3 substituents R⁷ selected from oxo, fluorine;chlorine; bromine; C₁₋₄ hydrocarbyl optionally substituted with one ormore fluorine atoms; C₁₋₄ hydrocarbyloxy optionally substituted with oneor more fluorine atoms; hydroxy; cyano; N(R^(c))₂; R^(c)—C(O)—;R^(c)—C(O)N(R^(c))—; (R^(c))₂NC(O)—; R^(c)—SO₂NR^(c)—; R^(c)—NHC(O)NH—;(R^(c))₂NSO₂—; and five and six-membered monocyclic groups containingfrom 0 to 3 heteroatom ring members selected from O, N and S, the fiveand six-membered monocyclic groups being unsubstituted or substitutedwith one or more substituents R⁸ selected from C₁₋₄ hydrocarbyl, C₁₋₄hydrocarbyloxy, cyano, hydroxy, oxo, halogen, amino, mono-C₁₋₄hydrocarbylamino and di-C₁₋₄hydrocarbylamino and wherein the hydrocarbylmoieties when present are optionally substituted with fluorine, C₁₋₂alkoxy, hydroxy, amino, mono-di-C₁₋₂alkylamino or di-C₁₋₄alkylamino; andwherein, in each substituent consisting of or containing a hydrocarbylgroup, the hydrocarbyl group is selected from alkyl, alkenyl, alkynyland cycloalkyl groups and combinations thereof.
 2. A compound accordingto claim 1 having the formula (1):

or a salt, tautomer or N-oxide thereof; wherein: one of Y and Z is R³and the other is Are; Q¹ is a C₁₋₈ alkylene group optionally substitutedby one or two substituents selected from hydroxy and C₁₋₄hydrocarbyloxy, provided that when a hydroxy substituent is present,there are at least two carbon atoms between the hydroxy substituent andthe nitrogen atom to which Q² is attached; Q² is a bond or a C₁₋₈alkylene group optionally substituted by one or two substituentsselected from hydroxy and C₁₋₄ hydrocarbyloxy, provided that when ahydroxy substituent is present, there are at least two carbon atomsbetween the hydroxy substituent and the nitrogen atom to which Q² isattached; R¹ is selected from hydrogen, NR^(x)R^(y) and a group Cy¹;R^(x) and R^(y) are the same or different and each is selected fromhydrogen, C₁₋₄ hydrocarbyl or hydroxy-C₁₋₄ hydrocarbyl; or NR^(x)R^(y)forms a 4 to 7-membered heterocyclic ring containing a total of 1 or 2heteroatom ring members of which one is N and the other is selected fromN, O and S and oxidised forms thereof, the heterocyclic ring beingoptionally substituted with one or two substituents selected from C₁₋₄hydrocarbyl, oxo, amino, mono-C₁₋₄ hydrocarbylamino,di-C₁₋₄hydrocarbylamino, fluorine and hydroxy, provided that there areat least two carbon atoms in line between the amino, mono-C₁₋₄hydrocarbylamino, di-C₁₋₄hydrocarbylamino and hydroxy substituents whenpresent and the nitrogen atom of the NR^(x)R^(y) group; Cy¹ is aC-linked 3 to 7 membered monocyclic non-aromatic carbocyclic orheterocyclic group containing 0, 1 or 2 heteroatom ring members selectedfrom N, O and S and oxidised forms of S, wherein the carbocyclic andheterocyclic groups are optionally substituted with one or twosubstituents selected from C₁₋₃ hydrocarbyl, fluorine, oxo and hydroxy;R² and R⁴ are the same or different and each is selected from hydrogen,fluorine, chlorine, C₁₋₂ alkyl and C₁₋₂ alkoxy, wherein each C₁₋₂ alkyland C₁₋₂ alkoxy is optionally substituted with two or more fluorineatoms; R³ is selected from hydrogen, fluorine, chlorine, C₁₋₂ alkyl andC₁₋₂ alkoxy, wherein each C₁₋₂ alkyl and C₁₋₂ alkoxy is optionallysubstituted with two or more fluorine atoms; Ar¹ is a monocyclic 5 or6-membered aryl or heteroaryl ring containing 0, 1 or 2 heteroatom ringmembers selected from O, N and S, the aryl or heteroaryl beingoptionally substituted with 1, 2 or 3 substituents R⁵ which are the sameor different and are selected from halogen, cyano and a groupR^(a)-R^(b); R^(a) is a bond, O, CO, X³C(X⁴), C(X⁴)X³, X³C(X⁴)X³, S, SO,SO₂, NR^(c), SO₂NR^(c) or NR^(c)SO₂; R^(b) is: hydrogen; a carbocyclicor heterocyclic group having from 3 to 7 ring members, of which 0, 1, 2or 3 are heteroatom ring members selected from O, N and S and oxidisedforms of S, the carbocyclic or heterocyclic group being optionallysubstituted with one or more substituents R⁶; or an acyclic C₁₋₈hydrocarbon group optionally substituted with one or more substituentsselected from hydroxy; oxo; halogen; cyano; carboxy; amino; mono- ordi-C₁₋₄ alkylamino; and carbocyclic and heterocyclic groups having from3 to 7 ring members, of which 0, 1, 2 or 3 are heteroatom ring membersselected from O, N and S and oxidised forms of S, the carbocyclic orheterocyclic group being optionally substituted with one or moresubstituents R⁶; wherein one or two but not all of the carbon atoms ofthe acyclic C₁₋₈ hydrocarbon group may optionally be replaced by O, S,SO, SO₂, NR^(c), X³C(X⁴), C(X⁴)X³ or X³C(X⁴)X³; R⁶ is selected from thesubstituents R⁵ except that R⁶ does not consist of or contain acarbocyclic or heterocyclic group; X³ is O, S or NR^(c); and X⁴ is ═O,═S or ═NR^(c); and R^(c) is hydrogen or C₁₋₄ hydrocarbyl; Ar² is abicyclic 8 to 11-membered heteroaryl group containing 1, 2, 3 or 4heteroatom ring members selected from O, N and S and being optionallysubstituted with 1, 2 or 3 substituents R⁷ selected from oxo, fluorine;chlorine; bromine; C₁₋₄ hydrocarbyl optionally substituted with one ormore fluorine atoms; C₁₋₄ hydrocarbyloxy optionally substituted with oneor more fluorine atoms; hydroxy; cyano; N(R^(c))₂; R^(c)-C(O)-;R^(c)-C(O)N(R^(c))-; (R^(c))₂NC(O)-; R^(c)—SO₂NR^(c)-; R^(c)-NHC(O)NH—;(R^(c))₂NSO₂-; and five and six-membered monocyclic groups containingfrom 0 to 3 heteroatom ring members selected from O, N and S, the fiveand six-membered monocyclic groups being unsubstituted or substitutedwith one or more substituents R⁸ selected from C₁₋₄ hydrocarbyl, C₁₋₄hydrocarbyloxy, cyano, hydroxy, oxo, halogen, amino, mono-C₁₋₄hydrocarbylamino and di-C₁₋₄hydrocarbylamino and wherein the hydrocarbylmoieties when present are optionally substituted with fluorine, C₁₋₂alkoxy, hydroxy, amino, mono-di-C₁₋₂alkylamino or di-C₁₋₄alkylamino; andwherein, in each substituent consisting of or containing a hydrocarbylgroup, the hydrocarbyl group is selected from alkyl, alkenyl, alkynyland cycloalkyl groups and combinations thereof.
 3. A compound accordingto claim 1 wherein Y is Are and Z is R³.
 4. A compound according toclaim 1 wherein Q¹ is C₁₋₄ alkylene optionally substituted by one or twosubstituents selected from hydroxy and C₁₋₄ hydrocarbyloxy, providedthat when a hydroxy substituent is present, there are at least twocarbon atoms between the hydroxy substituent and the nitrogen atom towhich Q² is attached.
 5. A compound according to claim 4 wherein Q¹ isselected from CH₂, CH(CH₃), CH(CH₂OH) and CH(CH₂CH₂OH).
 6. A compoundaccording to claim 1 wherein Q² is a bond or C₁₋₃ alkylene.
 7. Acompound according to claim 1 wherein R¹ is selected from: hydrogen; agroup Cy¹ wherein Cy¹ is selected from 4 to 7 membered saturatedheterocyclic groups containing a first ring member which is nitrogen andoptionally a second ring member selected from N, O and S, wherein theheterocyclic groups are optionally substituted with one or twosubstituents selected from C₁₋₃ alkyl, cyclopropyl, fluorine andhydroxyl; and NR^(x)R^(y), wherein R^(x) and R^(y) are the same ordifferent and each is selected from hydrogen, C₁₋₄ alkyl, cyclopropyl,methylcyclopropyl, cyclopropylmethyl, and hydroxy-C₂₋₄ alkyl.
 8. Acompound according to claim 7 wherein R¹ is hydrogen.
 9. A compoundaccording to claim 1 wherein Ar¹ is a monocyclic aryl or heteroaryl ringselected from phenyl, furyl, thienyl and pyridyl, each optionallysubstituted with 1, 2 or 3 substituents R⁵ which are the same ordifferent.
 10. A compound according to claim 9 wherein Ar¹ is a phenylring optionally substituted with 1, 2 or 3 substituents R⁵ which are thesame or different.
 11. A compound according to claim 1 wherein R² ishydrogen.
 12. A compound according to claim 1 wherein R³ is hydrogen.13. A compound according to claim 1 wherein R⁴ is hydrogen.
 14. Acompound according to claim 1 wherein the compound is of the formula(3):

or a salt, tautomer or N-oxide thereof, wherein R¹, R², R³, R⁴, Q¹, Q²and Ar¹ are as defined in claim
 1. 15. A compound according to claim 1wherein the compound is of the formula (4):

or a salt, tautomer or N-oxide thereof, wherein R¹, R², R³, R⁴, R⁵, Q¹and Q² are as defined in claim 1 and x is 0, 1, 2, or
 3. 16. Apharmaceutical composition comprising a compound as defined in claim 1and a pharmaceutically acceptable excipient.
 17. A compound according toclaim 1 which is selected from the group consisting of:((R)-1-Phenyl-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;((R)-1-(3-Chloro-phenyl)-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;((R)-1-(3-Fluoro-phenyl)-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;((R)-1-(4-Fluoro-phenyl)-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;((S)-2-Hydroxy-1-phenyl-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;Benzyl-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-methylamine;(3-Fluorobenzyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;((R)-1-Phenyl-ethyl)-[6-(1H-pyrazolo[3,4-b]pyridin-4-yl)-quinazolin-2-yl]-amine;Benzyl-(S)-1-morpholin-3-ylmethyl-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;[(R)-1-(3,4-Difluoro-phenyl)-ethyl]-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;Benzyl-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;(3,4-Difluoro-benzyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;N-(3-{[6-(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-methyl}-phenyl)-methanesulfonamide;[(R)-1-(3-Methoxy-phenyl)-ethyl]-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;[(R)-1-(2-Fluoro-phenyl)-ethyl]-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;N-(3-{(R)-1-[6-(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-ethyl}-phenyl)-methanesulfonamide;(R)-3-Phenyl-3-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-propan-1-ol[(R)-1-(2,4-Difluoro-phenyl)-ethyl]-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;[(R)-1-(2,6-Difluoro-phenyl)-ethyl]-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;2-{(R)-1-[6-(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-ethyl}-phenol;3-{(R)-1-[6-(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-ethyl}-phenol;4-{(R)-1-[6-(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-ethyl}-phenol;(S)-2-(2-Fluoro-phenyl)-2-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-ethanol;(S)-2-(3-Fluoro-phenyl)-2-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-ethanol;and(S)-2-(4-Fluoro-phenyl)-2-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-ethanol;and pharmaceutically acceptable salts thereof.
 18. A compound accordingto claim 1 which is selected from the group consisting of:((R)-1-Phenyl-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;((R)-1-(3-Chloro-phenyl)-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;((R)-1-(3-Fluoro-phenyl)-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;((R)-1-(4-Fluoro-phenyl)-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;(3-Fluorobenzyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;[(R)-1-(3,4-Difluoro-phenyl)-ethyl]-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;[(R)-1-(2-Fluoro-phenyl)-ethyl]-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;(R)-3-Phenyl-3-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-propan-1-ol;[(R)-1-(2,4-Difluoro-phenyl)-ethyl]-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;[(R)-1-(2,6-Difluoro-phenyl)-ethyl]-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;2-{(R)-1-[6-(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-ethyl}-phenol;3-{(R)-1-[6-(1H-Pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-ethyl}-phenol;and(S)-2-(2-Fluoro-phenyl)-2-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-ethanol;and pharmaceutically acceptable salts thereof.
 19. A compound accordingto claim 1 which is selected from the group consisting of:((R)-1-Phenyl-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;((R)-1-(3-Fluoro-phenyl)-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;((R)-1-(4-Fluoro-phenyl)-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;(3-Fluorobenzyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;[(R)-1-(3,4-Difluoro-phenyl)-ethyl]-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;[(R)-1-(2-Fluoro-phenyl)-ethyl]-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amine;and(S)-2-(2-Fluoro-phenyl)-2-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-ylamino]-ethanol;and pharmaceutically acceptable salts thereof. 20.((R)-1-Phenyl-ethyl)-[6-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-quinazolin-2-yl]-amineor a pharmaceutically acceptable salt thereof.